Mechanisms of sterile inflammation in the testis by Walenta, Lena
 
 
 
Mechanisms of Sterile Inflammation in the Testis 
 
 
 
 
Lena Walenta 
 
 
 
 
 
 
 
Dissertation der Fakultät für Biologie der  
Ludwig-Maximilians-Universität München 
 
 
 
München, 2018  
 
Diese Dissertation wurde angefertigt  
unter der Leitung von Prof. Dr. Artur Mayerhofer  
im Bereich Zellbiologie – Anatomie III 
des Biomedizinischen Centrums München 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Erstgutachter: PD Dr. Lars Kunz  
Zweitgutachterin: Prof. Dr. Gisela Grupe 
 
Tag der Abgabe:   24.04.2018 
Tag der mündlichen Prüfung: 17.07.2018 
  
Eidesstattliche Erklärung 
 
Ich versichere hiermit an Eides statt, dass meine Dissertation selbständig und ohne 
unerlaubte Hilfsmittel angefertigt worden ist. 
Die vorliegende Dissertation wurde weder ganz, noch teilweise bei einer anderen 
Prüfungskommission vorgelegt. 
Ich habe noch zu keinem früheren Zeitpunkt versucht, eine Dissertation einzureichen oder 
an einer Doktorprüfung teilzunehmen.  
 
 
München, den 24.04.2018 
 
 
 
Lena Walenta 
 
Table of Contents IV 
Table of Contents 
Table of Contents .................................................................................................. IV	
Abstract ...................................................................................................................... VII	
Zusammenfassung ............................................................................................... VIII	
1	 Introduction ..................................................................................................... 1	
1.1	 The human testis and male infertility ..................................................................... 1	
1.1.1	 Testicular organization and spermatogenesis ............................................................... 1	
1.1.2	 Testicular alterations and male infertility ..................................................................... 3	
1.1.3	 The peritubular compartment of the testis .................................................................... 5	
1.1.4	 Human testicular peritubular cells (HTPCs) as a cellular model .................................. 5	
1.1.5	 The AROM+ mouse as a systemic model of sterile inflammation ................................ 6	
1.2	 The extracellular matrix molecule biglycan .......................................................... 7	
1.2.1	 Structure and function of biglycan ................................................................................ 7	
1.2.2	 Biglycan in inflammatory signaling .............................................................................. 9	
1.3	 The system of purinergic signaling ...................................................................... 11	
1.3.1	 Purinergic receptors .................................................................................................... 11	
1.3.2	 Purinergic signaling in physiology and pathophysiology ........................................... 13	
1.3.3	 Purinergic signaling in inflammation .......................................................................... 14	
1.4	 The NLRP3 inflammasome ................................................................................. 15	
1.4.1	 NLRP3 inflammasome structure and assembly .......................................................... 15	
1.4.2	 Role of NLRP3 in inflammation ................................................................................. 17	
1.4.3	 Non-classical roles of NLRP3 ..................................................................................... 18	
1.5	 Objective .............................................................................................................. 20	
2	 Results .................................................................................................................... 21	
2.1	 Biglycan – an inducer of sterile inflammation in the testis? ................................ 21	
2.1.1	 Correlation of biglycan expression with sterile inflammation in the human testis ..... 21	
2.1.2	 Increase of biglycan, TLRs and purinergic receptors in in the AROM+ mouse .......... 22	
2.1.3	 Biglycan deficiency fails to rescue the inflammatory AROM+ phenotype ................. 22	
2.2	 Purinergic receptors – involved in testicular inflammation? ............................... 30	
2.2.1	 Expression profile of purinergic receptors in HTPCs ................................................. 30	
2.2.2	 Testicular expression of P2RX4 and P2RX7 .............................................................. 31	
2.2.3	 Functional purinergic receptor assessment by Ca2+ imaging in HTPCs ..................... 32	
2.2.4	 ATP-mediated effects in HTPCs ................................................................................. 34	
2.3	 NLRP3 – an inflammatory sensor in the testis? ................................................... 39	
2.3.1	 NLRP3 expression in human and mouse testes .......................................................... 40	
2.3.2	 NLRP3 expression in mixed atrophy patients ............................................................. 41	
Table of Contents V 
2.3.3	 NLRP3 regulation in a mouse model of sterile inflammation .................................... 42	
3	 Discussion ........................................................................................................... 45	
3.1	 Deficiency of biglycan does not rescue from an inflammatory environment ...... 45	
3.2	 ATP contributes to testicular inflammation dependent on purinergic signaling . 47	
3.3	 The NLRP3 inflammasome specifies a putative signaling pathway in testicular 
inflammation .................................................................................................................... 52	
4	 Material and Methods ................................................................................ 56	
4.1	 Material ................................................................................................................ 56	
4.1.1	 Testicular tissue material ............................................................................................ 56	
4.1.2	 cDNA .......................................................................................................................... 56	
4.1.3	 Cell culture media and supplements ........................................................................... 56	
4.1.4	 Antibodies ................................................................................................................... 56	
4.1.5	 Oligonucleotide primer ............................................................................................... 57	
4.1.6	 Chemicals .................................................................................................................... 60	
4.1.7	 Buffers and solutions .................................................................................................. 61	
4.1.8	 Kits, molecular-weight size markers and assays ......................................................... 62	
4.1.9	 Equipment ................................................................................................................... 63	
4.1.10	 Consumables ........................................................................................................... 64	
4.1.11	 Software and web-based tools ................................................................................ 65	
4.2	 Methods................................................................................................................ 66	
4.2.1	 Mouse model generation and analyses ........................................................................ 66	
4.2.2	 Immunohistochemistry ................................................................................................ 67	
4.2.3	 Peritubular cell culture ................................................................................................ 68	
4.2.3.1	 Cell cultivation ................................................................................................... 68	
4.2.3.2	 Thawing and freezing of cells ............................................................................. 68	
4.2.3.3	 Cell count determination and seeding ................................................................ 68	
4.2.3.4	 Treatment of HTPCs ........................................................................................... 69	
4.2.4	 Functional assessment of peritubular cells .................................................................. 69	
4.2.4.1	 Live cell imaging ................................................................................................ 69	
4.2.4.2	 Cytotoxicity Assay .............................................................................................. 70	
4.2.4.3	 Imaging of intracellular calcium transients ....................................................... 70	
4.2.5	 Molecular biology methods ........................................................................................ 70	
4.2.5.1	 RNA isolation ..................................................................................................... 70	
4.2.5.2	 RNA purification by precipitation ...................................................................... 71	
4.2.5.3	 cDNA synthesis ................................................................................................... 71	
4.2.5.4	 Quantitative real-time PCR ................................................................................ 71	
4.2.5.5	 Agarose gel electrophoresis and DNA sequencing ............................................ 72	
4.2.6	 Proteinbiochemical methods ....................................................................................... 73	
4.2.6.1	 Protein isolation ................................................................................................. 73	
4.2.6.2	 SDS-Polyacrylamide gel electrophoresis ........................................................... 73	
4.2.6.3	 Western Blot ....................................................................................................... 73	
4.2.6.4	 Supernatant profiling assay ................................................................................ 74	
Table of Contents VI 
4.2.6.5	 Mass spectrometry .............................................................................................. 74	
Bibliography ............................................................................................................... 75	
Abbreviations ............................................................................................................. 99	
List of Figures ......................................................................................................... 102	
List of Tables ............................................................................................................ 103	
Acknowledgements ............................................................................................. 104	
Appendix ...................................................................................................................... 106	
Supporting results .......................................................................................................... 106	
Additional projects during the thesis ............................................................................. 107	
a1-adrenergic signaling in HTPCs ........................................................................................ 107	
Publications .................................................................................................................... 108	
Scientific talks and posters ............................................................................................. 109	
	
Abstract VII 
Abstract 
Causes of human male infertility are only partially known. In the numerous idiopathic cases, 
the underlying causes remain unknown. Sterile inflammation of the testis, which frequently 
proceeds asymptomatically and therefore stays undetected, may be involved. This scenario 
has often been associated with increased numbers of immune cells infiltrating the testis and 
fibrotic remodeling of the seminiferous tubular wall. The peritubular cells forming the 
tubular wall together with extracellular matrix are thus hypothesized to participate in these 
pro-inflammatory processes. 
Peritubular cells produce the small leucine-rich repeat proteoglycan and extracellular matrix 
molecule biglycan. Once secreted, it is usually found sequestered in the extracellular matrix 
serving a structural purpose, but in its soluble form it has been shown to act as inducer of 
(pro-)inflammatory signaling in immune cells by activating toll-like receptors 2 and 4. To 
recapitulate these findings, a systemic mouse model of male infertility and sterile 
inflammation was examined. Biglycan and associated receptor levels were increased in the 
mouse model. However, a biglycan knock-out in this mouse failed to rescue the 
inflammatory testicular phenotype. 
Besides activating toll-like receptors 2 and 4, which are expressed by peritubular cells, 
biglycan can also act via purinergic receptors P2RX4 and 7. Expression of P2RX4 and 7 in 
human peritubular cells could be confirmed and a functional assessment through calcium 
imaging pointed to P2RX4 as predominantly acting ion channel in these cells. Treatment of 
human peritubular cells with the physiological purinergic ligand ATP revealed an induction 
of cytokine production and secretion, whereas synthesis of characteristic peritubular features 
like smooth muscle cell markers and extracellular matrix molecules declined. Thus, ATP 
can act as a danger molecule via purinergic signaling in peritubular cells, thereby 
contributing to testicular inflammation. 
One possible signaling mechanism integrating purinergic activation and release of cytokines 
is represented by activation of the NLRP3 inflammasome. This macromolecular complex 
consisting of the sensor NLRP3, the adapter ASC and the effector caspase1 assembles in 
response to cellular damage and induces inflammation and pyroptotic cell death. Expression 
of the NLRP3 molecule was confirmed in human and mouse Sertoli cells as well as human 
peritubular cells. In both species, NLRP3 was additionally linked to subfertile pathologies. 
Together, these findings argue for an involvement of NLRP3 in inflammatory as well as 
non-inflammatory mechanisms in the testis. 
In summary, biglycan deficiency could not attenuate testicular inflammation in a mouse 
model, but ATP-induced signaling by purinergic receptors was identified as a pathway to 
promote sterile testicular inflammation via cytokine production and putative activation of 
the NLRP3 inflammasome in a human cellular model.  
Zusammenfassung VIII 
Zusammenfassung 
Ursachen der männlichen Unfruchtbarkeit sind nur teilweise bekannt, in den zahlreichen 
idiopathischen Fällen bleiben sie unbekannt. Die sterile Entzündung des Hodens, die häufig 
asymptomatisch und dadurch unentdeckt verläuft, könnte eine mögliche Ursache sein. 
Oftmals wird dabei ein Anstieg der Anzahl an einwandernden Immunzellen im Hoden sowie 
die fibrotische Verdickung der Wand der Hodenkanälchen beobachtet. Die peritubulären 
Zellen, die diese Wand zusammen mit extrazellulärer Matrix bilden, tragen daher vermutlich 
zu entzündungsförderlichen Prozessen bei. 
Peritubuläre Zellen stellen das kleine Leucine-rich Repeat Proteoglykan und Extrazellulär-
Matrixmolekül Biglycan her. In sezernierter Form wird es meist zu strukturellen Zwecken 
in der extrazellulären Matrix eingelagert, aber in seiner löslichen Form kann es durch 
Aktivierung von Toll-like Rezeptoren 2 und 4 proinflammatorische Signalkaskaden in Gang 
setzen. Um diese Erkenntnisse zu überprüfen, wurde ein systemisches Mausmodell für 
männliche Unfruchtbarkeit und sterile Entzündung untersucht. Die Menge an Biglycan und 
die Anzahl der damit verknüpften Rezeptoren waren in diesem Mausmodell erhöht. Jedoch 
konnte der infammatorische Phänotyp nicht durch einen zusätzlichen Biglycan-Knockout 
gerettet werden. 
Neben der Aktivierung der Toll-like Rezeptoren 2 und 4, die in peritubulären Zellen 
exprimiert werden, kann Biglycan auch mittels der purinergen Rezeptoren P2RX4 und 7 
wirken. Die Expression von P2RX4 und 7 konnte in humanen peritubulären Zellen 
nachgewiesen werden und eine funktionelle Bewertung mittels Calcium Imaging deutete auf 
P2RX4 als vorwiegend aktiven Ionenkanal in diesen Zellen hin. Die Behandlung von 
peritubulären Zellen mit dem physiologischen purinergen Liganden ATP führte zu einem 
Anstieg in der Cytokinproduktion und -ausschüttung, während sich die Expression 
charakteristischer peritubulärer Merkmale wie Glattmuskelzellmarker und Extrazellulär-
Matrixmoleküle verminderte. ATP kann daher über purinerge Signalwege als Gefahren-
molekül in peritubulären Zellen wirken und so zur Entzündung des Hodens beitragen. 
Ein möglicher Signalweg der Umsetzung purinerger Aktionen bis zur Freisetzung von 
Cytokinen ist die Aktivierung des NLRP3 Inflammasoms. Dieser makromolekulare 
Komplex bestehend aus dem Sensor NLRP3, dem Adapter ASC und dem Effektor Caspase1 
fügt sich aufgrund von Beschädigung der Zelle zusammen und vermittelt Entzündung und 
pyroptotischen Zelltod. Die Expression von NLRP3 konnte in humanen und murinen Sertoli-
Zellen sowie in humanen peritubulären Zellen gezeigt werden. In beiden Spezies konnte 
NLRP3 zusätzlich mit subfertilen Pathologien verknüpft werden. Zusammen sprechen diese 
Erkenntnisse für eine Beteiligung von NLRP3 an entzündlichen wie nicht-entzündlichen 
Mechanismen im Hoden. 
Insgesamt konnte das Fehlen von Biglycan die sterile Entzündung des Hodens in einem 
Mausmodell nicht abschwächen. In einem humanen, zellulären Modell konnte jedoch ATP-
vermitteltes Signaling über purinerge Rezeptoren als Signalweg, der die sterile Entzündung 
des Hodens durch Cytokinproduktion und vermeintliche Aktivierung des NLRP3 
Inflammasoms begünstigt, identifiziert werden. 
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Introduction 
1.1 The human testis and male infertility 
 
1.1.1 Testicular organization and spermatogenesis 
The testis is the central male reproductive organ composed of the tubular and the interstitial 
compartment encapsulated in a layer of connective tissue, the tunica albuginea. Its main 
purpose is the generation of sperm in the tubular compartment and the production of steroid 
hormones in the interstitial compartment, thereby ensuring male fertility.  
The tubular compartment consists of coiled seminiferous tubules organized in lobules, which 
take up the majority of the testicular volume. The interior of the seminiferous tubules is lined 
by the tubular epithelium, formed by Sertoli cells, which enclose the developing germ cells 
(Figure 0.1). Seminiferous tubules are encompassed by the tubular wall, which is built from 
a basement membrane surrounded by concentric layers of peritubular cells and extracellular 
matrix (ECM). In the interstitial compartment, Leydig cells, blood and lymphatic vessels as 
well as nerve fibers and resident immune cells like macrophages are embedded in loose 
connective tissue1. 
 
Figure 0.1 Organization of the seminiferous tubule. 
A. Schematic cross section of a seminiferous tubule. Peritubular cells (orange) and the basement 
membrane (brown) form the wall surrounding the tubule. The tubular epithelium consisting of Sertoli 
cells (green), which line the tubular wall, embeds germ cells at different stages of their developmental 
process (blue) migrating from the basement membrane towards the tubular lumen (white). B. Schematic 
detail of a tubular cross section. Two Sertoli cells sitting on the tubular wall composed of basement 
membrane and peritubular cells enclose spermatogonium and resultant spermatocytes and spermatids. 
Elongated spermatids are found at the apical end of the Sertoli cells before their release into the tubular 
lumen. Modified on the basis of 2. 
Spermatogenesis is the developmental process of generating spermatozoa from 
spermatogonia via mitotic and meiotic division (Figure 0.2). It takes place in the 
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seminiferous tubule epithelium, where spermatogonia reside at the basement membrane. 
Spermatogonia are distinguished into A dark (Ad), A pale (Ap) and B spermatogonia3,4. The 
original classification was based on appearance, but it correlates with mitotic activity. Type 
Ad spermatogonia are the quiescent reserve, while type Ap spermatogonia either are self-
renewing or give rise to type B spermatogonia, thus type A spermatogonia represent the 
spermatogonial stem cell (SSC) population5-7. Type B spermatogonia divide mitotically into 
primary spermatocytes, which start to undergo meiotic division. Hence, diploid primary 
spermatocytes can be distinguished according to their prophase1 stage of meiosis 
(preleptotene, leptotene, zygotene and pachytene). After the first meiotic division, the 
resulting haploid intermediates have been termed secondary spermatocytes, which become 
round spermatids upon completion of the second meiotic division3,4. During the process of 
spermiogenesis, round spermatids mature through chromatin compaction and formation of 
acrosome and sperm tail. Emanating elongated spermatids or spermatozoa are subjected to 
spermiation, meaning detachment from the Sertoli cell and thus, release into the testicular 
lumen8,9. Subsequently, spermatozoa are transported through the seminiferous tubules via 
the rete testis into the epididymis for further maturation and storage10,11. 
 
Figure 0.2 Sequence of spermatogenesis. 
Schematic illustration of spermatogenic development from spermatogonium to elongated spermatid via 
mitotic and meiotic division. The spermatogonium divides asymmetrically resulting in a primary 
spermatocyte. Diploid primary spermatocytes undergo meiosis, thereby giving rise to haploid secondary 
spermatocytes, which further complete meiosis and become round spermatids. During spermiogenesis 
round spermatids are subjected to extensive remodeling to become elongated spermatids, which are 
released into to tubular lumen. 
The testis is an immune-privileged organ due to the blood-testis barrier12-14, which is 
comprised of anatomical, physiological and immunological barriers formed and maintained 
by different somatic cells of the testis15. Its primary physical components are tight junctions 
between adjacent Sertoli cells that divide the tubular epithelium in a basal and an adluminal 
compartment16,17. The blood-testis barrier serves three essential functional purposes. It 
shields developing germ cells from the immune system, limits the passage of molecules and 
provides a special environment for the completion of meiosis and spermiogenesis18,19. Thus, 
Elongated spermatid
Round spermatid
Secondary spermatocyte
Primary spermatocyte
Spermatogonium
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primary spermatocytes are the first to cross the blood-testis barrier before entering their 
second meiotic phase. 
Steroid hormone production is the second substantial function of the testis, primarily 
accomplished by Leydig cells in the interstitial compartment. Leydig cells predominantly 
synthesize testosterone dependent on stimulation with luteinizing hormone, but also further 
androgens and estradiol via testosterone conversion by the enzyme aromatase. Testosterone 
is critical to spermatogenesis and the development and maintenance of male phenotypic 
characteristics1,20-22. 
 
1.1.2 Testicular alterations and male infertility 
While there are many prerequisites for male fertility, testicular integrity is a crucial one. If 
disturbed, spermatogenesis is bound to fail resulting in non-obstructive azoospermia, 
meaning the absence of sperm in the semen without obstruction of the ductal system. 
Underlying causes can be genetic aberrations, disturbance in the hypothalamic-pituitary axis 
or varicocele, for instance, but the majority of cases is idiopathic, i.e. the reasons remain 
unknown23. Resulting hormonal imbalances or failure of somatic cells, Sertoli cells in 
particular, to support spermatogenic development manifest in testicular alterations 
characteristic to subfertile or infertile patients. 
Inflammation of the testis, although rarely reported due to its often asymptomatic course, is 
a well-established cause of male infertility evoked either by infection or sterile stimuli24. 
Sterile triggers include mechanical trauma, autoimmune reaction or pre-existing disorders 
that are accompanied by inflammatory processes24,25. This scenario is not very well 
investigated, but thereby released cytokines and chemokines from somatic cells and resident 
immune cells can serve as initial attractants for immune cell infiltration26. Inflammatory 
cytokines like interleukin 1 (IL1) or tumor necrosis factor a (TNFa) inhibit steroidogenesis 
and thus, reduce intra-testicular testosterone levels contributing to spermatogenic failure. In 
parallel, the cytokines increase the formation of reactive oxygen species (ROS), which may 
negatively impact sperm integrity24,27. Cytokines can furthermore act on components of the 
blood-testis barrier and by that overcome this barrier and enter the tubular lumen to induce 
germ cell apoptosis28-30. Eventually, cytokine signaling leads to production and deposition 
of ECM molecules and hence, fibrosis31,32. All these processes can substantially contribute 
to the overall picture of testicular pathologies. 
Typical testicular phenotypes include mixed atrophy (MA), germ cell arrest or Sertoli cell 
only (SCO) syndrome. In mixed atrophy patients, seminiferous tubules with intact 
spermatogenesis are located next to tubules with different extent of impaired spermatogenic 
function. These tubules are characterized by disorganized structure of the germinal 
epithelium as well as fibrotic tubular walls33. Germ cell or maturation arrest can appear at 
various stages of spermatogenesis resulting in tubules with incomplete spermatogenic 
development34,35. In SCO syndrome, germ cells are either completely absent or present in 
rare foci that do not develop further than spermatogonial stage5,36. 
Fibrosis is a classical hallmark of infertility-related pathophysiology37-39. It is defined as a 
process of extensive tissue remodeling in response to stress or injury characterized by excess 
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ECM production and deposition40. In the testis, the tubular wall typically undergoes fibrotic 
remodeling under pathophysiologic conditions as documented by increased wall thickness. 
Collagen fibers become overabundant and irregularly arranged between peritubular cell 
layers often accompanied by thickening of the basement membrane, thereby contributing to 
disorganization and fibrosing of the tubular wall38,41. In addition, peritubular cell 
morphology becomes altered including loss of cell polarity and hypertrophy42,43, which 
indicate impaired cellular function and signaling activity. 
A second characteristic trait of subfertile and infertile pathologies is the accumulation of 
immune cells, which occurs particularly in the tubular wall44-47. Mast cells and macrophages 
define the immune cell population of the human testis, complemented by few 
lymphocytes44,48,49. It is generally accepted, that resident testicular immune cells exert 
regulatory functions and thus, maintain the immune privilege of the testis. However, if 
immunoregulation is disturbed, circulating immune cells are able to infiltrate the testis and 
participate in inflammatory processes50. 
In the healthy human testis, mast cells are primarily located in the interstitial tissue, but can 
also be found intermingling with peritubular cells in the wall of the seminiferous tubules51,52. 
Both, increases in mast cell abundance and their more frequent localization in the tubular 
wall have been linked to infertile pathologies such as MA, germ cell arrest or SCO 
syndrome44,47,53-55. In particular, elevated mast cell presence coincides with fibrotically 
thickened tubular walls46,47. Further, the mast cell subpopulation expressing chymase in 
addition to tryptase is numerically enhanced56, particularly in the tubular wall57. Mast cell-
secreted tryptase promotes proliferation of fibroblasts58,59 as well as collagen58,60,61 and 
proteoglycan synthesis62. Tryptase is an activator of the protease activated receptor 2 
(PAR2), which mediates not only proliferative actions59,63, but induces pro-inflammatory 
actions via factors like cyclooxygenase 2 (COX2) and thereby prostaglandins or monocyte 
chemoattractant C-C motif chemokine ligand 2 (CCL2)59,64-66. PAR2 expression and 
function have been described in peritubular cells67, germ cells65,68,69 and macrophages46 of 
the testis. Mast cell-derived chymase cleaves angiotensin I to angiotensin II resulting in pro-
inflammatory interleukin 6 (IL6) production in peritubular cells57. Thus, mast cell products 
exert pro-fibrotic and pro-inflammatory effects in the testis, which are enhanced in infertile 
patients due to augmented mast cell abundance70,71. 
Macrophages in the human testis mainly reside in the interstitial tissue, but also in the tubular 
wall and even the lumen of the seminiferous tubules44,45,48. Similar to mast cells, a numerical 
increase of macrophages correlates with testicular pathologies, where macrophage 
localization shifts in favor of tubular wall and lumen44,45. Generation of pro-inflammatory 
molecules such as IL1 or TNFa by testicular macrophages45,72 implicates a contribution to 
testicular inflammation. 
The scarce testicular lymphocyte population mainly consists of interstitial T cells48,73. Albeit 
under inflammatory conditions, lymphocytes infiltrate interstitial and peritubular sites 
coinciding with tubular fibrosis and disturbed germinal epithelium50,74,75.  
 
1 Introduction 5 
1.1.3 The peritubular compartment of the testis  
The tubular wall is primarily created by two components at the basement membrane, 
peritubular cells and extracellular matrix. In human, the elongated spindle-like shaped 
peritubular cells are arranged in five to seven concentric layers separated by ECM and 
connective tissue, whereas there is merely one layer of peritubular cells in rodents76,77. 
Peritubular cells and adjacent Sertoli cells collaborate in synthesizing these ECM 
components, prevalently collagens, fibronectin, laminin and proteoglycans78-80, thereby 
forming and stabilizing the tubular wall. Apart from ECM production and deposition, 
smooth muscle cell-like contractile abilities are the second prime characteristic of 
peritubular cells, therefore also termed peritubular myoid cells. Smooth muscle cell-like 
features of mature peritubular cells are articulated by expression of smooth muscle 
actin67,81,82, myosin heavy chain 11 and calponin43,83 as well as the intermediate filament-
forming desmin84,85. The smooth muscle cell properties allow peritubular cells to contract 
and thus, transport the yet immotile spermatozoa from the lumen of the seminiferous tubules 
to the epididymis10,86,87. However, smooth muscle cell function can only be attributed to the 
inner layers of peritubular cells, whereas the outer layers display a fibroblast phenotype88. 
Due to the localization next to the basement membrane, in the immediate proximity to 
spermatogonial stem cells, Sertoli and Leydig cells as well as blood and lymph vessels or 
immune cells like mast cells or macrophages, peritubular cells are downright predestined to 
interact with their surroundings. Hence, substantial paracrine signaling activity by 
peritubular cells e.g. via growth factors has been identified. Peritubular cells modulate 
Sertoli cells function via secreted factors89,90 as well as Leydig cell differentiation and 
function in an androgen-dependent manner91. In turn, the peritubular phenotype is 
maintained by Sertoli cells92. In addition, peritubular cells anatomically contribute to the 
blood-testis barrier by forming a semi-permeable barrier to exclude large molecules from 
the tubular lumen16,17, although this function seems less pronounced in primates93. 
 
1.1.4 Human testicular peritubular cells (HTPCs) as a cellular model 
Peritubular cells of the seminiferous tubules are characterized by their smooth muscle cell 
functions that are of utmost relevance for sperm transport and their ability to produce and 
secrete ECM molecules to build and stabilize the tubular wall. Human Testicular Peritubular 
Cells (HTPCs) have been established as an in vitro and therefore cell culture model of the 
peritubular cells. These cells are derived from individual testicular tissue samples using an 
explant culture method67. To date, HTPCs are the sole available cell culture model of human 
somatic testicular cells that can be cultivated and subcultivated for a longer period of time. 
Hence, they provide an ideal model for mechanistic studies94. 
Characterization of cultured HTPCs revealed their ability to synthesize and release pro-
inflammatory molecules such as the cytokines IL6, the monocyte chemoattractant CCL2 or 
the soluble pattern recognition receptor (PRR) pentraxin 3 (PTX3)95,96. HTPCs harbor a 
functional Toll-like receptor (TLR) 2 inducing IL6, CCL2 as well as PTX3 expression and 
release by activation through its natural ligand, but alternatively through the proteoglycan 
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and ECM molecule biglycan95. Hence, HTPCs could participate in infectious and sterile 
testicular inflammation via cytokine secretion. 
In addition, release of IL6 and CCL2 attests a close interaction of HTPCs with testicular 
immune cells, since mast cell products TNFa and chymase modulate expression of these 
factors via their corresponding receptors on HTPCs57,96. TLR2 expression in HTPCs is also 
positively correlated with TNFa95. Further TNFa increases the expression of nerve growth 
factor by HTPCs96 whose proliferative actions are regulated via cleavage by another mast 
cell product, tryptase97. TNFa and tryptase both induce synthesis of the proteoglycan 
decorin62,98. As a result, secreted decorin restricts growth factor signaling62 and its abundant 
deposition is associated with impaired spermatogenesis62,98. 
Alterations of testicular morphology are also related to the production of prostaglandins and 
metabolites. Prostaglandins are synthesized by constitutively present COX1 and e.g. by 
TNFa inducible COX2 in HTPCs96,99. Prostaglandins and metabolites cause a partial loss of 
contractility markers such as calponin or SMA in peritubular cells as it has been observed in 
subfertile pathologies43,99,100. Hence, prostaglandin effects are able to disturb testicular 
function by reducing contractile abilities of HTPCs and thus, sperm transport. 
A proteomic approach101 confirmed secretory properties for ECM molecules, especially 
proteoglycans, and cytokines and brought closer insight into HTPC signaling functions. 
Together with in vitro and in vivo assessment of peritubular cells, it allowed for the 
identification of factors that imply a direct contribution to the stem cell niche. Stem cell 
niche regulatory factors Glial cell line-derived neurotrophic factor (GDNF) and C-X-C motif 
chemokine ligand 12 (CXCL12) are produced and secreted by HTPCs101,102. Both factors 
are synthesized by Sertoli cells as well103-105, yet a peritubular-specific knock-out confirmed 
that peritubular-derived GDNF, which is e.g. induced by prostaglandins99, is crucial in SSC 
maintenance106,107. Another factor identified in the HTPC secretome is pigment epithelium-
derived factor, which could promote tubular avascularity and thus, provides further evidence 
for a contribution of HTPCs to the blood-testis barrier108. 
Moreover, studies of HTPCs have attributed them steroidogenic capacity109 and implicated 
regulation of their functions via androgen and estrogen receptors94,110. 
Altogether, mechanistic studies on cultured HTPCs complemented by different approaches 
revealed capabilities in contributing to inflammatory processes, communicating with 
testicular immune cells and influencing testicular microenvironments. 
 
1.1.5 The AROM+ mouse as a systemic model of sterile inflammation 
The AROM+ transgenic mouse line has been established as valid model of sterile 
inflammation and male infertility111. The AROM+ mouse was created by introducing human 
P450 aromatase (CYP19A1) under control of a universal promoter112,113. Excess expression 
of aromatase was achieved in the testis as well as in extragonadal tissues112. Due to the 
systemic aromatase overexpression, the balance between testosterone and estradiol shifts 
gravely in favor of estradiol as aromatase is the rate-limiting enzyme for the conversion of 
androgens to estrogens114. The phenotype is characterized by malformation of endocrine 
organs such as adrenal glands, impairment of the urogenital tract and retarded bone 
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development. Male offspring suffer from disturbed development of reproductive organs, 
especially the testis as testosterone-sensitive organ is critically affected. Males exhibit 
cryptorchidism and reduced testis size. Testicular structure is dramatically altered in regard 
to seminiferous tubular architecture, collagen deposition, abundance and size of Leydig cells 
and number of macrophages and mast cells paralleled by spermatogenic arrest. Thus, males 
are collectively infertile, while female mice remain largely unaffected111-113. The severity of 
these phenotypic changes aggravates with increasing age. While at four months of age, 
Leydig cell hypertrophy and hyperplasia can already be observed, spermatogenesis is still 
ongoing. At nine months of age, merely few germ cells can be detected in the seminiferous 
tubules and at 15 months, tubules are almost completely devoid of germ cells, illustrating 
spermatogenic failure with age. Concomitantly, macrophages in the interstitial tissue 
become immensely more abundant and form giant multinucleated cells engulfing Leydig 
cells from nine months onward. Macrophages were identified as the source of the 
inflammatory cytokine TNFa in the testicular interstitium. TNFa levels, hence, increase 
with age of the AROM+ mice as well111. However, mast cells in the interstitial tissue, which 
also represent a putative origin of TNFa115, were not found before 15 months of age. 
Collagen deposition can hardly be observed at four months of age, albeit from nine months 
onward fibrosing through accumulation of collagen fibers is markedly enhanced111.  
Thus, inflammation-related changes such as the number of immune cell progress with age, 
accompanied by augmented TNFa levels and accumulating fibrosis in the tubular walls and 
the interstitial tissue. These findings provide evidence for severe chronic inflammation of 
the AROM+ testes, that is evoked by a sterile, therefore non-infectious cause, namely 
aromatase overexpression. In the human, similar phenotypic alterations have been reported 
in the testes of infertile patients. For instance, numbers of macrophages expressing TNFa 
are elevated in the testes in infertile men44,45 and fibrotic remodeling occurs in these 
patients46,47. Consequently, the sterile inflammatory situation observed in the AROM+ mouse 
can be employed as a model mimicking the human phenotype i.e. for systemic investigation 
of inflammation-associated male infertility45,47,111. 
 
1.2 The extracellular matrix molecule biglycan 
 
1.2.1 Structure and function of biglycan 
Small leucine-rich proteoglycans (SLRPs) are a subgroup of the family of proteoglycans that 
are characterized by a central domain of leucine-rich repeats (LRRs) flanked by two 
conserved cysteine-rich regions116. SLRPs have been classified according to their structural 
homology and functional similarity. The SLRP biglycan (BGN) belongs to the canonical 
class I, which distinctively displays two disulfide bonds in the N-terminal flanking cysteine 
cluster117,118. The biglycan gene contains eight exons and is located on the X chromosome 
in both, humans and mice119-121. Biglycan is a 42 kDa modularly arranged protein (Figure 
0.3) with a core unit of twelve leucine-rich repeats, the last one exhibiting a so-called “ear 
repeat”116,122-124. Its N-terminus is modified by attachment of one or two glycosaminoglycan 
(GAG) side chains consisting of chondroitin or dermatan sulfate depending on the tissue125-
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127. Biglycan is ubiquitously expressed and was discovered in the human testis, originating 
from the peritubular compartment in particular, over two decades ago128,129. After synthesis, 
the biglycan precursor protein is secreted into pericellular space, where the N-terminus is 
removed by cleavage through bone morphogenetic protein 1 (BMP1) to gain the mature 
protein130.  
 
 
Figure 0.3 Structure of the small leucine-rich proteoglycan biglycan. 
A. The modular protein structure of biglycan consists of twelve leucine-rich repeats. The repeat core is 
flanked by two cysteine (C)-rich regions including two disulfide bonds between cysteine residues in the 
N-terminal cluster. Two GAG chains are covalently linked at the N-terminus. For maturation, N-
terminal cleavage is necessary (arrowhead; modified on the basis of 116,131). B. Putative three-
dimensional biglycan structure (SWISS-MODEL) based on the crystalline dimer123 shows the tandem 
LRRs in a concave assembly with the “ear repeat” at the last LRR. 
Secreted biglycan interacts with a variety of ECM structural molecules, e.g. different types 
of collagens, via its core sequence or the GAG chains132,133. Thereby, biglycan contributes 
to fibrillogenesis and fibril structure and regulates matrix assembly without being part of the 
fibrils themselves, while simultaneously becoming sequestered in the ECM134. Besides 
serving structural purposes, biglycan can interact with numerous cell surface receptors and 
modulate cell-matrix interactions due to its location in the pericellular compartment135. For 
instance, there is interplay with growth factors or cytokines, such as transforming growth 
factor b (TGFb)136, TNFa137 or BMP2 and 4138-140, as well as involvement in Wnt 
signaling141-143. Yet, for most direct interactions biglycan has to regain its soluble state, either 
by release from the matrix via proteolysis upon tissue stress or injury or by de novo synthesis 
through resident cells or macrophages144,145. 
As indicated by the diversity of interacting partners, biglycan has been implicated as a factor 
in many biological processes. Mainly transgenic mouse models contributed new evidence to 
the versatile roles of biglycan. Loss of biglycan results in an osteoporosis-like phenotype146 
crucially impacting skeletal bone formation138,147-150 by modulating TGFb/BMP and Wnt 
C CC C
C C
A
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signaling pathways127,151. Further, biglycan has been shown to be of similar importance in 
tendon152-155 and cartilage156 formation and atherosclerosis prevention157,158 as well as a 
stabilizer of muscle159-161 and neuromuscular synapses162. In contrast, its part in tissue 
fibrosis remains unresolved, although accumulation and deposition of biglycan in renal, 
hepatic or pulmonary fibrosis have been established163-166. Biglycan does not exhibit 
antifibrotic potential like its closely related sister molecule decorin167, but has been 
suggested to promote fibrogenesis via inflammatory signaling163,168,169. Still, it is beneficial 
in fibrotic scar remodeling after myocardial tissue injury170. Meanwhile its pro-inflammatory 
signaling properties, namely the interaction with TGFb and Wnt143,171, as well as regulation 
of the cell cycle172,173 have linked biglycan to cell growth and proliferation and thus, 
tumorigenesis. In this context, promotion of angiogenesis via, for instance, biglycan-
regulated VEGF (Vascular endothelial growth factor)174-176 has, together with biglycan 
overexpression, formed a connection of biglycan with tumor progression177-179. 
 
1.2.2 Biglycan in inflammatory signaling 
Besides its structural abilities as extracellular matrix stabilizer, biglycan has emerged as 
regulator of immune signaling acting as a danger-associated molecular pattern (DAMP) in 
both, the innate and the adaptive immune response127,165,180. These actions were thus mainly 
deciphered in immune cells, primarily macrophages. In injury or stress conditions, 
sequestered biglycan and fragments thereof can be liberated from the extracellular matrix by 
matrix degradation through metalloproteinases165. Soluble biglycan binds TLR2 and TLR4 
(Figure 0.4) on the surface of immune cells via the central domain169,181 mimicking 
recognition features of the native pathogenic TLR ligands180,182. At least the core domain 
and one GAG chain of biglycan are needed for TLR activation169 rendering some of the 
released fragments ineffective in introducing an inflammatory response, therefore 
supporting speculation that in addition to proteolysis de novo synthesis of biglycan might be 
necessary180. Since biglycan triggers activation of both, TLR2 and 4, it is able to amplify the 
immune response in pathogen-induced inflammation through the non-pathogen-sensing 
TLR183. Via TLRs biglycan indirectly activates mitogen-activated protein kinases (MAPK) 
p38 and extracellular-signal regulated kinase (ERK) 1/2 or nuclear factor kappa B (NFkB) 
signaling leading to expression of the pro-inflammatory cytokines and chemokines 
interleukin (IL) 1b, CCL2, 3, 5 and 20, CXCL1, 2, 10 and 13 and TNFa169,181,184-186.  
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Figure 0.4 Biglycan autonomously triggers inflammatory signaling. 
Soluble biglycan activates TLR2 and 4 thereby inducing expression and secretion of cytokines and 
chemokines via p38/ERK or NFkB signaling as it has been discovered in macrophages. CCL2 and 20 
and CXCL1 and 2 are synthesized dependent on MyD88, whereas CCL5 and CXCL10 production is 
solely achieved via the TLR4/TRIF axis. Biglycan prompts clustering of TLRs with P2RX4/7 leading 
to activation of the NLRP3 inflammasome followed by IL1b maturation and subsequent release. 
Modified on the basis of 163,180,186. 
Secretion of cytokines and chemokines contributes to the inflammatory environment and to 
gradient formation attracting immune cells to the site of injury, thereby connecting innate 
and adaptive immune response127. For instance, B cells can be recruited via biglycan-
controlled CXCL13184. CCL2, CXCL1 and CXCL2 production depends on the TLR adaptor 
and signaling molecule MyD88 (myeloid differentiation primary response 88) and recruits 
macrophages and neutrophils, while MyD88-dependent CCL20 synthesis leads to Th17 
chemoattraction. TLR4 can additionally signal through the adaptor TRIF (TIR-domain-
containing adapter-inducing interferon β) inducing CCL5 and CXCL10 expression and 
consecutive T cell migration185,186. More additional determinants of activation and regulation 
of these signaling processes, e.g. interferon g receptor186 or sphingosine kinase 1187, become 
unraveled, although it will take considerable time and effort to reveal all factors in this 
complex signaling network. Besides binding Toll-like receptors, biglycan is able to 
introduce clustering of TLR2 and 4 with purinergic receptors P2RX4 or 7. This interaction 
promotes NLRP3 (NLR family pyrin domain containing 3) inflammasome activation and 
subsequent IL1b maturation and release188. Biglycan further modulates this process 
dependent on NADPH oxidases and heat shock proteins188,189. 
Consequently, biglycan knock-out mice exhibit reduced caspase 1 activation via the NLRP3 
inflammasome and lower cytokine levels in non-infectious inflammation models causing 
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less inflammatory damage188,189. Hence, biglycan is viewed as autonomous trigger of sterile 
inflammation. 
 
1.3 The system of purinergic signaling 
 
1.3.1 Purinergic receptors  
The system of purinergic receptors has originally been classified into two subgroups, P1 and 
P2 receptors, according to their ligands. P1 receptors bind adenosine, whereas P2 receptors 
recognize various nucleotides, prevalently adenosine triphosphate (ATP) and adenosine 
diphosphate (ADP)190. P2 receptors were subsequently divided into ligand-gated ion 
channels (P2X receptors) activated by ATP and G-protein coupled receptors (GPCRs; P2Y 
receptors; Figure 0.5)191,192. Activation of all purinergic receptors is interconnected. 
Extracellular ATP can be converted into its metabolites ADP, adenosine monophosphate 
(AMP) and finally adenosine by ectonucleotidases. Thus, activation of P2Y or adenosine 
receptors can occur as a downstream effect of ATP signaling as well193. 
 
Figure 0.5 Purinergic receptor signaling. 
The purinergic receptors are subdivided into receptor families, P1, P2X and P2Y receptors. P2RX 
monomers consist of two transmembrane domains, which assemble in trimers to form ligand-gated ion 
channels initiating ionotropic responses. P2RX are activated by ATP as their natural ligand. P2RY and 
P1R are both seven transmembrane domain G-protein coupled receptors mediating metabotropic 
responses. P2RY subtypes display different affinities to their ligands, the most common ones being 
ATP, ADP, UTP and UDP. P1R are activated by adenosine solely. Ectonucleotidases are able to 
metabolize ATP to ADP, AMP and finally adenosine, thus linking purinergic actions induced by 
different ligands. Modified on the basis of 194. 
P1 receptors or adenosine receptors are comprised of a family of four GPCRs, A1, A2A, 
A2B and A3195,196. A1 and A2A display high affinity to their ligand adenosine, whereas A2B 
and A3 are of low affinity197. All four P1 receptors possess a seven transmembrane helix 
domain structure coupled to Gs protein in case of A2A and A2B and to Gi/o protein in case 
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of A1 and A3. This means A2A and A2B positively stimulate adenylate cyclase (AC) via Gs 
leading to cyclic adenosine monophosphate (cAMP) formation and consecutive downstream 
signaling. On the contrary, A1 and A3 activation inhibits adenylate cyclase signaling via 
Gi/o197. 
P2Y receptors are also seven transmembrane helix domain GPCRs, similar to P1 receptors. 
Eight subtypes have been identified, P2RY1, P2RY2, P2RY4, P2RY6, P2RY11, P2RY12, 
P2RY13 and P2RY14198. P2RY12-14 prevalently couple to Gi/o protein thereby preventing 
AC activation. The other five P2RY subtypes mainly induce phospholipase C (PLC) 
signaling via Gq protein resulting in cytosolic inositol triphosphate (IP3) increase and 
subsequent Ca2+ mobilization from intracellular stores198,199 with the exception of P2RY11, 
which can couple to Gs protein and thus, signal through AC, too200,201. In contrast to P1 and 
P2X receptors, P2Y receptors recognize more than one native agonist, purines as well as 
pyrimidines and derivatives, albeit with considerably different affinities. While P2RY1, 
P2RY12 and P2RY13 exhibit their highest affinity to ADP202-204, P2RY11 is most efficiently 
activated by ATP205. Uridine triphosphate (UTP) is the most potent ligand on P2RY2 and 
P2RY4, closely followed by ATP in case of P2RY2206. P2RY6 possesses topmost affinity 
to uridine diphosphate (UDP)206 and P2RY14 is primarily activated by UDP-glucose207. 
Contrary to the GPCR structure of P1 and P2Y receptors, P2X receptor monomers consist 
of two transmembrane-spanning domains with intracellular N- and C-termini connected by 
an extracellular loop208-211. Dependent on the subtype, they assemble as homo- or 
heteromeric trimers to form cation permeable channels. Seven members have been assigned 
to the P2X receptor family, P2RX1-7191,197. Homotrimers have been detected for each 
member and a variety of heterotrimers has been established, for instance P2RX1/2, 
P2RX1/4, P2RX1/5, P2RX2/3, P2RX2/5, P2RX2/6 and P2RX4/6212-214. Heterotrimer 
formation by P2RX7 is a current topic of discussion, but accumulating evidence suggests 
that it forms heterotrimers with P2RX4215,216. All P2X receptors share ATP as physiological 
ligand, yet effective concentrations (EC) of ATP stretch from low-nanomolar to mid-
micromolar range217. Activation of P2X receptor trimers occurs via ATP binding to the 
interface of two subunits in a cooperative manner218-220 inducing a conformational change 
and rearrangement of the subunits that leads to channel opening221,222. In the open state, the 
channel pore is permeable to sodium and calcium influx and potassium efflux inducing 
membrane depolarization and a rise in intracellular Ca2+ concentration223-225. Channel 
activation is followed by desensitization and a final cease of the ion flow. Desensitization 
kinetics highly depend on the involved P2RX subtypes. While P2RX1 and P2RX3 
desensitize rapidly, the process occurs slowly for P2RX2, P2RX4 and P2RX5. P2RX7, 
however, does not appear to desensitize217,224. Prolonged ATP stimulation leads to enhanced 
membrane permeability for large cations therefore termed pore dilation. This hallmark of 
P2X receptor activation has been observed for P2RX2, P2RX4 and P2RX7 as well as several 
heterotrimers226-228. Whether the P2X-formed channel pore can actually dilate to the required 
diameter to allow the passage of large cations remains to be determined. A second option is 
the interaction of activated P2RXs with a separate membrane channel mediating large cation 
influx229,230. 
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In the testis, presence of different purinergic receptors was confirmed mostly based on 
studies conducted in the rodent. P1 receptors were found to be expressed in the testis231,232 
suggesting a role in sperm physiology233-236. P2 receptors display a diverse expression 
pattern, which is oftentimes inconsistent between reports237,238. Murine spermatogonia 
exhibit functional P2RX4 and P2RX7 signaling as part of a paracrine signaling network in 
spermatogenesis239, whereas stage-dependent expression of P2RX2, P2RX3 and P2RX5 has 
been shown in postmeiotic germ cells in the rat240. In murine sperm, P2RX2 signaling was 
found to be crucial in preserving fertility241, while the human sperm transcriptome revealed 
the presence of P2RX3, P2RX4, P2RX5 and P2RX7 transcripts242. In Sertoli cells, P2RX 
and P2RY signaling intermingles243-245 exemplified by expression of P2RY1, P2RY2, 
P2RX2, P2RX3, P2RX4, P2RX5 and P2RX7 in rat Sertoli cells240,246. In mouse Sertoli cells, 
P2RX2 and P2RY2 were recently identified as purinergic signal mediators of ATP247. 
P2RX2, P2RX4, P2RX6 and P2RX7 were discovered in Leydig cells, which predominantly 
exhibit pharmacological properties of P2RX2248,249. In regard to peritubular cells, until now 
solely faint and infrequent expression of P2RX2 and P2RX5 was described240. Hence, 
distinguishing purinergic signaling contributors and resulting physiological impact in the 
testis remains a challenging field. 
 
1.3.2 Purinergic signaling in physiology and pathophysiology 
Purinergic signaling is an omnipresent mechanism found throughout tissues. Thus, it 
engages in numerous processes establishing and maintaining tissue function250. The concept 
of purinergic signaling was first introduced when the purine nucleotide ATP was discovered 
as a neurotransmitter acting in extracellular space251,252. Consequently, ATP is now 
established as co-transmitter in synaptic transmission of neurons in the central nervous 
system, but also known to modulate synaptic interaction with glial cells or astrocytes, which 
are all affected via their different repertoire of purinoceptors253. This process belongs to the 
short-term, i.e. directly effective purinergic actions. Another major short-term effect is the 
control of smooth muscle cell contraction. In the periphery, ATP release by sympathetic 
neurons causes smooth muscle contraction, while simultaneously promoting relaxation via 
endothelial cells254,255. In the male reproductive system, purinergically controlled smooth 
muscle contraction in the vas deferens is crucial to sperm ejaculation256,257 supported by the 
notion that P2RX1 knock-out mice are significantly less fertile due to declined contraction 
ability of the vas deferens258. It contributes to penile erection via contraction and relaxation 
events and ATP signaling has been indicated in sperm motility and fertilizing capacity238. 
Short-term purinergic actions further comprise induction of endocrine and exocrine 
secretion, chemoattraction and acute inflammation and nociception259,260. 
Long-term or trophic purinergic signaling is executed through the vast variety of intracellular 
signaling cascades that are activated by purinergic receptors and it is related to fundamental 
processes, such as cell proliferation, differentiation, motility and death261. Substantial roles 
have been identified in development starting from the early embryo via differentiation of 
organ structures and systems and ending with ageing process262. Purinergic signaling 
participates for instance in synaptic plasticity263,264 or bone formation and resorption265,266. 
At the same time it is indicated in pathophysiologic conditions, which renders purinergic 
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receptors putative targets for treatment of these conditions267. Depending on the involved 
subset of purinergic receptors, extracellular purines can promote or constrain processes like 
atherosclerosis268, brain injury and neurodegenerative diseases253, tumor progression269-271 
or tissue regeneration versus chronic inflammation and pain272-274. Generally speaking, ATP-
mediated signaling rather fosters the pathological conditions, while adenosine actions exert 
a protective effect counterbalancing the ATP-induced processes275. 
 
1.3.3 Purinergic signaling in inflammation 
Under physiologic conditions concentrations of extracellular nucleotides are marginal276-278. 
Upon injury, ATP is released from damaged cells e.g. via exocytosis or the opening of 
plasma membrane channels279 and eventually through apoptotic cell death280. Extracellular 
ATP is able to act as a danger signal activating autocrine or paracrine purinergic signaling 
thereby attracting immune cells281-283. Response of immune cells to ATP is shaped by their 
distinct repertoires of purinergic receptors. Thus, dependent on the extracellular ATP 
concentration different purinoceptors become activated mediating e.g. neutrophil or 
macrophage migration to the site of cellular damage to induce phagocytic clearance280,282-
284. Recruitment of immune cells is further promoted indirectly by ATP-dependent release 
of chemoattractants like CCL2, CXCL8 or IL6 from fibroblasts or endothelial cells285,286. 
Among the P2X receptors, P2RX7 has been found to be particularly involved in 
inflammatory processes through both, its ion channel permeability and its intracellular 
signaling properties287. Most prominently, P2RX7 activation triggers formation of the 
NLRP3 inflammasome via potassium efflux or potentially direct interaction288 including 
subsequent IL1b and IL18 maturation and release289-291. Moreover, P2RX7 initiates pro-
inflammatory gene expression through MyD88-dependent activation of NFkB292-294, which 
is the primary inducer of IL1B transcription, but also of a variety of other pro-inflammatory 
cytokines and chemokines295. Via NLRP3 inflammasome signaling, P2RX7 has been 
identified as crucial to pyroptotic cell death296, but has also been implicated in other forms 
of cell death, namely apoptosis297,298, necrosis299,300 and autophagy301, depending on the cell 
type287. In contrast, P2RX7 can act as mediator of cell proliferation and growth270,302,303. In 
chronic inflammation, P2RX7 substantially contributes to tissue fibrosis304,305. 
P2RX4-mediated ATP-dependent responses came into focus more recently. P2RX4 is co-
expressed with P2RX7 in most types of immune cells284 where it has been found to exhibit 
significant impact on the ionotropic Ca2+ response in monocytes and macrophages306 or 
amplify the immune response in T cell activation307. Like P2RX7, P2RX4 has been 
uncovered as an activator of the inflammasome308-310. P2RX4 and P2RX7 cooperate through 
direct functional interaction215,311-313, yet it appears that P2RX4 acts as regulator of P2RX7-
mediated inflammatory functions314-316. 
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1.4 The NLRP3 inflammasome 
 
1.4.1 NLRP3 inflammasome structure and assembly 
Inflammasomes are multiprotein complexes composed of sensor, adaptor and effector 
components, which assemble in the cytosol of immune cells for the purpose of inflammatory 
caspase activation317. Sensor proteins were established as intracellular pattern recognition 
receptor (PRR) of the innate immune system detecting pathogen-associated molecular 
patterns (PAMPs) and danger- associated molecular patterns (DAMPs). The concept of 
pattern recognition evolves around the invariability of exogenous signals shared by 
innumerous pathogens (PAMPs) and endogenous signals of cellular or tissue damage and 
thus sterile inflammation (DAMPs). Due to their invariability, PAMPs and DAMPs can be 
sensed by a constant repertoire of innate immune receptors (PRRs)318-320. 
Several different sensor proteins of inflammasomes have been described, most of them 
belonging to the NOD-like receptor (NLR) family321. One of them is NLR family pyrin 
domain containing 3 (NLRP3; 118 kDa) consisting of three major domains, an N-terminal 
Pyrin domain (PYD), a central nucleotide-binding and oligomerization domain called 
NACHT (AIP, CIITA, HET-E and TP1 domain with NTPase activity) and a C-terminal 
leucine-rich repeat domain322. Together with the adapter protein ASC (apoptosis associated 
speck-like protein containing a caspase activation and recruitment domain (CARD)) and the 
effector protein pro-caspase1, it forms the NLRP3 inflammasome323.  
Its canonical activation mechanism requires two independent hits by a priming and an 
activating stimulus, respectively (Figure 0.6). In the priming step, PAMPs or DAMPs trigger 
NFkB-dependent transcription of NLRP3 itself and cytokines of the IL1 family, IL1B and 
IL18, resulting in increased availability of NLRP3, pro-IL1b and pro-IL18 in the cytosol324-
328. In addition, cytosolic NLRP3 becomes deubiquitinated by BRCC3 (BRCA1/BRCA2-
containing complex subunit 3)329,330. Prototypical priming is achieved, for instance via 
activation of TLRs, IL1 receptor or TNFa receptor and their downstream signaling 
molecules by their respective ligands321. As a second and activating stimulus, a vast range 
of triggers has been identified. PAMPs like viral or bacterial products, especially 
lipopolysaccharide (LPS) or pore-forming toxins, induce inflammasome formation331. A 
particular broad spectrum of activating DAMPs includes particulates like uric acid 
crystals332 or silica333 and extracellular ATP triggering P2RX7 pore formation290,334, which 
result in potassium efflux from the cytosol. Further, mitochondrial dysregulation leading to 
mitochondrial reactive oxygen species (mROS)335 or oxidized mitochondrial DNA336 has 
been uncovered. Alternatively, calcium sensing receptor (CASR) can induce an increase of 
cytosolic Ca2+, which evokes inflammasome assembly either directly or via mitochondrial 
damage337,338 to name some examples among the inflammasome activating triggers331. 
Still, direct binding of a stimulus to NLRP3 for activating purposes has not been confirmed, 
arguing that NLRP3 rather senses and integrates a consensus signal of altered cell 
homeostasis induced by the varying second stimuli339. Potassium efflux was proposed to be 
the sought consensus trigger since it is the common downstream effect of multiple activating 
stimuli including pore-forming toxins, P2RX7 activation or lysosomal disintegration340,341. 
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However, the immediate connection between potassium efflux and NLRP3 activation 
remains elusive. Identification of NIMA-related kinase 7 (NEK7), which directly binds 
NLRP3 and is critical for inflammasome assembly, but acts downstream of the potassium 
efflux342-344 could be the next step in determining this link340. 
 
Figure 0.6 Canonical activation of the NLRP3 inflammasome. 
The NLRP3 inflammasome activation occurs according to a two-hit hypothesis. As a first, priming hit, 
PAMPs or DAMPs increase NLRP3, IL1B and IL18 transcription dependent on NFkB. In addition, 
NLRP3 becomes deubiquitinated. The second, activating hit can be triggered by a variety of stimuli: 
For instance, intracellular calcium recruitment due to CASR signaling, potassium efflux due to P2RX7 
activation, pore-forming toxins or lysosomal damage caused by particulates, mitochondrial ROS 
(mROS) production and oxidized mitochondrial DNA (oxDNA) can induce the inflammasome 
assembly, but not through direct interaction (indicated by grey arrows). Binding of NEK7 to NLRP3 is 
also critical. Thus, NLRP3, ASC and pro-caspase1 assemble via homotypic domain interactions to form 
a functional inflammasome (here illustrated by dimerization). Upon assembly, caspase1 is 
proteolytically activated from pro-caspase1. Caspase1 cleaves GasderminD resulting in pyroptosis and 
maturates pro-IL1b and pro-IL18 into IL1b and IL18, respectively, which are then released into 
extracellular space. Modified on the basis of 345,346. 
In response to the second hit, the NLRP3 inflammasome assembles from its components in 
the cytosol. Via a homotypic PYD-PYD interaction, NLRP3 can associate with ASC, which 
comprises a PYD and a CARD347-349. In turn, ASC recruits pro-caspase1 via a homotypic 
CARD-CARD interaction350. After nucleation of NLRP3 by oligomerization via the 
NACHT domains, ASC can adhere to the multimeric complex and polymerize in helical 
filament-like structures also known as the ASC speck347,351. Thereby ASC filaments provide 
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a scaffold for pro-caspase1 recruitment and filament formation resulting in caspase 
dimerization and activation352. Once assembled, the NLRP3 inflammasome is a director of 
two main effector pathways, interleukin synthesis and inflammatory cell death termed 
pyroptosis. In the inflammasome complex, pro-caspase1 becomes activated due to 
autocatalytic cleavage353. Active caspase1, in turn, is able to convert pro-IL1b and pro-IL18 
into their mature forms by N-terminal cleavage354-357. In addition, active caspase1 promotes 
pyroptosis by Gasdermin D (GSDMD) cleavage358,359. The N-terminal GSDMD fragment 
then forms a membrane-spanning pore resulting in a collapse of the osmotic gradient across 
the plasma membrane and thus, cell death by cell swelling, membrane damage and release 
of cytosolic content360,361. 
A non-canonical mode of NLRP3 inflammasome activation has additionally been identified. 
This pathway starts with oligomerization of human caspases4 and 5, homologous to murine 
caspase11, upon encounter of intracellular LPS and their subsequent activation362-365. Active 
caspase4/11 requires potassium efflux for canonical NLRP3 inflammasome assembly and 
consecutive caspase1-mediated IL1b maturation366-369 whereas cleavage of Gasdermin D 
and thus pyroptosis induction can also proceed in a caspase1-independent manner370,371. 
 
1.4.2 Role of NLRP3 in inflammation 
NLRP3 inflammasome signaling is crucial to both, sterile and pathogen-induced 
inflammation rendering NLRP3 inflammasome mediated interleukin production and release 
as well as pyroptosis early signals in the line of host defense372. Release of mature IL1b and 
IL18 can occur via several pathways, for instance, exocytosis of secretory lysosomes373,374, 
shedding of microvesicles375,376 or exosome liberation377. Apart from these mechanisms, 
direct release via transporters378, membrane pores379 or Gasdermin D induced pore 
formation359,360,380 were identified. Extracellular IL1b and IL18 serve as triggers for 
activation of innate immune cells like macrophages, mast cells or dendritic cells. Secondly, 
along with cytokines secreted by the activated innate immune cells, IL1b and IL18 
contribute to recruitment and proliferation of adaptive immune cells, for instance T helper 
cells or B cells thereby connecting innate with adaptive immune response. Ultimately 
clearance of injured cells is induced via both lines of immune response381.  
Another mechanism identified in mediating inflammation across cell membranes has been 
termed inflammasome spreading. In case of cell death due to pyroptosis, ASC specks are 
released into the extracellular space, where they continue to persist and maturate IL1b. 
Phagocytosis allows ASC specks to re-enter the cytosol and propagate inflammatory 
signaling to bystander cells as means of enhancing inflammatory signaling beyond the 
damaged cell382-385. 
As both, the canonical and the non-canonical NLRP3 inflammasome activation pathways 
are highly complex processes, each step is tightly regulated to prevent unnecessary 
activation321. Consequently, constant inflammasome activity prompts loss of tissue 
homeostasis and chronic inflammation. Involvement of the deregulated NLRP3 
inflammasome has been shown in various cardiovascular, metabolic or neurologic disorders. 
For example, NLRP3 inflammasome activation via internalized cholesterol crystals causing 
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lysosomal disintegration has been implicated in the progression of plaque formation and 
rupture in atherosclerosis386-389. In type 2 diabetes mellitus (T2D), hyperglycemia can 
promote NLRP3 activation in pancreatic b cells probably via the intracellular stimulus 
TXNIP390,391, whereas saturated fatty acids and soluble islet amyloid polypeptide (IAPP) or 
its amyloid aggregates induce inflammasome activation in myeloid cells through different 
mitochondrial ROS production and lysosome disintegration, respectively392-395. Thereby 
generated IL1b release significantly contributes to b-cell loss and thus, insulin resistance in 
T2D pathogenesis396,397. Similar to IAPP, the amyloid-b peptide is internalized and triggers 
inflammasome activation through lysosomal perturbation in Alzheimer’s disease 
development398-400. Comparable observations have been established for deposited uric acid 
crystals in gout332,401. 
In contrast to these chronic inflammatory diseases, cyropyrin-associated periodic syndrome 
(CAPS) is caused by constant NLRP3 inflammasome activity due to gain-of-function 
mutations predominantly occurring in the nucleotide binding site of the NLRP3 gene402-404. 
Permanent NLRP3 inflammasome activity with consecutive IL1b overproduction results in 
familial autoinflammatory diseases, namely familial cold autoinflammatory syndrome 
(FCAS)405, Muckle-Wells syndrome (MWS)406,407 and chronic infantile neurological 
cutaneous articular (CINCA) syndrome408. Fever and rash due to inflammation are 
characteristic symptoms common in all three disease manifestations, often accompanied by 
hearing loss, bone defects, renal amyloidosis or abnormalities in the central nervous system 
depending on the severity of the disease402,409,410. The Muckle-Wells syndrome is of 
particular interest since it has been connected to perturbed spermatogenesis and infertility in 
men. Yet, the extent of infertility has not been investigated in detail and molecular 
mechanisms remain undetermined406,411-413. 
 
1.4.3 Non-classical roles of NLRP3 
Beyond its classical role in inducing inflammation and pyroptosis, the NLRP3 
inflammasome has been found to engage in regulation of additional cellular processes 
independent of interleukin-mediated effects414. The NLRP3 inflammasome has been 
identified to e.g. participate in a negative autoregulatory loop with autophagy. NLRP3 
inflammasome activation induces mitochondrial dysfunction and inhibits mitochondrial 
autophagy415, whereas autophagy proteins prevent NLRP3 and subsequent caspase 1 
activation416 implying an impact on cellular homeostasis. NLRP3-dependent caspase 1 
promotes phagosome maturation417, while caspase 4/11 facilitate phagolysosomal 
fusion414,418, thereby enhancing the anti-microbial response. NLRP3-dependent caspase 1 
further influences lipid metabolism419,420. 
Inflammasome activation and signaling is a mechanism prevalently described in myeloid 
cells supported by the fact that NLRP3 expression previously has been confined to the 
myeloid lineage421. Meanwhile NLRP3 expression has been found in lymphoid cells of the 
immune system422-425 as well as somatic cell types. This includes mesenchymal cells like 
osteoblasts or chondrocytes426-429, cardiac fibroblasts430,431 or vascular smooth muscle 
cells432. Further, epithelial expression of NLRP3 has been revealed in kidney433,434, 
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lung333,435 or retina436. In this context, it is noteworthy that NLRP3 expression in human and 
mouse testis has been established437,438. In a mouse model of testicular ischemia/reperfusion 
injury, NLRP3 knock-out or inhibition proved beneficial for preservation of histological 
integrity and spermatogenesis and displayed less inflammatory gene activation438. In 
addition, a functional NLRP3 inflammasome inducing IL1b production and release has been 
described in murine Sertoli cells439. Both studies related inflammatory actions to NLRP3 
and indicated a putative role in the onset of male infertility. 
In parallel to the finding of NLRP3 inflammasome actions in somatic cells, inflammasome-
independent functions of NLRP3 have begun to emerge. In the lung, NLRP3 can promote 
post-injury inflammation via the STAT3 pathway without IL1b induction440. In terms of 
non-inflammatory roles, NLRP3 is involved in preserving epithelial barrier integrity via cell 
adherence in the lung441, but contribution to epithelial barrier functioning has been revealed 
in kidney442 and testis439 as well. TGFb-induced NLRP3 has been reported to contribute to 
epithelial-mesenchymal transition in kidney epithelium443 and colon cancer cells444. 
Moreover, TGFb-dependent NLRP3 fosters fibrogenesis in cardiac myofibroblasts445. In 
contrast, NLRP3 can act as transcription factor in T helper type 2 cell differentiation425. 
Unraveling NLRP3-mediated effects in inflammatory and inflammation-associated 
processes, but simultaneously in a diverse set of cellular mechanisms introduces a new 
perspective to NLRP3 signaling.  
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1.5 Objective 
Impairment of spermatogenesis is often accompanied by fibrosis and both are exemplary 
hallmarks of male sub- and infertility. Fibrosis may result from sterile inflammation of the 
testis, yet underlying molecular mechanisms of have sparsely been investigated. The tubular 
wall is the testicular compartment that is critically affected through fibrotic remodeling and 
infiltrating immune cells. It may thus be involved in development of sterile inflammation, 
which putatively leads to male infertility. 
 
(1) The first goal of the thesis will be to discover and assess the role of the extracellular 
matrix molecule biglycan and biglycan signaling in the testis. Since biglycan is implicated 
in initiating inflammatory processes, biglycan and associated inflammation-mediating 
receptors (TLRs and P2X receptors) are to be identified and evaluated in an inflammatory 
context. Therefore, a previously described mouse model of male infertility associated with 
chronic sterile inflammation in the testis, the AROM+ mouse, will be employed. Besides 
assessing the AROM+ mouse as suitable model for this study, the mechanistic actions of 
biglycan will specifically be addressed by introducing a biglycan knock-out in the AROM+ 
mouse model. 
 
(2) As next step, the probability of purinergic receptors and signaling contributing to 
testicular inflammation will be examined. For this purpose, human testicular peritubular 
cells (HTPCs) as cell culture model for mechanistic studies will be exploited. The repertoire 
of purinergic receptors and their functionality in HTPCs is to be revealed. Inflammatory 
conditions in the testis provide increased availability of the physiological purinergic ligand 
ATP. Subsequently, the impact of purinergic signaling through ATP in terms of 
inflammatory gene regulation and the characteristic HTPC phenotype is to be assessed. 
 
(3) Third, as a putative downstream pathway of inflammatory signaling, NLRP3 expression 
in human and mouse testes will be inspected. Putative correlation of NLRP3 with phenotypic 
alterations in testicular pathophysiology is to be examined. To reveal an association of 
NLRP3 with testicular inflammation, the AROM+ mouse as a systemic mouse model of 
sterile inflammation will again be employed. 
 
Thus, precise investigation of biglycan, purinergic receptors and NLRP3 is to participate in 
the identification and clarification of sterile inflammatory processes and reveal mechanisms 
putatively contributing to subfertile testicular pathologies. 
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Results 
1.6 Biglycan – an inducer of sterile inflammation in the testis? 
Biglycan is expressed ubiquitously throughout the body128. In the testis, it is located in the 
extracellular matrix of the seminiferous tubular wall in particular129. It has further been 
associated with fibrotic remodeling of the tubular wall in subfertility patients95. Biglycan has 
been implicated as inducer of sterile inflammation via TLRs and purinergic receptors in cells 
of the innate immune system180. Abundance and functionality in the testis was evaluated 
using human testicular tissue and a mouse model of sterile inflammation and male infertility. 
 
1.6.1 Correlation of biglycan expression with sterile inflammation in the human testis 
Biglycan expression in human testis was assessed using immunohistochemistry of testicular 
sections from patients displaying normal morphology and mixed atrophy (Figure 0.1). 
 
 
Figure 0.1 Biglycan expression in the human testis. 
Representative testicular sections displaying normal morphology (left panel) and mixed atrophy (right 
panel) were stained for BGN expression. Mixed atrophy samples were characterized by tubules showing 
normal spermatogenesis next to tubules with deteriorating spermatogenesis (crosses) and thickened 
tubular walls (arrowheads) as well as excess interstitial tissue (asterisk). BGN staining was present in 
the tubular wall and the interstitial tissue (upper panel) and appeared more prominent in 
morphologically altered samples from mixed atrophy patients. Controls (lower panel) consisted of 
primary antibody omission in consecutive sections. Staining was performed for n = 3 normal patients 
and n = 3 mixed atrophy patients. Bar = 25 µm. 
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In both sections, distinguished staining became obvious in the tubular wall and the interstitial 
tissue. In mixed atrophy patients, the wall of tubules displaying signs of impaired 
spermatogenesis was profusely altered regarding thickness and structural integrity indicating 
ongoing testicular remodeling33,38. Evidently, staining appeared more prominent in 
fibrotically thickened tubular walls as well as in the ample interstitial tissue of mixed atrophy 
patients. 
Fibrotic remodeling includes extensive ECM abundance and is considered a phenotypic sign 
following inflammation446, that can be observed in the tubular wall of the testis as well47,95. 
In a previous study, testicular biglycan expression has already been associated with fibrotic 
tubular walls and biglycan action in HTPCs was identified to induce pro-inflammatory 
cytokine production via TLR295. Together, these findings link enhanced biglycan expression 
to an inflammatory testicular state supporting the hypothesis that biglycan is not only a 
result, but also a putative cause of testicular inflammation. 
 
1.6.2 Increase of biglycan, TLRs and purinergic receptors in in the AROM+ mouse 
The AROM+ transgenic mouse line was chosen as a systemic model to investigate biglycan 
in a context of sterile inflammation. Initial examination of expression levels in the AROM+ 
mouse line revealed significantly increased abundance of Bgn transcripts in the testes of 
AROM+ animals compared to age-matched WT animals at five months of age (Figure 0.2). 
Similar observations were made for the cell surface receptors known for their interaction 
with biglycan. Tlr2 and Tlr4 as well as P2rx4 and P2rx7 relative expression levels were 
increased, albeit only significantly for Tlr4 and P2rx4. These findings support the hypothesis 
of biglycan and its associated cascade being involved in sterile inflammation of the testis. 
 
Figure 0.2 Elevated Bgn transcript expression and associated receptors in testes of AROM+ mice. 
Relative amounts of Bgn, Tlr2, Tlr4, P2rx4 and P2rx7 were increased in five months old AROM+ 
transgenic mice compared to WT littermates. Transcript levels are depicted normalized to WT control 
levels. Numbers of animals analyzed are denoted in the graphs. Data represent geometric means + 95% 
confidence interval. Asterisks denote statistical significance (unpaired t-test, p < 0.05). 
 
1.6.3 Biglycan deficiency fails to rescue the inflammatory AROM+ phenotype 
The putative role of biglycan in sterile inflammation of the testis was further evaluated in 
the AROM+ mouse line. Biglycan knock-out mice (Bgn-/0)146 were crossed with the AROM+ 
mouse line to investigate, if biglycan deficiency was able to counteract the inflammatory 
phenotype of this mouse line. Mice were evaluated at the age of four and ten months, 
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respectively. Differences in body and testis weights were assessed, as were histology and 
seminiferous tubule diameters. In addition, hormonal levels in the testes were determined at 
ten months of age. To complement the analysis, testicular mRNA expression levels of 
characteristic marker genes for relevant testicular cell types and inflammatory parameters 
were compared. Body weights were not significantly altered between mice of different 
genotypes in both age groups (Figure 0.3). At four months of age, testis weights were 
decreased in AROM+ Bgn-/0 and AROM+ animals compared to Bgn-/0 animals, yet there were 
no differences between WT animals and any other genotype. In contrast, at ten months of 
age testis weight differences could not be observed. Seminiferous tubule diameters did not 
display inter-genotype changes in both age groups. 
 
Figure 0.3 Comparison of body weights, testis weights and tubule diameters of mice from 
AROM+ x Bgn-/0 crossings. 
Body weights, testis weights and seminiferous tubule diameter were evaluated according to genotype 
of the AROM+ x Bgn-/0 F2 offspring at four and ten months, respectively. Numbers of animals analyzed 
are denoted in the graphs. Data represent means + SD. Asterisks denote statistical significance 
(ANOVA with Tukey’s post-test, p < 0.05). 
After discovering almost no differences in the general parameters, histological analysis of 
the genotypically different testes was performed (Figure 0.4). At four months of age, WT 
and Bgn-/0 mice testes were of regular appearance including spermatogenesis, yet AROM+-
containing genotypes comprised a visible increased abundance of interstitial tissue. In 
contrast, at ten months of age testicular phenotypes appeared heterogeneous even among 
animals of the same genotype. In AROM+ (Bgn-/0) mice, some animals maintained an almost 
intact tubular organization, while others displayed massive intratubular degeneration 
comprising germ cell vacuolization and loss of spermatogenesis. Interestingly, in some cases 
tubules with intact spermatogenesis were found directly besides tubules with completely 
disrupted structure. All AROM+ (Bgn-/0) animals displayed an excess of interstitial tissue 
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consisting putatively of infiltrating macrophages and hypertrophic Leydig cells, but 
differences between AROM+ Bgn-/0 and AROM+ testicular sections did not become evident. 
In comparison, Bgn-/0 and WT testes exhibited intact testicular morphology without obvious 
alterations. 
 
 
Figure 0.4 Testicular histology of mice from AROM+ x Bgn-/0 crossings. 
Hematoxylin and eosin staining of representative testicular sections from each genotype of the AROM+ 
x Bgn-/0 F2 offspring at four (left panel) and ten months (right panel). Differences in testicular 
morphology were hardly apparent at four months, but at ten months of age AROM+ Bgn-/0 and AROM+ 
mice displayed an altered testicular structure including interstitial infiltrates (asterisks), germ cell 
vacuolization (arrowheads) and disturbed tubular organization. Bar = 50 µm. 
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To complete the analyses of the testes, steroid hormonal levels of testosterone and estradiol 
were assessed in the testes of ten months old mice (Figure 0.5). Testosterone levels appeared 
scarcely but not significantly lower in all genotypes different from WT. In contrast, estradiol 
levels were considerably and significantly elevated in AROM+-containing genotypes 
regardless of the Bgn knock-out. 
 
Figure 0.5 Comparison of steroid hormone levels of mice from AROM+ x Bgn-/0 crossings. 
Testosterone and estradiol levels were determined from testicular lysates by MS/MS at ten months of 
age. Results are depicted according to genotype of the AROM+ x Bgn-/0 F2 offspring. Numbers of 
animals analyzed are denoted in the graphs. Data represent means + SD. Asterisks denote statistical 
significance (ANOVA with Tukey’s post-test, p < 0.05). 
Since general traits did not reveal a rescue of the AROM+ phenotype by Bgn deficiency, 
more detailed insight into alterations of testicular cell types and inflammatory parameters 
was obtained via transcription level analysis from whole testes. 
Biglycan transcripts were almost undetectable in the knock-out genotypes of both age 
groups, but Bgn levels in AROM+ mice were significantly elevated compared to WT as seen 
in the original mouse line. The SLRP decorin, which is a sister molecule to biglycan, 
displayed increased levels in all AROM+-containing animals, but differences between 
AROM+ mice with or without Bgn could not be observed (Figure 0.6). Hence, the hypothesis 
of a compensation of Bgn deficiency by Dcn, as previously discovered in Bgn- and/or Dcn-
deficient mouse models447,448, was rejected. 
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Figure 0.6 Comparison of Bgn and Dcn transcript levels in testes of mice from AROM+ x Bgn-/0 
crossings. 
Bgn and Dcn transcript levels were evaluated according to genotype of the AROM+ x Bgn-/0 F2 offspring 
at four and ten months, respectively. Transcript levels are depicted normalized to WT control levels. 
Numbers of animals analyzed are denoted in the graphs. Data represent geometric means + 95% 
confidence interval. Asterisks denote statistical significance (ANOVA with Tukey’s post-test, p < 0.05).  
Germ cell lineage and therefore spermatogenesis-specific marker gene DEAD-box helicase 
4 (Ddx4)449,450 levels remained unaltered at four months of age, whereas they decreased in 
AROM+-containing mice at ten months, albeit only significantly to the Bgn-/0 genotype. 
Although Ddx4 levels appeared reduced in AROM+ compared to AROM+ Bgn-/0 mice, this 
trend was not statistically significant. In comparison, transcript levels of spermatogonial 
stem cell marker fibroblast growth factor receptor 3 (Fgfr3)451 did not display significant 
changes in any age group. Levels of Cyp17a1 (Cytochrome P450 family 17 subfamily A 
member 1), a Leydig cell marker gene452,453, were heterogeneous within each genotype in 
both age groups, so no tendency became evident. In contrast, Cd68 levels indicating Cd68-
positive macrophages454 at four and ten months were markedly increased in AROM+ (Bgn-
/0) testes compared to both, Bgn-/0 and WT testes. Yet, differences between AROM+ Bgn-/0 
and AROM+ mice could not be identified (Figure 0.7). These marker-based results imply that 
spermatogonial germ cell and spermatogenesis levels are not substantially altered in the 
AROM+ x Bgn-/0 crossings, nor is the abundance of Leydig cells, although levels are 
inhomogeneous. However, Cd68-positive macrophages are significantly more frequent in 
AROM+ overexpressing mice and independent of the Bgn knock-out. 
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Figure 0.7 Comparison of testicular cell type-specific transcript levels in testes of mice from 
AROM+ x Bgn-/0 crossings. 
Ddx4, Fgfr3, Cyp17a1 and Cd68 transcript levels were evaluated according to genotype of the AROM+ 
x Bgn-/0 F2 offspring at four and ten months, respectively. Transcript levels are depicted normalized to 
WT control levels. Numbers of animals analyzed are denoted in the graphs. Data represent geometric 
means + 95% confidence interval. Asterisks denote statistical significance (ANOVA with Tukey’s post-
test, p < 0.05). 
To characterize inflammatory events in the testes of the AROM+ x Bgn-/0 offspring, receptor 
expression levels previously evaluated in the AROM+ mouse line were compared (Figure 
0.8). At four months of age, Tlr2 and Tlr4 levels were elevated in AROM+-containing mice 
compared to WT mice, but also in AROM+ Bgn-/0 animals compared to AROM+ animals. The 
same pattern was detected for P2rx7, but not for P2rx4, where levels between AROM+ Bgn-
/0 and AROM+ mice were not significantly dissimilar. These findings in four months old mice 
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could not be recapitulated in the ten months old. While AROM+ (Bgn-/0) animals constantly 
exhibited higher receptor levels than WT and Bgn-/0 animals, differences between the two 
could no longer be observed leading to the conclusion that the Bgn deficiency in AROM+ 
mice at four months rather fosters the inflammation-associated receptor expression, whereas 
there appears to be no difference between these two genotypes at ten months. 
 
Figure 0.8 Comparison of Toll-like and purinergic receptor transcript levels in testes of mice 
from AROM+ x Bgn-/0 crossings. 
Tlr2 and 4 and P2rx4 and 7 transcript levels were evaluated according to genotype of the AROM+ x 
Bgn-/0 F2 offspring at four and ten months, respectively. Transcript levels are depicted normalized to 
WT control levels. Numbers of animals analyzed are denoted in the graphs. Data represent geometric 
means + 95% confidence interval. Asterisks denote statistical significance (ANOVA with Tukey’s post-
test, p < 0.05). 
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Possible implications of elevated inflammation-associated receptor expression were 
determined via a selected panel of presumably affected inflammatory cytokines and 
chemokines (Figure 0.9). Transcript levels of the prototypical pro-inflammatory Il1b 
revealed heterogeneous expression in both age groups, albeit without significant changes. 
Consistently, pro-inflammatory cytokine Il6 levels were unaltered or even decreased 
between AROM+ Bgn-/0 and Bgn-/0 mice at ten months of age. In contrast, Tnfa transcript 
expression increased in AROM+ (Bgn-/0) ten months old animals compared to controls. A 
similar development was witnessed for chemokine Ccl2. Its transcript levels were 
significantly elevated in AROM+-containing mice at four and ten months of age, but as for 
Tnfa no difference between AROM+ Bgn-/0 and AROM+ mice was uncovered. Consequently, 
increased cytokine expression, if detectable, appears to be entirely dependent on the AROM+ 
genotype and independent of the Bgn knock-out. 
 
Figure 0.9 Comparison of pro-inflammatory cytokine and chemokine transcript levels in testes 
of mice from AROM+ x Bgn-/0 crossings. 
Il1b, Ccl2, Il6 and Tnfa transcript levels were evaluated according to genotype of the AROM+ x Bgn-/0 
F2 offspring at four and ten months for Il1b and Ccl2 and at ten months only for Il6 and Tnfa. Transcript 
levels are depicted normalized to WT control levels. Numbers of animals analyzed are denoted in the 
graphs. Data represent geometric means + 95% confidence interval. Asterisks denote statistical 
significance (ANOVA with Tukey’s post-test, p < 0.05). 
Taken together, Bgn deficiency did neither alter testicular morphology including cellular 
composition and steroid hormone levels nor inflammation-associated gene expression when 
comparing AROM+ Bgn-/0 and AROM+ mice. Hence, the Bgn knock-out did not gravely 
influence all parameters examined and thus, did not rescue the inflammatory phenotype of 
the AROM+ mouse line. 
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1.7 Purinergic receptors – involved in testicular inflammation? 
In a chronic inflammatory environment as provided in testes of the AROM+ mouse line, 
purinergic receptor levels P2rx4 and P2rx7 in the testes were markedly elevated (Figure 
0.2). The receptors of the purinergic system, especially P2RX4 and P2RX7, have previously 
been linked to inflammatory events and fibrosis in various scenarios455,456. Hence, purinergic 
signaling presumably contributes to testicular inflammation, also in the human. This 
hypothesis was tested utilizing human testicular peritubular cells as a human in vitro model. 
Since biglycan could not be identified as a key factor of testicular inflammation in the 
AROM+ mice, purinergic signaling in peritubular cells was assessed by employing the 
physiologically omnipresent and prevalent purinergic ligand ATP. 
 
1.7.1 Expression profile of purinergic receptors in HTPCs 
As first step, the expression profile of the known seven P2X and eight P2Y receptor isoforms 
was evaluated in HTPCs. For that purpose, HTPCs from four representative individuals were 
assessed employing whole testis lysate as a positive control (Figure 0.10). Expression of 
P2RX2, P2RX3 and P2RY4 mRNAs was found in none of the HTPCs from the four patients 
examined, but in the whole human testis sample. P2RX1, P2RX6, P2RY2, P2RY11, P2RY12, 
P2RY13 and P2RY14 transcript expression was dependent on the individual patient and no 
general pattern among the four patients was discovered. Consistent expression was only 
detected for P2RX4, P2RX5, P2RX7, P2RY1 and P2RY6. These results indicate expression 
of various receptor isoforms providing the possibility of purinergic signaling in HTPCs. 
 
Figure 0.10 Qualitative expression of purinergic receptor transcripts in whole human testis and 
HTPCs. 
Transcript expression of seven P2RX and eight P2RY subtypes in whole human testis lysate (+) and 
HTPCs from four individual patients (1-4) revealed ubiquitous expression for P2RX4, P2RX5, P2RX7, 
P2RY1 and P2RY6, patient-dependent expression for P2RX1, P2RX6, P2RY2, P2RY11, P2RY12, 
P2RY13 and P2RY14 and whole testis expression solely for P2RX2, P2RX3 and P2RY4. Figure shows 
RT-PCR reaction fragments visualized on agarose gels. Negative controls consisted of non-reverse 
transcribed RNA as template (-RT) and a non-template reaction (–). Amplicon lengths are indicated to 
the right of the corresponding fragments. 
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1.7.2 Testicular expression of P2RX4 and P2RX7 
Since P2RX4 and P2RX7 are the receptor subtypes that have been associated with 
inflammatory signaling and tissue fibrosis304,456,457, these two isoforms were examined more 
closely. In addition to consistent basal P2RX4 and P2RX7 transcript expression in cultured 
peritubular cells, transcript level variation was analyzed. In comparison to the mean 
expression, inter-individual P2RX4 levels were similar, whereas inter-individual P2RX7 
levels varied considerably under control conditions. This was observed for control 
conditions at both time points, 6 h and 24 h, that were chosen for RNA evaluation after 
HTPC treatment (only shown at 24 h, Figure 0.11A). Expression of the mature protein in 
HTPCs was found for P2RX4 and P2RX7 in all individuals considered (Figure 0.11B). 
 
Figure 0.11 P2RX4 and P2RX7 expression in cultured peritubular cells. 
A. Basal transcript levels variation among individual patients compared to a hypothetical patient mean 
was moderate for P2RX4 (n = 8) and relatively high for P2RX7 (n = 5) under control conditions (24 h). 
Data represent geometric means ± 95% confidence interval. B. P2RX4 and P2RX7 expression was 
confirmed on protein level in three individual HTPC samples (a-c) via Western blotting. Labels indicate 
corresponding protein ladder weight in [kDa]. A pre-absorption control for P2RX4 expression in 
HTPCs can be found in the Appendix, Supplementary Figure 1. Reproduced and modified from 458 
under a Creative Commons BY license. 
In human testicular sections receptor protein expression was verified by 
immunohistochemistry (Figure 0.12). P2RX4 staining was found in peritubular cells, but 
also in cells of the tubular compartment and in the interstitial tissue. Specificity of the P2RX4 
staining was demonstrated by pre-adsorbed control staining. P2RX7 staining was confined 
to peritubular cells. In sections from patients displaying fibrotically altered tubular wall 
structure, both P2RX4 and P2RX7 expression appeared enhanced in these fibrotically 
thickened wall segments implying a possible association of P2RX4 and P2RX7 expression 
with subfertility-related fibrosis. 
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Figure 0.12 P2RX4 and P2RX7 expression in the human testis. 
Immunohistochemical staining indicating P2RX4 expression in peritubular cells as well as in tubular 
and interstitial compartment (left panel). Staining for testicular expression of P2RX7 was restricted to 
cells of the tubular wall (right panel). In patients exhibiting fibrotically thickened segments of the 
tubular wall (lower panel), receptor staining intensified in these areas (arrowheads). Insets: Negative 
controls (pre-adsorption for P2RX4, omission of primary antibody for P2RX7). Staining was performed 
for n = 4 patients. Bars = 20 µm. Reproduced and modified from 458 under a Creative Commons BY 
license. 
1.7.3 Functional purinergic receptor assessment by Ca2+ imaging in HTPCs 
To explore purinergic receptor functionality, especially potential P2RX4 and P2RX7 
functionality, in HTPCs and thus, putative signal transduction, Ca2+ imaging via an 
intracellular fluorescent dye was employed (Figure 0.13). Since the native purinergic ligand 
ATP activates almost all purinergic receptors except P2RX7 in the low micromolar range217, 
its more specific derivative BzATP was used as agonist for characterization purposes. 
P2RX4 and P2RX7 are sensitive to BzATP (EC50 ~3 µM for P2RX4 and ~5 µM for 
P2RX7)459,460 in particular, yet the applied concentration of 100 µM is also effective on 
further members of the P2X family (EC50 ~1-50 µM)217, but putatively not on members of 
the P2Y family except for P2RY11205,461. 
Response of HTPCs to BzATP as agonist was firmly established since the cells showed 
immediate and transient [Ca2+] elevations as long as exposed to the stimulating agent (Figure 
0.13A1/B1) thereby pointing to the presence of functional purinergic receptors. To 
distinguish, if BzATP-induced Ca2+ signals were mediated via P2X or P2Y receptors, 
external [Ca2+] was removed from the environment. Since P2X receptors are ligand-gated 
ion channels, activation induces pore opening of the receptor to cations in the extracellular 
environment leading to Ca2+ influx into the cytosol. 
P2RX4 P2RX7
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Figure 0.13 Functional purinergic receptor assessment in HTPCs via calcium imaging. 
Top: Graphic representation of representative Ca2+-dependent fluorescent signals in individual HTPCs 
loaded with Fluo4 or Fluoforte (5 µM) over time when exposed to different conditions. Stimulation 
time periods are indicated by horizontal bars. 0.005% trypsin was used as a positive control (+) in all 
experiments. y axis bar represents 20 a.u. fluorescent intensity. Bottom: Pseudocolor single frame 
images of fluorescent intensity at the beginning of the experiment (0 s) and at peak elevations during 
agent and positive control exposure depict the response of the measured HTPCs (arrowhead). 
Bars = 50 µm. A1/B1. Response to agonist exposure (a, 100 µM BzATP) revealed robust Ca2+ transients 
in HTPCs of two different patients. A2. Response to the agonist BzATP was nearly abolished by 
removal of extracellular Ca2+(–), but reestablished after addition of Ca2+ (1.8 mM). B2/B3. Response to 
the agonist BzATP in antagonist (aa, 0.5 µM AZ11645373) pre-treated cells appeared to be of lower 
intensity compared to Ca2+ signals during agonist exposure after antagonist washout.  
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P2Y receptors, however, are G-protein coupled transmembrane receptors. Their activation 
entails signaling processes that eventually lead to the depletion of intracellular Ca2+ stores 
into the cytosol. Thus, Ca2+ signals in the absence of extracellular [Ca2+] indicate 
involvement of the P2RY family, whereas signal abrogation points to P2RX signaling. As 
Figure 0.13A2 illustrates, in the absence of external [Ca2+], the fluorescent signal was almost 
abolished, but recovered when [Ca2+] was added to the environment. This finding implies 
that P2X receptors are the predominant functional receptors in HTPCs. To investigate, if 
P2RX7 is the responsible ion channel in response to BzATP, imaging with the specific 
P2RX7 inhibitor AZ11645373 (0.5 µM; KB = 5-20 nM)462,463 was carried out. Pre-treatment 
of HTPCs with the antagonist led to an attenuated [Ca2+] elevation during BzATP exposure 
compared to the BzATP response without the presence of the inhibitor (Figure 0.13B2-3). 
This suggests, that P2RX7 is a contributing factor, but not the prevalent P2X receptor in 
HTPCs. 
In collaboration with the Spehr Lab at RWTH Aachen University, these findings in HTPCs 
were confirmed and expanded. ATP was applied as agonist and found to induce 
concentration-dependent [Ca2+] elevations in HTPCs (EC50 = 41 µM). Treatment with two 
further antagonists excluded major signal mediation by P2RX1, P2RX2, P2RX3 and P2RX5. 
Together with electrophysiological recordings, which suggested involvement of a highly 
ATP-sensitive P2X receptor, P2RX4 was putatively identified as the prevalently acting 
purinergic receptor in HTPCs458. 
 
1.7.4 ATP-mediated effects in HTPCs 
To correlate ATP activation of purinergic receptors with regulation of cellular mechanisms 
and functions in the human testis, the impact of ATP was evaluated in HTPCs. As 
prerequisite, the possibility of ATP being an endogenous ligand at purinergic receptors of 
peritubular cells was examined. In the testis, extracellular ATP can originate from various 
sources. Sertoli cells have been described to release ATP as physiologic stimulus in 
presumably paracrine activity464,465. In contrast, ATP is also able to act as a danger signal, if 
released from cells undergoing apoptosis280, infiltrating macrophages or mast cells284,466,467. 
While apoptosis is an omnipresent yet tightly controlled process that recruits macrophages 
amongst others281,468, macrophages per se are not common in the healthy human testis and 
their presence has been associated with infertility45. Mast cells, however, are more abundant 
in the testis and increased numbers and localization in and around the peritubular 
compartment have been observed in subfertile patients47,66. Thus, extracellular ATP levels 
are hypothesized to be elevated in the testis under pathophysiologic conditions. 
Immunohistochemical staining for the mast cell marker tryptase in human testicular sections 
confirmed that tryptase-positive mast cells reside in the immediate vicinity of the 
seminiferous tubular wall or even within the tubular wall (Figure 0.14). Hence, they 
represent a natural origin of extracellular ATP in the testis, capable to act on peritubular 
cells. This hypothesis was evaluated using HTPCs as in vitro model. 
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Figure 0.14 Presence of mast cells in and near the tubular wall of the human testis. 
Immunohistochemical staining of the mast cell marker tryptase in testicular sections derived from three 
individual patients revealed presence of tryptase-positive mast cells near and embedded into 
(arrowheads) the tubular wall. Bars = 20 µm. 
Cell viability of HTPCs in response to ATP treatment (1 mM) was assessed (Figure 0.15). 
Via live cell imaging cell number and confluence were determined over a period of 72 h 
exhibiting no significant difference between treated and untreated HTPCs, except that cell 
number at 6 h was even increased in ATP-treated compared to untreated cells. ATP-mediated 
cytotoxicity was monitored via lactate dehydrogenase (LDH) release as a means to detect 
disruption of cellular membranes. ATP-treated HTPCs displayed slightly lower LDH release 
at all time points examined. Although this finding did not reach statistical significance, it 
coincides with marginally elevated cell counts and confluence in ATP-treated HTPCs. 
Altogether, this definitely supports the conclusion that ATP at the concentration used in the 
following studies did not affect HTPC proliferation or viability. 
 
Figure 0.15 Viability of HTPCs during ATP treatment. 
ATP treatment (1 mM) did not negatively alter HTPC viability assessed via determination of cell 
number, confluence and LDH release. Cell number and confluence (n = 4 individual patients) were 
evaluated at 6 h, 24 h, 48 h and 72 h post treatment, LDH release (n = 3 individual patients) was 
measured 24 h, 48 h and 72 h after treatment. Data represent means ± SEM relative to starting point 
(cell number, confluence) or control conditions (cytotoxicity). Asterisks denote statistical significance 
(paired t-test for cell number and confluence, one-sample t-test for LHD release, p < 0.05). Reproduced 
and modified from 458 under a Creative Commons BY license. 
To identify parameters altered by ATP treatment of HTPCs, transcript expression of 
purinergic receptors, peritubular cell characteristic markers and putatively affected pro-
inflammatory cytokines and chemokines was quantified after 6 h and 24 h (Figure 0.16). 
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Transcript levels of purinergic receptors P2RX4 and P2RX7 significantly declined due to 
ATP treatment (Figure 0.16A) implying a negative feedback of ATP on its receptors. 
Concomitantly, transcript levels of smooth muscle cell markers, smooth muscle actin (Actin, 
aortic smooth muscle, ACTA2) and calponin 1 (CNN1) and therefore indicators of 
characteristic peritubular features were significantly decreased as well (Figure 0.16B). 
The known HTPC-secreted stem cell niche regulatory factors CXCL12 and GDNF were 
investigated, too (Figure 0.16C). CXCL12 transcript levels were diminished after 6 h of ATP 
treatment, but restored at 24 h, whereas GDNF transcript levels were increased after 6 h and 
also restored at 24 h.  
 
 
Figure 0.16 Transcript regulation by ATP treatment of HTPCs. 
A. Purinergic receptor P2RX4 and P2RX7 transcript levels significantly decreased by ATP treatment at 
both time points. B. Smooth muscle cell marker ACTA2 and CNN1 transcript levels were significantly 
diminished after ATP treatment at 6 h and 24 h. C. Stem cell niche regulatory factor CXCL12 and GDNF 
transcript levels were up-regulated and down-regulated, respectively, after 6 h of ATP treatment, but 
unaltered at 24 h. D. Cytokine IL1B, IL6 and IL33 and chemokine CCL2 and CCL7 transcript levels 
were all significantly elevated at 24 h of ATP treatment except for IL6, but only IL1B and IL6 transcript 
levels displayed significant increase at 6 h. HTPCs from eight patients were analyzed except for four 
transcripts at 24 h (n = 6 for P2RX7, GDNF and CCL7 and n = 5 for IL1B). Data represent geometric 
means + 95% confidence interval relative to controls. Asterisks denote statistical significance (one-
sample t-test, p < 0.05). Reproduced and modified from 458 under a Creative Commons BY license. 
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These results suggest that ATP-mediated processes may be involved in modulation of stem 
cell niche regulatory factors, albeit in a time-dependent manner. The ultimately expected 
effect of stimulating cells with the danger molecule ATP was an induction in inflammation-
associated molecules, so transcript levels of cytokines IL1B, IL6, IL33 and chemokines 
CCL2 and CCL7 were assessed (Figure 0.16D). Transcript levels of the pro-inflammatory 
IL1B were the only ones significantly up-regulated at both examined time points, while the 
other cytokine and chemokine transcript levels were obviously underlying a time-dependent 
regulation. IL6 transcript levels were significantly elevated solely after 6 h of ATP treatment, 
IL33, CCL2 and CCL7 only after 24 h of ATP treatment. 
To confirm transcriptional results and correlate it with protein secretion of cytokines and 
chemokines, a cytokine profiling assay was used to analyze supernatants of ATP-treated 
HTPCs after 48 h (Figure 0.17 and Figure 0.18). Among the cytokines and chemokines 
altered on transcript level, IL1b and IL33 signals could not be detected in the assay. 
CXCL12, IL6 and CCL2 secretion levels did not seem to be increased, yet CCL7 secretion 
appeared to be augmented, albeit not significantly. An additional chemokine that stood out 
in the profiling assay was CXCL5. Although its protein levels in the supernatant were not 
significantly elevated (Figure 0.17A), a significant increase of CXCL5 transcript abundance 
after 24 h, but not 6 h of ATP treatment became evident (Figure 0.17B). Altogether, 
transcript and supernatant data indicate an ATP-mediated increase in cytokine and 
chemokine production and secretion. However, the underlying processes seem to be 
regulated in a time-dependent manner. 
 
Figure 0.17 Influence of ATP treatment on cytokine and chemokine secretion in HTPCs. 
A. Secreted CXCL12, IL6, CCL2, CCL7 and CXCL5 protein levels were not significantly increased in 
ATP-treated supernatants after 48 h of incubation (n = 4). B. The newly identified CXCL5 was also 
elevated on transcript level by ATP treatment, yet significantly only at 24 h (n = 6) but not 6 h (n = 8). 
Data represent geometric means + 95% confidence interval relative to controls. Asterisks denote 
statistical significance (one-sample t-test, p < 0.05). Reproduced and modified from 458 under a Creative 
Commons BY license. 
Supernatant cytokine profiling also identified factors with diminished secretion levels 
leading to the discovery of a decline in insulin-like growth factor-binding protein 3 
(IGFBP3), osteopontin (secreted phosphoprotein 1, SPP1) and thrombospondin 1 (THBS1) 
secretion (Figure 0.18A). Still, only IGFBP3 and SPP1 decrease reached a level of statistical 
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significance. Transcript level determination of these three candidates revealed reduced 
expression levels (Figure 0.18B), albeit IGFBP3 levels did not decline significantly, SPP1 
levels were only significantly diminished 6 h after ATP treatment and THBS1 levels were 
significantly decreased at both time points reinforcing the proposition of a time-dependent 
regulation of ATP-induced events. 
 
Figure 0.18 Influence of ATP treatment on ECM-associated protein secretion in HTPCs. 
A. Secreted IGFBP3, SPP1 and THBS1 protein levels decreased in ATP-treated supernatants after 48 h 
of incubation (n = 4), albeit only IGFBP3 and SPP1 levels diminished significantly. B. Transcript levels 
of IGFBP3 did not decline significantly in response to ATP treatment, SPP1 transcript levels solely 
after 6 h of ATP treatment and THBS1 transcript levels at 6 h and 24 h after treatment. HTPCs from 
eight patients were analyzed except for SPP1 at 24 h (n = 6). Data represent geometric means + 95% 
confidence interval relative to controls. Asterisks denote statistical significance (one-sample t-test, 
p < 0.05). Reproduced and modified from 458 under a Creative Commons BY license. 
Besides secreted proteins, whole cell lysates of HTPCs that were treated with ATP for 48 h, 
were analyzed by mass spectrometry. In total, 3533 proteins were identified and quantified 
(false discovery rate < 1%; complete list provided in the Supplementary Dataset 1 of 458). 83 
of these proteins were affected in abundance (p-value < 0.05; log2-fold change > |0.6|), 
comprising 38 proteins of decreased and 45 proteins of increased abundance. By interaction 
annotation, clustering of proteins with decreased abundance became evident (Figure 0.19A; 
PPI enrichment p-value 2.61e-11). Significant functional enrichment of KEGG pathways and 
GO terms related to ECM-cell interaction, ECM organization and collagen metabolism was 
observed. The complete lists of candidates and enriched pathways are depicted in the 
Supplementary Dataset 1 of 458. No functional clustering was found among proteins 
increased in abundance. 
From the clustering proteins of decreased abundance, COL1A1, COL1A2, COL3A1, 
COL4A2, COL6A2 and LOX were chosen for transcript analysis in response to ATP (Figure 
0.19B). Levels of all six selected transcripts were significantly diminished 6 h after ATP 
treatment, but recovered control levels 24 h after treatment. These findings support the idea 
of a time-dependent regulation of ATP-induced ECM molecule decrease. 
In summary, ATP principally affected two sets of factors in HTPCs. On one side, smooth 
muscle cell characteristic markers, ECM molecules and ECM-associated factor generally 
declined in abundance. On the other side, pro-inflammatory cytokines and chemokines 
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became up-regulated by ATP. Thus, ATP appears to act as danger molecule on HTPCs 
evoking pro-inflammatory gene expression, meanwhile shifting the HTPC phenotype from 
producing and secreting ECM factors to pro-inflammatory factors. 
 
Figure 0.19 Regulation of ECM components by ATP treatment of HTPCs. 
A. ATP-treated HTPC lysates (n = 6, 48 h) were analyzed by MS/MS and in abundance decreased 
proteins were identified. Interaction annotation uncovered enrichment of in abundance decreased 
proteins for KEGG pathways and GO terms related to ECM organization and collagen metabolism. The 
cluster of interaction between the enriched proteins was visualized via STRING analysis tool469. B. Of 
the in abundance decreased interacting proteins COL1A1, COL1A2, COL3A1, COL4A2, COL6A2 and 
LOX were selected for transcript analysis. After 6 h of ATP treatment all transcript levels were 
significantly reduced, but restored at 24 h post ATP stimulation. HTPCs from eight patients were 
analyzed. Data represent geometric means + 95% confidence interval relative to controls. Asterisks 
denote statistical significance (one-sample t-test, p < 0.05). Reproduced and modified from 458 under a 
Creative Commons BY license. 
 
1.8 NLRP3 – an inflammatory sensor in the testis? 
The NLRP3 molecule is an intracellular sensor of danger to the cell470,471. ATP-gated 
purinergic receptors P2RX4 and P2RX7 are activators of NLRP3290,309,334, which assembles 
together with the adapter molecule ASC and the effector molecule pro-caspase 1 to form the 
NLRP3 inflammasome323. Inflammasome signaling includes maturation and release of IL1 
family cytokines317,470. Thus, this pathway provides one of many possible signaling 
mechanisms for ATP-mediated effects discovered in HTPCs. Hence, NLRP3 expression in 
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the testis was characterized regarding putative inflammatory events. In this context, the 
AROM+ mouse was again employed as a systemic model of sterile inflammation in the testis. 
 
1.8.1 NLRP3 expression in human and mouse testes 
Since testicular NLRP3 has scarcely been described, NLRP3 expression in human and 
mouse testes was characterized. Immunohistochemical staining of testicular sections 
revealed expression in Sertoli cells of both species (Figure 0.20). Staining of Sertoli cells 
primarily ranged from the basal lamina to the lumen of the seminiferous tubules. 
Interestingly, NLRP3 positive staining of Sertoli cells was not restricted to adult, matured 
seminiferous tubules, but already discovered in Sertoli cells of the new-born mouse. In 
addition, interstitial tissue appeared to be stained in the adult mouse. In human, distinct 
staining of peritubular cells was observed, yet staining was less intense than in Sertoli cells 
and heterogeneously distributed among sectors of the seminiferous tubular wall. 
 
Figure 0.20 Expression of NLRP3 in somatic cells of human and mouse testis. 
Immunohistochemical staining indicating NLRP3 expression in representative testicular sections of 
adult human (left panel) and adult and new-born mouse (right panel). Sertoli cell staining (examples 
indicated by arrows) was detected in all sections. In human, peritubular cells were immunopositive as 
well (examples indicated by arrowheads). In mouse, interstitial areas were stained. Insets: Negative 
controls consisting of primary antibody omission in consecutive sections. Bars = 25 µm. ). Reproduced 
and modified from 472 with permission from BioScientifica Ltd. in the format Republish in a 
thesis/dissertation via Copyright Clearance Center. 
Qualitative transcript evaluation confirmed NLRP3 expression in whole human and mouse 
testis as well as in cultured human peritubular cells (Figure 0.21). Hence, it can be stated 
that NLRP3 is expressed in somatic cells of the testis. 
adult
adult new-born
adult
human mouse
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Figure 0.21 Qualitative NLRP3 transcript expression in human and mouse testis. 
NLRP3 transcripts were present in whole human testis and in HTPCs (two individual patients shown; 
left panel). In mouse, Nlrp3 transcripts were detected in WT testes (three individuals shown; right 
panel). Figure shows RT-PCR reaction fragments visualized on agarose gels. Negative controls 
consisted of non-reverse transcribed RNA as template (-RT) and a non-template reaction (–). Amplicon 
lengths are indicated to the right of the corresponding fragments. 
1.8.2 NLRP3 expression in mixed atrophy patients 
NLRP3 as a mediator of inflammatory events may play a part in idiopathic male infertility 
provoked by sterile inflammatory processes in the testis. To explore this possibility, mixed 
atrophy samples were investigated to the advantage of examining seminiferous tubules of 
normal development residing next to tubules of impaired germ cell development (Figure 
0.22).  
 
Figure 0.22 NLRP3 expression in human testes exhibiting mixed atrophy pathology. 
Immunohistochemical staining indicating NLRP3 expression (upper panel) in human testicular sections 
derived from mixed atrophy patients revealed intense Sertoli cell staining (arrow) in seminiferous 
tubules exhibiting impairment of the germ cell lineage (left upper panel). In degenerated tubules 
(asterisks) in another mixed atrophy sample (upper right panel) Sertoli cell staining was completely 
missing while the tubular wall (arrowheads) was intensely stained. Controls (lower panel) consisted of 
primary antibody omission in consecutive sections. Staining was performed for n = 3 mixed atrophy 
patients. Bar = 25 µm. Reproduced and modified from 472 with permission from BioScientifica Ltd. in 
the format Republish in a thesis/dissertation via Copyright Clearance Center. 
human 143 mouse 144
mixed atrophy
NL
RP
3
co
nt
ro
l
*
*
2 Results 42 
As described, staining implying NLRP3 expression was mostly found in Sertoli and 
peritubular cells. Sertoli cells in tubules displaying disturbed germ cell lineage development 
stained prominently for NLRP3, while peritubular cells of these tubules exhibited rather faint 
staining. In contrast, in tubules containing spermatogenic impairment, peritubular cells 
stained intensely, especially in thickened sectors of the seminiferous tubular wall, whereas 
distinct staining of Sertoli cells was entirely lacking. These results point to a probable link 
of the observed NLRP3 expression pattern with events associated with tubular degeneration 
and disturbed spermatogenesis, which are phenotypic characteristics in male subfertile 
patients. 
 
1.8.3 NLRP3 regulation in a mouse model of sterile inflammation 
Again, the AROM+ mouse line was used as a systemic model of chronic sterile inflammation 
and male infertility, to investigate the putative connection of inflammatory processes and 
NLRP3 expression in the testis. Histologic morphology of the WT male testicular sections 
was inconspicuous at the examined age of 2.5 and ten months, respectively. 
 
Figure 0.23 NLRP3 expression in the testis of WT and AROM+ mice. 
Immunohistochemical staining indicating NLRP3 expression in testicular sections of 2.5 and ten months 
old WT and AROM+ mice. WT phenotypes were considered normal, in AROM+ sections germ cell 
vacuolization (crosses) was evident, followed by tubular degeneration (circles) and increased 
abundance of interstitial tissue (asterisk) (ten months only). Staining was primarily observed in Sertoli 
cells, but also in the interstitial tissue of ten months old AROM+ mice. Insets: Negative controls 
consisting of primary antibody omission in consecutive sections. Bars = 25 µm. Reproduced and 
modified from 472 with permission from BioScientifica Ltd. in the format Republish in a 
thesis/dissertation via Copyright Clearance Center. 
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In 2.5 months old AROM+ mice, phenotypic alterations were already emerging in terms of 
germ cell vacuolization, whereas at ten months of age, disturbed tubular structure with 
partial depletion of germ cell lineage cells and interstitial cell conglomerates dominated the 
phenotypic picture (Figure 0.23).  
Staining for NLRP3 expression was prevalently observed in Sertoli cell at all stages. A 
noticeable difference of staining location and intensity between AROM+ and WT animals 
was not recognized at 2.5 months, but became obvious at ten months of age. In addition to 
Sertoli cells, prominent staining in the interstitial region, presumably consisting of a 
combination of hypertrophic macrophages and Leydig cells, was detected. Thus, the altered 
staining pattern for NLRP3 expression with progressing severity of the testicular phenotype 
implies a link between AROM+ overexpression and NLRP3 presence. 
Concomitantly, changes in Nlrp3 expression were quantified by assessing testicular Nlrp3 
transcript levels in AROM+ compared to WT mice at two, five and ten months of age (Figure 
0.24). Nlrp3 transcript levels were elevated in all three age groups, albeit the difference to 
WT levels was statistically significant only in five and ten months old animals. Remarkably, 
comparison of relative transcript expression between AROM+ mice of different age groups 
revealed increasing Nlrp3 levels, supporting the notion of impaired testicular function in the 
AROM+ phenotype coinciding with elevated Nlrp3 expression and inflammatory events. 
 
 
Figure 0.24 Elevated Nlrp3 transcript expression in testes of AROM+ mice. 
Nlrp3 transcript levels were increased in two, five and ten months old AROM+ mice compared to WT 
littermates. Notably, relative Nlrp3 transcript levels of AROM+ mice increased with age. Transcript 
levels are depicted normalized to WT control levels. Numbers of animals analyzed are denoted in the 
graphs. Data represent geometric means + 95% confidence interval. Asterisks denote statistical 
significance (unpaired t-test, p < 0.05). Reproduced and modified from 472 with permission from 
BioScientifica Ltd. in the format Republish in a thesis/dissertation via Copyright Clearance Center. 
To verify a relation between ascending Nlrp3 expression levels and the AROM+ phenotype, 
four weeks old mice treated with an aromatase inhibitor (AI) and a placebo control, 
respectively, for six weeks were analyzed. Nlrp3 transcript levels in the testis were 
significantly elevated in AROM+ (±AI) mice compared to WT (±AI) mice (Figure 0.25). 
Importantly, AI treatment in AROM+ mice significantly reduced Nlrp3 transcript levels, 
although the initial basal levels of the WT could not be restored completely. In contrast, AI 
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treatment did not exhibit an effect in WT mice regarding Nlrp3 levels. Therefore, AI 
treatment reversed increased Nlrp3 expression evoked by aromatase overexpression. 
 
Figure 0.25 Comparison of Nlrp3 transcript levels in testes of 2.5 months old AROM+ mice 
treated with an aromatase inhibitor (AI). 
Nlrp3 transcript levels were evaluated according to genotype of 2.5 months old WT and AROM+ mice 
treated with AI and placebo for six weeks, respectively. Transcript levels are depicted normalized to 
WT control levels. Numbers of animals analyzed are denoted in the graphs. Data represent geometric 
means + 95% confidence interval. Asterisks denote statistical significance (ANOVA with Tukey’s post-
test, p < 0.05). Reproduced and modified from 472 with permission from BioScientifica Ltd. in the format 
Republish in a thesis/dissertation via Copyright Clearance Center. 
In conclusion, NLRP3 expression by somatic cells of the testis in human and mouse 
appeared to be altered in subfertile and infertile pathologies. In the human, NLRP3 was 
differentially expressed in morphologically altered tubules. In the AROM+ mouse 
phenotypic changes associated with chronic inflammation and infertility were accompanied 
by increased Nlrp3 expression levels, that were due to aromatase overexpression. 
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Discussion 
1.9 Deficiency of biglycan does not rescue from an inflammatory environment  
Long-standing work from Schäfer and colleagues established the ECM molecule biglycan 
(BGN) as an autonomous trigger of sterile inflammation, primarily in mouse models of 
hepatic and renal diseases127,180. Its mechanism of joint signaling through TLR2 and 4 and 
P2RX4 and 7 activation was elucidated, thereby implicating biglycan in NLRP3 
inflammasome activation and cytokine production and release169,188. 
 
In this work, initial experiments on human testicular sections showed association of biglycan 
with fibrotic remodeling of the tubular wall, supported by the fact, that biglycan is a known 
contributor to the ECM of the tubular wall129 and vastly produced by cultured peritubular 
cells101. Additionally, I observed an increase of Bgn as well as Tlr2, Tlr4, P2rx4 and P2rx7 
in the testes of AROM+ mice compared to WT mice, which implied augmented abundance 
of biglycan and presumable target receptors in an inflammatory context. Thus, these primary 
findings indicated a putative role of biglycan in contributing to an inflammatory environment 
in the testis. This hypothesis was further supported by the study from Mayer et al., 
confirming the connection of testicular biglycan with tubular fibrosis and reporting signaling 
of biglycan through TLR2 leading to an increment of the pro-inflammatory factors IL6, 
CCL2 and PTX3 in human testicular peritubular cells (HTPCs)95. 
Based on these conclusions, introducing the Bgn knock-out into the AROM+ mouse would 
attenuate or even counteract the chronic inflammatory phenotype observed in the testis of 
this mouse line. Contrasting to this assumption, Bgn deficiency did not substantially affect 
the testicular phenotype of AROM+ mice in terms of weights, testicular morphology, steroid 
levels or transcription profile in both examined age groups. Significant changes between 
AROM+ and AROM+ Bgn-/0 genotypes were noticed solely in transcription levels analyses of 
Tlr2, Tlr4 and P2rx7 in four months old mice. Transcript levels of Tlr2, Tlr4 and P2rx7 were 
found to be enhanced by the Bgn knock-out, an effect that could not be recapitulated at ten 
months of age. However, the cytokine transcript levels associated with TLR and P2X 
receptor signaling remained unaltered in both, four and ten months old mice, contrary to the 
reported increase in HTPCs95. This prompts the notion that biglycan probably has a different 
means of action in the mouse compared to the human testis and might modulate receptor 
expression at a certain age without affecting inflammatory signaling. 
 
Very little is known about biglycan expression in the murine testis. Estradiol has been 
identified as an inducer of biglycan expression the mouse skin473 and in human peritubular 
cells95. Studies of the developing mouse gonads implicated expression in the basement 
membrane as well as in interstitial cells474,475, but the overall amount of biglycan has not 
been investigated. Immunohistochemical staining of testicular sections yielded different 
results in the mouse and human specimens examined. While in human samples, the tubular 
wall and parts of the interstitial tissue stained prominently (Figure 0.1), mouse samples 
exhibited faint to no staining at all (not shown). Different antibodies were tested, but staining 
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in the mouse proved to be difficult and therefore, reliable results could not be produced. 
Other than antibody failure, biglycan levels might be considerably lower in the mouse 
compared to the human testis. 
It is further unexplored, if or how sequestered biglycan regains its soluble state in the testis, 
that is compulsory for biglycan actions on TLRs and P2X receptors127,169,188. Thus, 
bioavailability of biglycan or its fragments might be low in the murine testis and therefore 
not a key element in testicular inflammation. De novo synthesis is the second factor 
influencing bioavailability of biglycan, putatively carried out by infiltrating 
macrophages144,145,165. This correlates with the co-occurrence of macrophages and elevated 
biglycan transcript levels in the AROM+ testes. Yet, in this scenario biglycan production is 
more likely a downstream effect of the initial inflammatory signaling events that evoke 
macrophage infiltration, than their putative cause. 
 
While the sole Bgn knock-out did not exhibit differences in all parameters examined, 
including testicular morphology and inflammatory gene expression compared to WT, a 
phenotype in other systems has been well-documented, particularly in bone and connective 
tissue formation and homeostasis127,151,476. Several knock-out studies evaluated biglycan 
deficiency in combination with the knock-out of another proteoglycan150,154,156,477,478 and 
were able to show synergistic phenotypic defects in case of a double knock-out, thereby 
implying a compensating effect between biglycan and the other proteoglycan. This has 
especially been shown for decorin, the sister molecule of biglycan148,447,448,479. In the human 
testis, decorin abundance has been linked to male infertility62,98 and levels were shown to be 
increased in the testes of AROM+ mice98. Subsequently, decorin transcript levels were 
significantly elevated in AROM+ and AROM+ Bgn-/0 mouse testes, yet a compensating effect 
in the AROM+ Bgn-/0 mice in response to the biglycan knock-out could not be observed. 
 
It has to be noted that the inflammatory phenotype of AROM+ mice in the mixed background 
(FVB/N and C57BL6) seemed less pronounced than in the original mouse line (FVB/N 
background)111-113. AROM+ mice exhibited fewer cases of cryptorchidism and testis weights 
were not significantly reduced compared to the original study112. The AROM+ hallmark, the 
decrease in intratesticular testosterone levels111,112, could not be recapitulated, although 
estradiol levels were strongly elevated. At four months of age testicular morphology in the 
AROM+-containing genotypes was altered regarding the accumulation of interstitial tissue, 
but germ cell vacuolization and disturbed tubular epithelial structures were not detected 
before ten months of age. This again contrasts with the previous findings112,113, where these 
phenotypic changes were visible already at the age of four months. The hypothesis of a lower 
inflammatory degree is further supported by the comparison of Cd68 and Tnfa transcript 
expression. Both were significantly elevated in AROM+ testes, Cd68 indicating an increased 
abundance of macrophages, Tnfa as a marker of inflammatory events, yet fold changes 
between WT and AROM+ mice were smaller than in the original report111. Morphological 
evaluation together with assessment of germ cell lineage and spermatogonial stem cell 
markers Ddx4 and Fgfr3 transcript levels did not imply disturbed spermatogenesis in the 
AROM+ testes of four months old mice at all. Decreased levels of Ddx4 and Fgfr3 in ten 
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months old AROM+ mice, albeit not significantly compared to WT, along with partial 
disruption of the tubular epithelium suggest spermatogenic failure to some, but not full 
extent. These findings could point to either a later onset of infertility characteristics or an 
alleviated phenotype in comparison with the original AROM+ transgenic line. However, it 
has to be stated that a vast degree of heterogeneity between individual mice was observed, 
particularly in histological and transcript level evaluation. The underlying causes for the 
phenotypical differences between original and the backcrossed AROM+ mice cannot readily 
be elucidated. It can only be speculated that the mixture of background may play a part. 
Recently, AROM+ mice in a C57BL6 background were described to display a lower rate of 
cryptorchidism but an almost similar testicular phenotype480,481. 
 
In the AROM+ transgenic line, inflammation-associated male infertility is provoked by a 
hormonal imbalance between estradiol and testosterone. The underlying molecular 
mechanisms of how estradiol causes this phenotype have begun to emerge only recently. 
Estradiol signaling through estrogen receptor a was reported to cause Leydig cell 
hyperplasia, activate macrophages482 and subsequently promote Leydig cell engulfment by 
activated macrophages480. Since excess estradiol increases with age in the AROM+ 
mice111,480, these findings may explain why phenotypic alterations like abundance of Leydig 
cell-macrophage conglomerates and presence of inflammatory signaling factors aggravate 
with increasing age. As a result, loss of spermatogenesis-supporting Leydig cells advances 
with age leading to infertility483. Still, the origin of increasing estradiol levels with age 
remains unclear and further mechanisms participating to the development of the 
inflammatory phenotype have yet to be clarified. 
Thus, results obtained from the AROM+ mice certainly provide valuable insight of 
mechanisms in a sterile inflammatory milieu, but it has to be acknowledged that despite the 
phenotypic similarities of the impaired testes, there are differences between the mouse and 
the human regarding testicular structure and immune cell population, which have to be taken 
into account here.  
 
Altogether, closer investigation is definitely necessary to determine the role of biglycan in 
the testis. Knowledge of testicular expression sites and bioavailability, for instance, will 
contribute to assessing, if biglycan is cause or effect of inflammatory processes in the testis. 
While in vitro results in HTPCs and murine immune cells and in vivo results in murine 
models suggest biglycan as cause, the failure of the biglycan knock-out strategy to counter 
the inflammatory testicular phenotype in the AROM+ infertility mouse model indicates 
otherwise and hints at a more diverse function.  
 
1.10 ATP contributes to testicular inflammation dependent on purinergic signaling  
Extracellular ATP acts as physiological activator of purinergic signaling in the testis. In the 
healthy testis, ATP can be released by Sertoli cells464 or apoptotic cells280, whereas the 
number of ATP-liberating macrophages45 and mast cells47,66 is elevated under 
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pathophysiologic conditions. Thus, ATP signaling is supposed to be amplified under these 
conditions. 
Analysis of HTPCs revealed their vast repertoire of purinergic receptors as putative ATP 
targets. Yet, P2RX4 and P2RX7 were determined prime candidates for ATP-mediated 
signaling, since their in vivo expression in peritubular cells could be related to thickened 
sectors of the tubular wall (Figure 0.12) and thus, infertility-associated fibrotic remodeling. 
These findings correspond to several in vivo studies reporting P2RX4- as well as P2RX7-
mediated fibrosis in various organs, including lung32,457, kidney484, liver485 or heart486.  
Functionality assessment of purinergic receptors in collaboration with the Spehr group at 
RWTH Aachen University revealed the prevalent action of P2RX4 in HTPCs, but joint 
assembly and activation of P2RX4 with P2RX7 could not be completely excluded. At this 
point, further investigation is needed to dissect the exact contributions of individual P2RX 
isoforms, their possible functional interactions or heterotrimer formation and subsequent 
involvement in downstream signaling. 
ATP was found to orchestrate a series of altered transcript and secretion levels in HTPCs. 
Negative feedback on P2RX4 and P2RX7 transcript levels proposes self-limiting actions of 
ATP and provides evidence, that despite contrary results of functionality assessment, P2RX4 
and P2RX7 could both be involved in ATP signal mediation in HTPCs. Several studies 
already suggested a functional regulation of P2RX7 by P2RX4314-316. 
 
The ATP actions discovered in HTPCs essentially promote regulation of two subsets of 
factors. Inflammatory cytokines and chemokines became elevated, while smooth muscle cell 
characteristics and ECM factors declined in expression. 
Among the pro-inflammatory factors positively altered in expression by ATP, especially 
CCL2, IL6 and IL33 abundance have been associated with fostering fibrosis31 and IL1b is a 
prominent promotor of collagen deposition32,487. The monocyte chemoattractant CCL2 and 
the cytokine IL6 have previously been identified in HTPCs96,101 and implicated in 
inflammatory signaling following TLR activation95. IL6 can be produced through P2RX4 
signaling in pro-inflammatory environments308,488, but it is induced via P2RX7 as well489-
492. CCL2 expression, however, has thus far extensively been linked to P2RX7 activation491-
494. Yet, IL6 and CCL2 transcript levels were merely elevated approximately two-fold and 
secretion levels were hardly affected by ATP. In contrast, transcript levels of monocyte 
chemoattractant and sister molecule to CCL2, CCL7, vigorously increased after 24 h of ATP 
treatment and its secretion levels rose threefold compared to untreated controls. This finding 
is consistent to in vitro experiments in murine mast cells, where this effect was attributed to 
P2RX7492. The second factor with increased transcript and secretion levels, CXCL5, is 
prevalently acting as a chemoattractant recruiting neutrophils495, but can be a ligand at the 
same receptor, CC chemokine receptor 2, as CCL2 and CCL7496 and may thus exert mutual 
effects. P2RX4-dependent production and secretion of CXCL5 was very recently discovered 
by another group and seems to be a unique feature of P2RX4 since it has not been related to 
any other P2X receptor including P2RX7497. IL1b and IL33 both belong to the IL1 family 
of pro-inflammatory cytokines. Both were increased in transcript levels by ATP treatment, 
albeit IL33 considerably less than IL1b. IL33 is constitutively expressed in smooth muscle 
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cells498,499 and although IL33 production through the ATP/P2RX7 axis has previously been 
determined in mast cells500, the direct link to P2RX4 is still missing. IL33 and P2RX4 have 
both independently been implicated in neuropathic pain501-504, which could emerge as the 
sought connection between them. IL1b as the prototypical pro-inflammatory cytokine has 
been associated with P2RX4308,309 as well as P2RX7 signaling305,334,377,505, separately or in 
combination314-316,488. Elucidating the underlying mechanisms of P2X receptor-dependent 
IL1b induction identified NLRP3 inflammasome activation as one putative pathway. ATP 
is able to trigger both, the P2RX4/NLRP3 axis309,310 or the P2RX7/NLRP3 axis305,377,505,506 
in different environments and conditions. In addition, an NLRP3 inflammasome-
independent mechanism of IL1b release has been described507. However, IL33 and IL1b 
could not be detected in the supernatant of ATP-treated HTPCs suggesting either that release 
required a certain, missing stimulus or that released amounts were still below detection limit. 
In this context, future investigations regarding the exact ATP signaling pathways will be 
crucial. Pivotal questions, that need to be addressed are a possible interplay of purinergic 
receptors in cytokine synthesis and the potential self-regulation of cytokine induction. 
Immediate responses of HTPCs to ATP revealed functional prevalence of P2RX4. Yet, 
several studies suggested P2RX4 actions controlling P2RX7 signaling314-316, which could 
still indicate an involvement of both receptor isoforms and would not have been detected in 
the immediate time course of the Ca2+ transients monitored for assessing purinergic 
functionality. Distinguishing their roles in ATP-mediated signaling in HTPCs could 
simultaneously reveal mechanisms of cytokine induction since time-dependent regulation 
and differing expression amounts indicate involvement of more than one signaling pathway. 
Initiation of cytokine production, however, could not only be assigned to P2RX signaling, 
but also be influenced by cytokines themselves. IL1B and IL6 transcript levels were 
increased shortly after ATP treatment of HTPCs. IL1b, for instance, holds the ability to 
trigger CCL2 and IL6 induction508, but also prompts CCL7509 or CXCL12510 synthesis. In 
turn, IL6 can initiate CCL2 or CXCL5 production511-514. Hence, some of the observed 
alterations in transcript levels could simply be a by-product of ATP-induced IL1b or IL6 
signaling giving a probable explanation for their time-dependence and different extent. 
 
Smooth muscle cell factors and ECM synthesis are regarded as defining characteristics of 
the peritubular cell type67,83,101,515. Loss of contractile markers in HTPCs has been shown to 
connect to subfertile phenotypes100. Since ATP signaling in HTPCs is to mimic responses 
under pathologic conditions, the observed decline of smooth-muscle cell markers in response 
to ATP agrees with the proposed correlation with subfertile pathologies In line with the 
decrease of smooth muscle cell hallmarks is the link of P2RX4 to reduced smooth muscle 
actin expression in airway remodeling457. Additionally, P2RX4 was reported to influence 
actin cytoskeletal reorganization516,517 and has been negatively related to smooth muscle 
actin as well as collagen production in kidney disease518. 
Collagens are at the core of ECM formation, while the other down-regulated ECM 
components IGFBP3, osteopontin and thrombospondin 1 do not primarily provide ECM 
structure but rather operate in the regulation of matrix-matrix and cell-matrix interactions. 
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IGFBP3 is known as an important modulator of IGF bioavailability in serum and tissues, but 
is expressed by smooth muscle cells as well519. In smooth muscle cells, it has been shown to 
prompt collagen production520 and in turn, can be bound by collagen521. In reverse 
conclusion, decline in IGFBP3 levels could negatively impact collagen expression. IGFBP3 
is further a direct binding partner to osteopontin and thrombospondin 1522. Osteopontin and 
thrombospondin 1 both, are matricellular proteins involved in cell-matrix communication 
and regulation of cellular functions523,524. Osteopontin, which is also expressed by smooth 
muscle cells525, can be induced via P2RX4 signaling in stress conditions526. Moreover, 
osteopontin is an inducer of pro-inflammatory cytokine expression and mediator of 
inflammation527, collagen deposition528 and fibrosis529,530. These findings clearly contrast to 
the detected decrease in osteopontin after ATP treatment. However, most reports indicating 
pro-inflammatory osteopontin function were performed in immune cells, whereas studies 
conducted in human testis are not available. The diverse osteopontin expression pattern 
identified in the testes of other species indicates a complex regulation and function in 
spermatogenesis531-534 and may thus point to an altogether different role of osteopontin in 
peritubular cells, which has yet to be uncovered. Thrombospondin 1, on the contrary, 
interacts not only with collagens535, but is able to induce collagen deposition536. Lack of 
thrombospondin 1 leads to lung inflammation524,537,538. These results are perfectly in line 
with thrombospondin 1 decline simultaneously to collagen decrease and inflammatory factor 
induction in ATP-treated HTPCs. 
Both, smooth muscle cell factors like smooth muscle actin and ECM molecules like 
collagens, lysyl oxidase or thrombospondin 1 are commonly up-regulated in tissue fibrosis31. 
ECM abundance is further associated with fibrotic tubule remodeling and has thus been 
described to be augmented in subfertile phenotypes38. Since up-regulated ECM production 
and secretion could not be found in ATP-treated HTPCs, it can only be deduced that in this 
case the in vitro results do not completely reflect the in vivo situation in infertile patients. In 
this respect, it can only be hypothesized that ATP signaling does not take part in fibrogenesis 
via ECM secretion and smooth muscle actin regulation in pathologic conditions. Still, 
fibrosis is a result of long-term inflammation539 and therefore, the examined time range 
might not be sufficient to detect changes in ECM production. Further, cooperativity of 
peritubular cells with Sertoli cells has been described in regard to ECM synthesis78 and might 
thus argue for the difference of in vitro and in vivo results.  
 
The transiently affected factors, CXCL12 and GDNF are of special nature. Both have 
previously been identified to be secreted by HTPCs101,102 and in vivo crucially contribute to 
spermatogonial stem cell maintenance104,106,107. CXCL12 and ATP have previously been 
suggested to synergistically guide stem cell recruitment540. Yet, the impact of ATP on their 
transcription level was short-lived and marginal (below twofold) and the secretion level of 
CXCL12 was found to remain unaltered by ATP. 
 
On transcript level, time dependence of expression after ATP treatment was observed. In a 
shorter mode of action, ATP treatment induced immediate regulation of smooth muscle cell 
characteristics (ACTA2, CNN1), stem cell niche regulatory factors (CXCL12, GDNF), ECM 
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secretive properties (COLs, LOX, SPP1, THBS1) and a first wave of pro-inflammatory 
factors (IL1B, IL6, CCL2). Subsequently, the effect ceased except for ACTA2, CNN1 and 
IL1B transcript levels, while a second wave of pro-inflammatory cytokines and chemokines 
(IL33, CCL7, CXCL5) was established, that obviously required prolonged ATP stimulation. 
The effects detected on transcript level basis were not necessarily reflected in cell lysates 
and accumulated amounts of protein in the supernatant. This may point to a discrepancy in 
the dynamics of transcript and protein synthesis that could not be mirrored in the 
experimental set-up. These differences could be due to transcript regulation, for instance via 
degradation, before translation. In case of cell lysate analysis, the mass spectrometric 
approach was designed to cover the maximum possible range of proteins. Hence, small 
proteins like cytokines and chemokines were hardly detected. In the supernatant, proteins 
corresponding to transcripts with highly altered relative levels remained below detection 
limit of the profiling assay or did apparently not become secreted more abundantly.  
 
In conclusion, ATP acts as danger molecule in the testis by creating an inflammatory 
environment dependent on purinergic signaling through cytokine and chemokine production 
in HTPCs. Since ATP signaling exhibits a negative effect on contractile and ECM secreting 
properties of HTPCs, a direct connection to fibrogenesis as seen in subfertile pathologies 
could not be proven. With respect to basal receptor expression and transcript and secreted 
protein evaluation, variability of results is likely due to variation of HTPC donors. Donors 
cannot be recruited controlling factors such as age, genetic background and most importantly 
lifestyle and health status, which most certainly account for variation in HTPC responses to 
treatment. Yet, inflammation is a critical factor in infertility and further investigation will 
unravel underlying mechanisms to a greater extent. 
Putative relevance of ATP break-down by ectonucleotidases into its metabolites ADP, AMP 
and adenosine is another point to be considered in future experiments. Ectonucleotidases 
CD39, which catalyzes ATP degradation to ADP/AMP541, and CD73, which generates 
adenosine from AMP542, are readily expressed in immune cells275 including 
macrophages543,544 and mast cells545,546. In addition, expression in the murine testis has been 
identified comprising peritubular cells as well as interstitial macrophages547,548. ATP 
metabolites ADP and adenosine are activators of the P2Y receptors and the P1 receptors, 
respectively549. Hence, ATP degradation could not only cease the observed ATP effects, but 
lead to pro-inflammatory signaling via P2RYs or anti-inflammatory signaling via P1 
receptors275. Consequently, expression of ectonucleotidases in HTPCs, course of putative 
ATP degradation and (joint) activation and functional contribution of all purinergic receptors 
need to be assessed. 
However, cytokines promote inflammation and are thus eminent in infertility. Cytokines are 
not only able to recruit immune cells to the testis, which amplify the immune response to a 
danger signal such as ATP26. They have been implicated in breaching the blood-testis 
barrier, inhibition of steroidogenesis, impairment of sperm integrity and germ cell 
apoptosis27,30. Consequently, cytokine levels, especially in the semen, have already been 
proposed as indicators of testicular health550. ATP-mediated cytokine production could thus 
be monitored as a first sign of testicular inflammation associated with infertility. 
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1.11 The NLRP3 inflammasome specifies a putative signaling pathway in testicular 
inflammation 
Signaling via the NLRP3 inflammasome is a highly feasible mechanism in P2X receptor-
mediated cytokine induction. In this work, the sensor component of the NLRP3 
inflammasome, NLRP3, was discovered to be expressed in somatic cells of the testis of both, 
human and mouse. 
 
In human samples, presence of NLRP3 was validated in Sertoli cells and peritubular cells 
by immunohistochemistry and transcript expression. Although an earlier study failed to 
detect NLRP3 expression in the testis551, these results are in line with a more recent transcript 
analysis in the human testis437. Cooperativity between Sertoli cells and peritubular cells is 
well-established78,79 and both substantially contribute to the blood-testis barrier15,552. 
Further, Sertoli cells as well as peritubular cells have been described to exhibit 
immunoregulatory properties95,553, which may provide a link to the immune factor NLRP3. 
Samples from mixed atrophy (MA) patients were examined for the benefit of analyzing 
seminiferous tubules with normal and disturbed morphology in the same section. I found 
that NLRP3 abundance in MA samples was connected to Sertoli cells in germ cell-depleted 
tubules and peritubular cells in fibrotically thickened walls of degenerated tubules lacking 
Sertoli cells and spermatogenesis. These findings provided evidence for a putative 
association of testicular NLRP3 expression with subfertile pathologies. The NLRP3 
inflammasome pathway has previously been described to be involved in collagen deposition 
and the development of fibrosis in various organs, whereas inhibition of NLRP3 reduced 
fibrogenesis554-557. Further inflammasome-independent NLRP3 is able to contribute to 
collagen production and fibrosis as evidenced in (cardiac) myofibroblasts445. Thus, NLRP3 
could directly contribute to fibrotically thickened walls of seminiferous tubules, where it is 
pronouncedly expressed in MA patients and might provide a putative target for therapeutic 
interference to alleviate the MA phenotype. 
 
In the mouse, I detected NLRP3 expression predominantly confined to Sertoli cells, being 
present already in the immature testes of new-born animals as well as in the adult mouse. 
NLRP3 expression in peritubular cells, unlike in the human, could not be confirmed. Yet, 
the possibility cannot readily be excluded since the peritubular layer in mouse is much 
slimmer than in human515 and staining might therefore not be detectable using 
immunohistochemistry. These results correspond to a previous study of NLRP3 expression 
in primary immature Sertoli cells and an adult Sertoli cell line of the mouse. This report 
further encompassed NLRP3 inflammasome functionality in vitro, including IL1b 
production and thereby implicated the NLRP3 inflammasome in the development of 
inflammation-associated infertility558.  
In the inflammation-associated infertile AROM+ mouse, testicular NLRP3 expression was 
found to be elevated and increased levels corresponded to the severity of the disease. 
Augmented NLRP3 expression in AROM+ testes was reversed by aromatase inhibitor 
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treatment although WT levels were not entirely reestablished. These findings indicate 
NLRP3 elevation as a downstream effect of the hormonal imbalances due to aromatase 
overexpression that also lead to the inflammatory AROM+ phenotype. Hence, NLRP3 
expression in the mouse testis could participate in mechanisms fostering testicular 
inflammation. 
 
In another sterile inflammation and infertility-related mouse model caused though testicular 
ischemia/reperfusion injury by testicular torsion438, a state that can result in infertility if not 
treated appropriately559,560, inhibition of NLRP3 signaling ameliorated testicular damage 
regarding disturbed morphology as well as pro-inflammatory interleukin production. 
Interference with P2RX7 activation resulted in the same phenotype, implying that the 
P2RX7/NLRP3 axis drives testicular inflammation under sterile conditions. NLRP3 
activation has been reported in sterile injury of brain or lung as well561,562 and similarly to 
the testicular study, endogenous ATP as danger signal elicited inflammation via 
P2RX7/NLRP3 signaling by directing neutrophils to the site of sterile hepatic injury286. 
These reports render an involvement of NLRP3 in sterile testicular inflammation in the 
AROM+ line a very likely scenario. Yet, mechanistic action of NLRP3 in the AROM+ testis 
remains to be unraveled. 
This mechanistic ignorance applies to the human testis as well. Although expression of 
NLRP3 in peritubular cells was established in vivo and in vitro, I did not observe an increase 
of NLRP3 transcript levels in ATP-treated compared to untreated HTPCs (not shown). Still, 
IL1B transcript levels were vigorously enhanced (Figure 0.16). This elicits the question, if 
ATP treatment is insufficient for NLRP3 activation or if IL1B elevation is mediated 
independently of the NLRP3 inflammasome in HTPCs. According to the generally accepted 
hypothesis stating that two independent hits of danger are necessary for NLRP3 
inflammasome assembly, sole ATP treatment cannot suffice for NLRP3 inflammasome 
activation. Yet, there are reports of one-step inflammasome activation by stimuli that engage 
in ATP release simultaneously to the priming process289,563-565. ATP then provides the 
second hit by autocrine or paracrine signaling. Even though the possibility of ATP-triggered 
ATP release und thus, ATP acting as first and second hit, exists566-569, ATP has neither been 
reported as priming stimulus nor as lone activator of the NLRP3 inflammasome. This argues 
for an inflammasome-independent mechanism of IL1b induction in ATP-treated HTPCs. 
ATP evoking production of IL1b in an NLRP3 inflammasome-independent manner has 
already been observed in cells of the myeloid lineage507,570, but mechanistic steps still need 
to be resolved. Since IL1B transcription, but not IL1b secretion, was triggered in HTPCs, 
ATP may be solely involved in transcriptional activation in HTPCs. Nevertheless, adding 
the required priming stimulus before ATP treatment could alter the proposed mechanism 
completely in favor of an NLRP3-dependent event. Therefore, ATP actions regarding the 
molecular impact in HTPCs remain to be determined. 
 
Prominent NLRP3 expression in subfertile, inflammatory conditions relates to Muckle-
Wells syndrome (MWS), where constitutively active NLRP3 signaling provides an 
autoinflammatory milieu due to increased IL1b signaling throughout the body323,402. 
3 Discussion 54 
Subfertility is an issue reported in MWS patients412,571. Very few data are available and 
overall systematic assessment of subfertility cases is missing, but patients displayed 
oligozoospermia (reduced sperm count) due to decreased sperm concentration or low semen 
volume or suffered from azoospermia (no sperm count)412. Although the mechanism leading 
to infertility in MWS has not been clarified, excess IL1b production has been 
suggested411,412, since IL1b has been shown to affect steroid synthesis and is associated with 
sperm pathology27,572-574. Treatment with IL1b inhibitors did improve clinical disease 
symptoms but had marginal effects regarding sperm counts412,575. The results led to the 
hypothesis that impairment of spermatogenesis in MWS patients may manifest and progress 
with age and that effective intervention may be achieved by earlier treatment, for instance 
before puberty575. Though, IL1 is considered critical to sperm maturation, at least in rodents, 
so that an optimal time window for treatment with IL1b inhibitors must be determined 
carefully to avoid unwanted side-effects411. 
However, case studies have to be expanded and systematic investigation is needed to provide 
insight to mechanistic details. A direct correlation of the gain-of-function mutations in the 
NLRP3 gene to subfertility remains to be confirmed. Still, excess NLRP3 signaling appears 
to be associated with subfertile phenotypes as discovered in testicular sections of MA 
patients. 
 
NLRP3 in the testis could further promote inflammasome-independent actions. A variety of 
alternative NLRP3 functions has been described, in particular in non-immune cells. In some 
cases, NLRP3 actions are of inflammatory nature434,440, while especially in epithelial cells 
NLRP3 is involved in non-inflammatory processes. Maintenance of epithelial barriers has 
been suggested441,442 and NLRP3 activity in murine Sertoli cells implicated NLRP3 in the 
regulation of claudins, which are critical components to the tight junctions participating to 
the blood-testis barrier. Hence, NLRP3 has been proposed to contribute to formation and 
maintenance of the blood-testis barrier439. Yet, the blood-testis barrier is established in 
parallel to spermatogenesis at the onset of puberty576, whereas NLRP3 was constitutively 
expressed at different stages of sexual development in the mouse, i.e. before and after onset 
of sexual maturity. Together with the increased NLRP3 expression associated with 
inflammation and/or subfertility in mouse and human, this finding argues for two distinct 
roles of NLRP3 in the testis. 
NLRP3 was constantly present in Sertoli cells throughout developmental stages and 
expression was independent of an inflammation-related phenotype, which indicates a non-
inflammatory and therefore most likely inflammasome-independent function in the healthy 
testis. It is tempting to speculate on a non-inflammatory role of NLRP3 in testicular 
immunoregulation or testicular homeostasis, but there is currently no evidence suggesting 
either. However, under certain circumstances, which might be evoked by hormonal 
imbalances or release of endogenous DAMPs, the NLRP3 inflammasome in the testis could 
be activated and participate to inflammatory events via IL1b secretion and pro-fibrotic 
collagen deposition that eventually promote subfertile or infertile pathologies. 
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The results altogether confirm NLRP3 expression in somatic testicular cells of mouse and 
human and indicate involvement in non-inflammatory as well as inflammatory processes 
putatively leading to subfertile phenotypes. Despite promising initial observations, the 
investigation of NLRP3 actions in the testis has to be extended. It remains to be determined, 
if NLRP3 forms a functional inflammasome with ASC and caspase 1 that yields cytosolic 
ASC specks and induces IL1b release as well as pyroptotic cell death or if NLRP3 can 
contribute to testicular inflammation in an inflammasome-independent manner. HTPCs 
could be employed as an in vitro model to study these questions in terms of molecular 
mechanisms, the AROM+ mouse line could serve as a model to place the discovered 
mechanistic actions into a systemic inflammatory and subfertile context. Regardless the 
efforts in elucidating testicular NLRP3 function, NLRP3 activation and signaling can solely 
provide one possible option in generating a cytokine and chemokine response in the testis 
and alternative pathways need to be considered as well. 
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Material and Methods 
1.12 Material 
1.12.1 Testicular tissue material 
Human testicular tissue samples for immunohistochemistry and explant culture of HTPCs 
were obtained via collaborations with Prof. Dr. J.U. Schwarzer (Andrology Center, Munich, 
Germany) and Prof. Dr. F.-M. Köhn (Andrologicum, Munich, Germany). Samples for HTPC 
culture and immunohistochemistry stemmed from patients undergoing surgery to obtain 
tissue for TESE (testicular sperm extraction) or reconstructive surgery of the vas deferens. 
Thus, samples were derived from patients exhibiting normal spermatogenesis as well as 
patients suffering sub- or infertility symptoms. All patients granted informed consent for the 
scientific use of the material and the local ethical committee (Ethikkommission, TUM 
School of Medicine, Technical University of Munich, Munich, Germany, project number 
5158/11 in terms of DFG MA 1080/23-1) approved the study. Experiments were performed 
in compliance with all relevant guidelines and regulations. 
 
1.12.2 cDNA 
cDNA Manufacturer 
Human testis Primerdesign, Cambridge, UK 
Human testis Daniel Aigner, Anatomy III – Cell Biology, 
BMC, LMU, Munich, Germany 
 
1.12.3 Cell culture media and supplements 
Medium/Supplement Manufacturer 
CASYclean Omni Life Sciences, Bremen, Germany 
CASYton Omni Life Sciences, Bremen, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, MO, USA 
DMEM, high glucose Gibco, Paisley, UK 
DMEM, high glucose, no glutamine, no phenol 
red 
Gibco, Paisley, UK 
Dulbecco’s PBS Gibco, Paisley, UK 
Fetal bovine serum (FBS) Capricorn Scientific, Ebsdorfergrund, 
Germany 
Glutamine (200 mM) Gibco, Paisley, UK 
Penicillin/streptomycin Biochrom, Berlin, Germany 
Trypsin/EDTA Biochrom, Berlin, Germany 
 
1.12.4 Antibodies 
Antibody Dilution Manufacturer 
Biotinylated goat anti mouse secondary 
antibody 
IHC: 1:500 Jackson Immunosearch 
Laboratories, Newmarket, UK 
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Biotinylated goat anti rabbit secondary 
antibody 
IHC: 1:500 Jackson Immunosearch 
Laboratories, Newmarket, UK 
Monoclonal mouse anti-Mast Cell 
Tryptase antibody (M70529) 
IHC: 1:300 Dako, Carpinteria, CA, USA 
Monoclonal rabbit anti-P2RX7 IgG 
(GTX62830) 
WB: 1:500 GeneTex/Biozol, Eching, 
Germany 
Mouse IgG from serum IHC: 1:5000, 
1:10000 
Sigma-Aldrich, St. Louis, MO, 
USA 
Peroxidase (POX) conjugated goat anti 
rabbit secondary antibody 
WB: 1:5000, 
1:10000 
Jackson Immunosearch 
Laboratories, Newmarket, UK 
Polyclonal rabbit anti-BGN IgG 
(HPA003157) 
IHC 1:500 Sigma-Aldrich, St. Louis, MO, 
USA 
Polyclonal rabbit anti-NLRP3 IgG 
(R30750) 
IHC: 1:500, 
1:1000 
NSJ Bioreagents, San Diego, CA, 
USA 
Polyclonal rabbit anti-P2RX4 IgG 
(HPA039494) 
IHC: 1:50 
WB: 1:100 
Atlas Antibodies, Stockholm, 
Sweden 
Blocking peptide PrEST Antigen P2RX4 20x of antibody Atlas Antibodies, Stockholm, 
Sweden 
Polyclonal rabbit anti-P2RX7 IgG 
(HPA042013) 
IHC: 1:50 Atlas Antibodies, Stockholm, 
Sweden 
Rabbit IgG IHC: 1:5000, 
1:10000 
Chemicon/ EMD Millipore, 
Temecula, CA, USA 
 
1.12.5 Oligonucleotide primer 
Gene Reference ID Nucleotide sequences 
Amplicon 
size 
Annealing 
temperature 
Bgn NM_007542.4 
5´-GAC AAC CGT ATC CGC AAA GT-3´ 
5´-CAA AGG CTC CTG GTT CAA AG-3´ 
115 bp 60°C 
Ccl2 NM_011333.3 
5’-GGC TCA GCC AGA TGC AGT TAA-3’ 
5’-CCA GCC TAC TCA TTG GGA TCA-3’ 
80 bp 60°C 
Cd68 NM_001291058.1 
5´-CCA GCT GTT CAC CTT GAC CT-3´ 
5´-AGA GGG GCT GGT AGG TTG AT-3´ 
208 bp 60°C 
Cyp17a1 NM_007809.3 
5´-CAA GCC AAG ATG AAT GCA GA-3´ 
5´-AGG ATT GTG CAC CAG GAA AG-3´ 
165 bp 59°C 
Dcn NM_001190451.1 
5´-TGA GCT TCA ACA GCA TCA CC-3´ 
5´-AAG TCA TTT TGC CCA ACT GC-3´ 
181 bp 60°C 
Ddx4 NM_001145885.1 
5´-CCA AGC GAG GTG GCT GCC AAG ATG-3´ 
5´-AGA ACC AAA AAG GCC ACC ACC ACG-3´ 
170 bp 60°C 
Fgfr3 NM_008010.5 
5´-ATG ACG AAG ATG GGG AGG ACG-3´ 
5´-CAG CGG AAG CGG ACA GTG TT-3´ 
118 bp 58°C 
Hprt NM_013556.2 
5´-CTG GTG AAA AGG ACC TCT CGA A-3´ 
5´-CTG AAG TCA TCA TTA TAG TCA AGG 
GCA T-3´ 
110 bp 60°C 
Il1b NM_008361.3 
5´-TGA AGT TGA CGG ACC CCA AA-3´ 
5´-TGA TGT GCT GCT GCG AGA TT-3´ 
101 bp 60°C 
Il6 NM_031168.1 
5´-GTT CTC TGG GAA ATC GTG GAA A-3´ 
5´-AAG TGC ATC ATC GTT GTT CAT ACA-3´ 
78 bp 60°C 
Nlrp3 NM_145827.3 5´-TCT CCA CAA TTC TGA CCC ACA-3´ 144 bp 60°C 
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5´-ACA TTT CAC CCA ACT GTA GGC-3´ 
P2rx4 NM_011026.2 
5´-GAC CAA CAC TTC TCA GCT TGG-3´ 
5´-GTG ACG ATC ATG TTG GTC ATG-3´ 
105 bp 60°C 
P2rx7 NM_011027.3 
5´-TTA TGG CAC CGT CAA GTG G-3´ 
5´-TCT CCG TCA CCT CTG CTA TG-3´ 
146 bp 60°C 
Ppia NM_008907.1 
5´-CATCCTAAAGCATACAGGTCCTG-3´ 
5´-TCCATGGCTTCCACAATG-3´ 
165 bp 60°C 
Ptx3 NM_008987.3 
5´-TAG TGT TGG TGG TGG GTG GA-3´ 
5´-CAT GCT CCC CTG CTC TGA AC-3´ 
110 bp 60°C 
Rpl19 NM_009078.2 
5´-CTG AAG GTC AAA GGG AAT GTG-3´ 
5´-GGA CAG AGT CTT GAT GAT CTC-3´ 
195 bp 60°C 
Tlr2 NM_011905.3 
5´-CTC CCA CTT CAG GCT CTT TG-3´ 
5´-TTA TCT TGC GCA GTT TGC AG-3´ 
110 bp 60°C 
Tlr4 NM_021297.2 
5´-GGA CTG GGT GAG AAA TGA GC-3´ 
5´-AGC CTT CCT GGA TGA TGT TG-3´ 
125 bp 60°C 
Tnfa NM_013693.3 
5’-CAC AGA AAG CAT GAT CCG CG-3’ 
5’-TGA TGA GAG GGA GGC CAT TTG-3’ 
209 bp 59°C 
 
Gene Reference ID Nucleotide sequences 
Amplicon 
size 
Annealing 
temperature 
ACTA2 NM_001613.2 
5’-ACA ATG AGC TTC GTG TTG CC-3’ 
5’-GAG TCA TTT TCT CCC GGT TGG-3’ 
90 bp 59°C 
CCL2 NM_002982.3 
5’-CAG CCA GAT GCA ATC AAT GCC-3’ 
5’-TGG AAT CCT GAA CCC ACT TCT-3’ 
190 bp 58°C 
CCL7 NM_006273.3 
5´-TGG AGA GCT ACA GAA GGA CCA-3´ 
5´-GTG GGG TCA GCA CAG ATC TC-3´ 
94 bp 58°C 
CNN1 NM_001299.5 
5´-CGA AGA CGA AAG GAA ACA AGG T-3´ 
5´-GCT TGG GGT CGT AGA GGT G-3´ 
186 bp 62°C 
COL1A1 NM_000088.3 
5´-AAG AGG AAG GCC AAG TCG AG-3´ 
5´-CAC ACG TCT CGG TCA TGG TA-3´ 
91 bp 60°C 
COL1A2 NM_000089.3 
5´-CCG GAG ATA GAG GAC CAC GT-3´ 
5´-CAG CAA AGT TCC CAC CGA GA-3´ 
132 bp 60°C 
COL3A1 NM_000090.3 
5´-GGT GGT TTT CAG TTT AGC TAC GG-3´ 
5´-TGA TGT TCT GGG AAG CTC GG-3´ 
106 bp 59°C 
COL4A2 NM_001846.3 
5´-AAG GAA TCA TGG GCT TTC CT-3´ 
5´-CTC TGG CAC CTT TTG CTA GG-3´ 
204 bp 60°C 
COL6A2 NM_001849.3 
5´-GTC ATG AAA CAC GAA GCC TAC G-3´ 
5´-CAC CCT TCT GTC CAC GGT AG-3´ 
97 bp 59°C 
CXCL12 NM_000609.6 
5´-TCA GCC TGA GCT ACA GAT GC-3´ 
5´-CTT TAG CTT CGG GTC AAT GC-3´ 
161 bp 60°C 
CXCL5 NM_002994.4 
5´-CAG CGC TCT CTT GAC CAC TA-3´ 
5´-GAA CTC CTT GCG TGG TCT GT-3´ 
194 bp 60°C 
GDNF NM_000514.3 
5´-GCA GAC CCA TCG CCT TTG AT-3´ 
5´-ATC CAC ACC TTT TAG CGG AAT G-3´ 
93 bp 60°C 
HPRT NM_000194.2 
5´-CCT GGC GTC GTG ATT AGT GA-3´ 
5´-GGC CTC CCA TCT CCT TCA TC-3´ 
163 bp 60°C 
IGFBP3 NM_001013398.1 
5’-ACA GCC AGC GCT ACA AAG TT-3’ 
5’-CTA CGG CAG GGA CCA TAT TC-3’ 
100 bp 59°C 
IL1B NM_000576.2 
5´-CTT GGT GAT GTC TGG TCC ATA TG-3´ 
5´-GGC CAC AGG TAT TTT GTC ATT AC-3´ 
127 bp 60°C 
IL33 NM_001199641.1 5´-AGG TGA CGG TGT TGA TGG TAA-3´ 142 bp 60°C 
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5´-AAG GAC AAA GAA GGC CTG GT-3´ 
IL6 NM_000600.4 
5´-AAC CTG AAC CTT CCA AAG ATG G-3´ 
5´-TCT GGC TTG TTC CTC ACT ACT-3´ 
159 bp 60°C 
LOX NM_001317073.1 
5´-CAC ACA CAC AGG GAT TGA GTC-3´ 
5´-AGT CAG ATT CAG GAA CCA GGT-3´ 
147 bp 60°C 
NLRP3 NM_004895.4 
5´-GTG TTT CGA ATC CCA CTG TG-3’ 
5´-TCT GCT TCT CAC GTA CTT TCT G-3’ 
143 bp 59°C 
P2RX1 NM_002558.3 
5´-CTG GGA TGT GGC TGA CTA CG-3´ 
5´-AAG TTC TCG GCC TCT CGG A-3´ 
303 bp 60°C 
P2RX2 NM_001282164.1 
5´-GCC TCT GTC AGC CAA TTT CTG-3´ 
5´-TCT CCA CGA TAA AGC CCA GC-3´ 
196 bp 60°C 
P2RX3 NM_002559.3 
5´-TCC CCA GGC TAC AAC TTC AG-3´ 
5´-TTG AAC TTG CCA GCA TTC CC-3´ 
128 bp 60°C 
P2RX4 NM_001256796.1 
5´-AGA TGC GAC CAC TGT GTG TA-3´ 
5´-GTT GAG ACT CCG TTG CTG TG-3´ 
78 bp 60°C 
P2RX5 NM_175080.2 
5´-GTC AGA AGG GGA ACG GAT CT-3´ 
5´-GCA ATT CAC GTG CTC CTG T-3´ 
64 bp 60°C 
P2RX6 NM_005446.3 
5´-TGA GAT CTG GAG TTG GTG CC-3´ 
5´-ATT GTG GTT CAT AGC GGC AG-3´ 
188 bp 60°C 
P2RX7 NM_002562.5 
5´-TGT CCC ATT TTC CGA CTA GG-3´ 
5´-CCA ACG GTC TAG GTT GCA GT-3´ 
120 bp 60°C 
P2RY1 NM_002563.4 
5´-AGT TTT ACT ACC TGC CGG CT-3´ 
5´-CAG CAC GTA CAA GAA GTC GG-3´ 
158 bp 60°C 
P2RY2 NM_176072.2 
5´-ATC AAT GGC ACC TGG GAT GG-3´ 
5´-ACG CAT TCC AGG TCT TGA GG-3´ 
169 bp 60°C 
P2RY4 NM_002565.3 
5´-CGT GCC CAA CCT GTT CTT TG-3´ 
5´-GCA AAC AAG AGT GAC CAG GC-3´ 
157 bp 60°C 
P2RY6 NM_176797.2 
5´-CCG CGA GAAC TTC AAG CAA C-3´ 
5´-AAG GGC CAG TGA TCA CCT TG-3´ 
222 bp 60°C 
P2RY11 NM_001198690.1  
5´-GCG GCC TAC AGA GCG TAT AG-3´ 
5´-GCA CAT AGG AGC TGG CGT AG-3´ 
190 bp 60°C 
P2RY12 NM_022788.4 
5´-GCA GCC GAG AGA CAA GAA TG-3´ 
5´-GGG GAC TTT ACC TAC ACC CC-3´ 
196 bp 60°C 
P2RY13 NM_176894.2 
5´-ACT GCC GCC ATA AGA AGA CA-3´ 
5´-GCA CCG CTC AGA TCT GTT GA-3´ 
105 bp 60°C 
P2RY14 NM_001081455.1 
5´-AAA CGC TCA CTG GGC AAA AC-3´ 
5´-GAG GCT GTG TGG AGG TTG AA-3´ 
120 bp 60°C 
RPL19 NM_000981.3 
5´-AGG CAC ATG GGC ATA GGT AA-3´ 
5´-CCA TGA GAA TCC GCT TGT TT-3´ 
199 bp 60°C 
SPP1 NM_001040058.1 
5´-TTT TCA CTC CAG TTG TCC CC-3´ 
5´-TAC TGG ATG TCA GGT CTG CG-3´ 
109 bp 59°C 
THBS1 NM_003246.3 
5´-AGT CGT CTC TGC AAC AAC CC-3´ 
5´-AGC TAG TAC ACT TCA CGC CG-3´ 
148 bp 60°C 
 
All oligonucleotides, including the random 15mer oligonucleotides for cDNA synthesis, 
were synthesized by Metabion (Planegg, Germany). 
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1.12.6 Chemicals 
Chemical Manufacturer 
2′(3′)-O-(4-Benzoylbenzoyl)adenosine 5′-
triphosphate (BzATP) 
Sigma-Aldrich, St. Louis, MO, USA  
3-[1-[[(3'-Nitro[1,1'-biphenyl]-4-
yl)oxy]methyl]-3-(4-pyridinyl)propyl]-2,4-
thiazolidinedione (AZ11645373) 
Tocris, Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
Acetic acid Merck, Darmstadt, Germany  
Acrylamide AppliChem, Darmstadt, Germany  
Adenosine triphosphate (ATP) Sigma-Aldrich, St. Louis, MO, USA  
Agarose  Biozym, Hessisch Oldendorf, Germany  
Albumin standard  Pierce, Thermo Fischer Scientific, Waltham, 
MA, USA  
Ammonium persulfate (APS)  Merck, Darmstadt, Germany  
Boric acid  Roth, Karlsruhe, Germany  
Bovine serum albumin (BSA) Sigma-Aldrich, St. Louis, MO, USA  
Bromophenol blue Serva, Heidelberg, Germany  
Citric acid monohydrate Roth, Karlsruhe, Germany  
dNTPs (dATP/dCTP/dGTP/dTTP)  Qiagen, Hilden, Germany 
EDTA  Roth, Karlsruhe, Germany  
Entellan Merck, Darmstadt, Germany  
Ethanol, absolute AppliChem, Darmstadt, Germany  
Ethanol/Walkol Waldeck, Münster, Germany 
Finrozole Vetcare, Helsinki, Finland 
Fluo4-AM Molecular Probes, Eugene, OR, Germany 
Fluoforte Enzo Life Sciences, Lausen, Switzerland 
Formaldehyde (37%), acid-free Roth, Karlsruhe, Germany  
Glycerol Merck, Darmstadt, Germany  
Glycine  
H2O2 (30%)  
AppliChem, Darmstadt, Germany  
Sigma-Aldrich, St. Louis, MO, USA  
Glycoblue Coprecipitant Invitrogen, Life Technologies, Carlsbad, CA, 
USA 
Hemalum solution acid Roth, Karlsruhe, Germany  
Hydrochloric acid Roth, Karlsruhe, Germany  
Isopropanol  Roth, Karlsruhe, Germany  
Methanol  Roth, Karlsruhe, Germany  
MidoriGreen Advance DNA Stain Nippon Genetics, Düren, Germany  
Milk powder Vitalia, Bruckmühl, Germany  
N,N,N’,N’-Tetramethylethylenediamine 
(TEMED)  
Bio-Rad, Hercules, CA, USA  
Normal goat serum Sigma-Aldrich, St. Louis, MO, USA 
Normal mouse serum Dianova, Hamburg, Germany 
Normal rabbit serum Chemicon/ EMD Millipore, Temecula, CA, 
USA 
Nuclease eliminator Amresco, Solon, OH, USA 
Nuclease free water Ambion, Austin, TX, USA 
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PBS Dulbecco Biochrom, Berlin, Germany 
pH calibration standard pH 4/7/10  Roth, Karlsruhe, Germany  
Picric acid AppliChem, Darmstadt, Germany  
Piperazine-N,N′-bis(2-ethanesulfonic acid) 
(PIPES) 
Roth, Karlsruhe, Germany  
Ponceau S  Sigma-Aldrich, St. Louis, MO, USA 
Protease and Phosphatase Inhibitor Tablets  Pierce, Thermo Fischer Scientific, Waltham, 
MA, USA  
RNase free water Qiagen, Hilden, Germany 
RNasin Plus Promega, Madison, WI, USA 
Sodium acetate (NaAc) Roth, Karlsruhe, Germany  
Sodium chloride (NaCl) Roth, Karlsruhe, Germany  
Sodium deoxycholate, DOC Roth, Karlsruhe, Germany  
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe, Germany  
Sodium(II) citrate dihydrate Roth, Karlsruhe, Germany  
Sucrose Merck, Darmstadt, Germany  
Tris Roth, Karlsruhe, Germany  
TRIsure Bioline reagents Ltd., London, UK 
Triton X 100  Roth, Karlsruhe, Germany  
Tween 20 Roth, Karlsruhe, Germany  
Xylol Roth, Karlsruhe, Germany  
β-Mercaptoethanol  Sigma-Aldrich, St. Louis, MO, USA 
 
1.12.7 Buffers and solutions 
Buffer Composition 
100x Ponceau S 2% (w/v) Ponceau S 
1% (v/v) Acetic acid 
10x Laemmli buffer 0.25 M Tris 
1.92 M Glycine 
1% (w/v) SDS 
10x TBE 0.9 M Tris 
0.9 M Boric acid 
0.2 M EDTA 
pH 8.0 
10x Transfer buffer 0.25 M Tris 
1.92 M Glycine 
pH 8.3 
1x Transfer buffer 10% (v/v) 10x Transfer buffer 
10% (v/v) methanol 
20x TBST 2 M NaCl 
0.08 M Tris 
1% (v/v) Tween 20 
pH 7.5 
4x Separating gel buffer 1.5 M Tris 
0.01 M EDTA 
0.4% (w/v) SDS 
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pH 8.8 
4x Stacking gel buffer 0.5 M Tris 
0.01 M EDTA 
0.4% (w/v) SDS 
pH 6.8 
APS (10%) 10% (w/v) APS in ddH2O 
Bouin’s solution 0.9% (v/v) Picric acid 
9% (v/v) Formaldehyde 
5% (v/v) Acetic acid 
Bromophenol blue 0.1 M Tris 
24% (v/v) Glycerol 
5% (w/v) SDS 
Traces of Bromophenol blue 
pH 6.8 
Citrate buffer 1.8 mM Citric acid 
8.2 mM Sodium(II) citrate 
pH 6.0 
NPE buffer 0.15 M NaCl 
10 mM PIPES 
1 mM EDTA 
pH 7.2 
PBS 9.55 g PBS Dulbecco in 1 L dH2O 
pH 7.5 
Protease and Phosphatase inhibitor cocktail 1 Inhibitor tablet in 10 mL Sample buffer 
RIPA buffer 0.15 M NaCl 
50 mM Tris 
0.5% (w/v) Sodium deoxycholate 
0.1% (w/v) SDS 
1% (v/v) Triton X 100 
pH 8.0 
Sample buffer for protein lysates 62.5 mM Tris 
0.3 M Sucrose 
2% (w/v) SDS 
pH 6.8 
Tris/HCl (50 mM) 50 mM Tris 
40 mM HCl 
pH 7.6 
 
1.12.8 Kits, molecular-weight size markers and assays 
Kit Manufacturer 
BCA Protein Assay Kit Pierce, Thermo Scientific, Rockford, IL, USA 
DC Protein Assay Kit Bio-Rad, Hercules, CA, USA  
DNase I Amplification Grade Kit Invitrogen, Life Technologies, Carlsbad, CA, 
USA 
GeneRuler Low Range DNA Ladder Thermo Scientific, Rockford, IL, USA 
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LDH Cytotoxicity Assay Kit Pierce, Thermo Scientific, Rockford, IL, USA 
Loading dye (6x) Thermo Scientific, Rockford, IL, USA 
PageRuler Plus Prestained Protein Ladder Thermo Scientific, Rockford, IL, USA 
Protease and Phosphatase Inhibitor Tablets Pierce, Thermo Scientific, Rockford, IL, USA 
Proteome Profiler Human XL Cytokine Array 
Kit 
R&D Systems, Minneapolis, MN, USA 
QuantiFast SYBR Green PCR Kit  Qiagen, Hilden, Germany 
RNeasy Plus Micro Kit Qiagen, Hilden, Germany 
SensiFAST cDNA Synthesis Kit Bioline reagents Ltd., London, UK 
SIGMAFAST 3,3’-Diaminobenzidine (DAB) 
tablets  
Sigma-Aldrich, St Louis, MO, USA 
SuperScript II Reverse Transcriptase Kit Invitrogen, Life Technologies, Carlsbad, CA, 
USA  
SuperSignal West Femto Maximum Sensitivity 
Substrate 
Pierce, Thermo Scientific, Rockford, IL, USA 
Vectastain ABC Kit  Vector Laboratories, Burlingame, CA, USA  
Wizard SV Gel and PCR Clean-Up System Promega, Madison, WI, USA 
 
1.12.9 Equipment 
Equipment Manufacturer 
-20°C freezer Liebherr, Bulle, Switzerland 
-80°C freezer Herafreeze HFU Thermo Fisher Scientific, Rockford, IL, USA 
4°C fridge Liebherr, Bulle, Switzerland 
Analytical balance DualRange XS 205  Mettler-Toledo, Greifensee, Switzerland  
Bio-Rad gel Doc XR+ Bio-Rad, Hercules, CA, USA  
Camera 18.2 Color Mosaik Visitron Systems, Puchheim, Germany  
Camera ProgRes MF cool  Jenoptik, Jena, Germany  
CASY TT Cell Counter and Analyser System Schärfe System, Reutlingen, Germany 
Centrifuge 5418 Eppendorf, Hamburg, Germany 
Centrifuge Microfuge 1-14  Sigma, Osterode am Harz, Germany 
Centrifuge Multifuge X3 Heraeus, Hanau, Germany  
Chemi Smart 5000  PeqLab, Erlangen, Germany 
CoolCell Cell Freezing Container BioCision, San Rafael, CA, USA 
Cooling centrifuge Biofuge Fresco Heraeus, Hanau, Germany  
Drying oven Heraeus, Hanau, Germany  
Electric stirrer Multipoint HP15  Variomag, Daytona Beach, FL, USA 
FastGene GelPic LED Box Nippon Genetics, Düren, Germany  
Gel chambers, gel combs, gel slides  Bio-Rad, Hercules, CA, USA  
Glass plates, combs, casting stand Bio-Rad, Hercules, CA, USA  
ibidi Gas Incubation System  ibidi, Planegg, Germany  
ibidi Heating System  ibidi, Planegg, Germany  
Ice maker Scotsman MF46 Scotsman Ice Systems, Ipswich, UK 
IKA magnetic stirrer RCT  IKA-Werke, Staufen, Germany  
IKA microtiter shaker MTS4  IKA-Werke, Staufen, Germany  
IKA minishaker MS 2  IKA-Werke, Staufen, Germany  
Incubation/Inactivation water bath 1003 GFL, Burgwedel, Germany 
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Incubator Galaxy 170 S New Brunswick/Eppendorf, Hamburg, 
Germany 
Leica DM2500 microscope Leica Microsystems, Wetzlar, Germany 
Leica DMC2900 CMOS Sensor camera Leica Microsystems, Wetzlar, Germany 
Leica DMIL LED Leica Microsystems, Wetzlar, Germany 
Light Cycler 96 System  Roche, Basel, Switzerland  
Membrane vacuum pump N86KN.18 KNF Neuberger, Freiburg, Germany  
Membrane vacuum pump PC 3004 vario Vacuubrand, Wertheim, Germany 
Microplate Reader Fluostar Optima BMG Labtech, Ortenberg, Germany  
Microtome Leica SM2000R Leica Microsystems, Wetzlar, Germany 
Microwave M690 Miele, Gütersloh, Germany  
Microwave Tender Cooker Nordic Ware, Minneapolis, MN, USA  
Mini-PROTEAN3 Cell System Bio-Rad, Hercules, CA, USA  
Multichannel pipette 20-200 µL Rainin, Greifensee, Switzerland  
Multipipette Plus Eppendorf, Hamburg, Germany  
Nanodrop 2000c Spectrophotometer Thermo Scientific, Rockford, IL, USA 
Peristaltic pump Chromapor, Duisburg, Germany 
pH meter FE20/EL20  Mettler-Toledo, Greifensee, Switzerland  
Pipette 5000 µL Gilson, Middleton, WI, USA 
Pipettes 2/10/20/100/200/1000 µL Eppendorf, Hamburg, Germany 
Pipetus Hirschmann Laborgeräte, Eberstadt, Germany 
Power Pac 300 Bio-Rad, Hercules, CA, USA 
Precision Balance BP 310 S  Sartorius, Göttingen, Germany  
Shaker Duomax 1030/2030  Heidolph, Schwabach, Germany  
Sprout minicentrifuge Biozym, Hessisch Oldendorf, Germany  
Sterile workbench FlowSafe B-[MaxPro]²-160 Berner, Elmshorn, Germany 
Sub Cell GT Agarose Gel System  Bio-Rad, Hercules, CA, USA 
Thermocycler PTC 200  Bio-Rad, Hercules, CA, USA 
TissueLyser LT Qiagen, Hilden, Germany 
Ultra Turrax T25  IKA-Werke, Staufen, Germany 
Ultrasound processor 50H Hielscher Ultrasonics, Teltow, Germany 
VacuuHandControl VHCpro Vacuubrand, Wertheim, Germany 
Vortex Genie 2  Scientific Industries, Bohemia, NY, USA  
Zeiss Z1 Axio Observer Carl Zeiss Microscopy, Jena, Germany 
Zeiss Axioplan 2 Carl Zeiss Microscopy, Jena, Germany 
Zeiss Axiovert 135 Carl Zeiss Microscopy, Jena, Germany 
Zeiss Axiovert 200M Carl Zeiss Microscopy, Jena, Germany 
Zeiss Colibri.2 System Carl Zeiss Microscopy, Jena, Germany 
Zeiss LSM 5 Laser Module  Carl Zeiss Microscopy, Jena, Germany 
 
1.12.10Consumables 
Consumable Manufacturer 
0.9 mm needle Sterican  B. Braun, Melsungen, Germany  
10 mL syringe Luer solo B. Braun, Melsungen, Germany  
24/48/96 Well Culture Plate  Nunc, Thermo Scientific, Rockford, IL, USA 
BZO Seal Film  Biozym, Hessisch Oldendorf, Germany  
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CASY cups  Omni Life Sciences, Bremen Germany 
Cell scraper Kisker, Steinfurt, Germany  
Combitips advanced 2.5/5 mL Eppendorf, Hamburg, Germany  
Cryotube vials (2 mL) Thermo Scientific, Rockford, IL, USA 
Disposable scalpel stainless steel Teqler, Netmed, Wasserbillig, Luxembourg 
Filter pipette tips (10/20/200/1250 µL) StarLab, Hamburg, Germany 
Nitrocellulose membrane Machery & Nagel, Düren, Germany  
Parafilm American National Can, Chicago, IL, USA 
Pasteur-plast pipettes  Ratiolab, Dreieich, Germany  
PCR 96 Well TW-MT plate white Biozym, Hessisch Oldendorf, Germany  
PD tips 0.5 mL Brand, Wertheim, Germany 
Perfusor tube Luer lock B. Braun, Melsungen, Germany  
Pipette tips (10/ 200/1000/5000 µL) Biozym, Hessisch Oldendorf, Germany  
Reaction tubes (0.2/0.5/1.5/2.0 mL)  Sarstedt, Nürnbrecht, Germany  
Reagent Reservoirs (25 mL)  VWR, Darmstadt, Germany  
Sempercare nitrile gloves Semperit, Vienna, Austria 
Serological pipettes (1/5/10/25/50 mL)  Sarstedt, Nürnbrecht, Germany  
Soy-free natural ingredient food pellets Special Diets Services, Witham, UK 
Syringe filter Filtropur S 0.2 µm Sarstedt, Nürnbrecht, Germany  
Superfrost Plus Microscope Slides Menzel Gläser, Braunschweig, Germany  
TC Dish 35/60  Sarstedt, Nürnbrecht, Germany  
Tubes (13 mL) Sarstedt, Nürnbrecht, Germany  
Tubes (15 mL, 50 mL) Greiner Bio-One, Frickenhausen, Germany 
Urine cups Sarstedt, Nürnbrecht, Germany  
Whatman gel blot paper GB003 Whatman, GE Healthcare, Maidstone, UK 
µ-Dish (35 mm Æ, glass bottom)  ibidi, Planegg, Germany  
 
1.12.11Software and web-based tools 
Software Origin 
AIM v.4.2 Carl Zeiss Microscopy, Jena, Germany 
Basic Local Alignment Search Tool 
(BLAST)  
http://blast.ncbi.nlm.nih.gov/  
ChemiCapt v.11.10 Vilber Lourmat, Marne-la-Vallée, France 
Fiji – ImageJ v.2.0.0 https://fiji.sc/ 
FinchTV v.1.5.0 Geospiza Inc., PerkinElmer, Seattle, WA, USA  
Graphpad Prism v.6.0 GraphPad Software Inc., San Diego, CA, USA 
ImageLab v.5.2.1 Bio-Rad, Hercules, CA, USA 
LAS v.4.6 Leica Microsystems, Wetzlar, Germany 
LAS X v.1.9 Leica Microsystems, Wetzlar, Germany 
Nanodrop 2000/2000c v.1.4.2 Thermo Scientific, Rockford, IL, USA 
PHANTAST plugin for Fiji https://github.com/nicjac/PHANTAST-FIJI/releases 
Primer3 v.4.0.0  http://primer3.ut.ee/ 
ProgRes CapturePro v.2.9.0.1 Jenoptik, Jena, Germany 
SerialCloner v.2.6.1 http://serialbasics.free.fr/Serial_Cloner 
SPOT advanced software v.4.6 SPOT Imaging Solutions, Sterling Heights, MI, 
USA 
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STRING v.10.0 http://string-db.org 
SWISS-MODEL https://swissmodel.expasy.org/ 
ZEN v.2 Carl Zeiss Microscopy, Jena, Germany 
 
1.13 Methods 
1.13.1 Mouse model generation and analyses 
Mouse models were generated in collaboration with the Institute of Biomedicine and Turku 
Center for Disease Modeling at the University of Turku, Finland. All animals were bred and 
housed in specific pathogen-free conditions with automatic light control (twelve hours light, 
twelve hours darkness) and temperature (21 ± 1°C) in specified pathogen-free conditions at 
the Central Animal Laboratory of the University of Turku under a license by the Finnish 
Animal Ethics Committee also complying to the institutional animal care policies of the 
University of Turku. Littermates were housed together in the same cage, one to six animals 
per cage. The mice had unrestricted access to soy-free natural ingredient food pellets and tap 
water. 
The AROM+ transgenic mouse was employed as a systemic model of male infertility. This 
mouse line expresses human P450 aromatase under control of the ubiquitin C promoter111-
113. Testes from two, three and five months old animals of this mouse line and age-matching 
wild type (WT) animals were used for immunohistochemistry and qRT-PCR studies. To link 
discovered changes between AROM+ and WT mice to the aromatase overexpression, four 
weeks old age-matched AROM+ and WT mice were divided in two subgroups and treated 
with the aromatase inhibitor (AI) Finrozole (daily with dose of 10 mg per kg of body weight 
by gavage in 0.2 ml of vehicle) and a placebo as control for six weeks, respectively (Aguilar-
Pimentel et al., unpublished). Testes from these 2.5 months old mice were used for 
immunohistochemistry and qRT-PCR experiments. 
To assess the impact of biglycan (Bgn, located on the X chromosome) deficiency in AROM+ 
mice, the AROM+ mouse line (FVB/N background) was bred to a Bgn knock-out line (Bgn-
/0, obtained from Dr. Marian Young, NIH NIDCR, Bethesda, MD, USA; C57BL6 
background) for two generations to obtain F2 males of all desired genotypes. The exact 
breeding scheme is displayed in Figure 0.1. 
 
Figure 0.1 Breeding scheme for AROM+ x Bgn-/0 
In the F0 generation female AROM+ mice (FVB/N background) were bred to male Bgn-/0 mice (C57BL6 
background). From this crossing’s offspring (F1 generation) female AROM+ Bgn+/- mice were bred to 
male Bgn-/0 mice to obtain equal numbers for the four genotypes to be investigated in male offspring 
(F2 generation): AROM+ Bgn-/0, AROM+ (Bgn+/0), Bgn-/0 and WT (Bgn+/0). 
F2 AROM+ Bgn-/0 AROM+ (Bgn+/0)  WT (Bgn+/0)Bgn-/0
F0
F1
AROM+ Bgn+/+ Bgn-/0
AROM+ Bgn+/- Bgn-/0
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Mice were genotyped by PCR with primer pairs for wild type (WT) (forward 5’-CAG GAA 
CAT TGA CCA TG-3’ and reverse 5’-GAA AGG ACA CAT GGC ACT GAA G-3’) and 
mutated allele (forward as in WT and reverse 5’-TGG ATG TGG AAT GTG TGC GAG G-
3’) at the University of Turku. Male F2 offspring was subdivided into four groups by 
genotype and analyzed at four and ten months of age. Animals were weighed before 
euthanasia, then testes were collected. Testicular weights were determined additionally. One 
testicle was frozen in liquid nitrogen for RNA and protein isolation, the other testicle was 
fixed in Bouin’s solution. Of the ten months old offspring, testicular steroid levels were 
determined at the Sahlgrenska Academy, Centre for Bone and Arthritis Research, University 
of Gothenburg using the gas chromatography tandem mass spectrometry method577. 
Therefore, testicular protein was isolated and measured using the BCA Protein Assay Kit at 
the University of Turku. Comparable steroid levels were calculated by total steroid mass per 
tissue mass analyzed. 
As means of quantifying altered testicular structure and morphology, mean seminiferous 
tubule diameters were determined for individual animals. Length of longitudinal and 
perpendicular axis of each tubular cross section were measured and the diameter calculated 
by dividing their sum by two. For each mouse tubular diameters were averaged. Body 
weights and testis weights per body weights as well as tubular diameters of different 
genotypes were compared using a one-way ANOVA with Tukey’s post-test to correct for 
multiple comparisons (statistical significance p < 0.05). 
 
1.13.2 Immunohistochemistry 
Tissue samples from human or mouse testis were fixed in Bouin’s solution for 24 h, then 
transferred to 70% EtOH. EtOH was changed daily until the solution remained colorless. 
Samples were embedded in paraffin, sectioned at a layer thickness of 5 µm and mounted on 
glass slides. Sections were de-paraffinized by 2x xylol and an EtOH series (2x 100%, 90%, 
80%, 70%, 3 min each) and rehydrated in PBS (10 min). Demasking of antigens was 
performed by boiling the sections in citrate buffer followed by a slow cool-down. All further 
incubation steps before DAB staining were performed in a humid chamber. Sections were 
washed with PBS (2x for 5 min), then the endogenous peroxidase activity was inhibited 
using 3% hydrogen peroxide / 9% methanol in PBS for 30 min. Sections were washed with 
PBS (3x for 5 min), then incubated with 5% or 10% normal goat serum in PBS for 30 min 
to block unspecific antibody binding. Primary antibody diluted in 5% or 10% normal goat 
serum in PBS applied over night at 4°C. Sections were washed with PBS (3x for 5 min), 
then the secondary antibody diluted in 5% or 10% normal goat serum in PBS was applied 
for 2 h. Subsequently, sections were treated with an avidin-biotin-peroxidase complex (ABC 
reagent)578 for 2 h before washing with PBS (3x for 5 min). Sections were incubated with 
Tris/HCl for 10 min. Staining was performed by applying the chromogen DAB for 10 min 
at most. The reaction was stopped in dH2O and sections were counterstained in a 
hematoxylin solution, then washed in tap H2O. Sections were de-hydrated in an ascending 
EtOH series (70%, 80%, 90%, 2x 100%, 3 min each) and xylol (2x for 5 min). Sections were 
mounted using entellan and dried over night. 
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Negative controls consisted of pre-adsorbed primary antibody or host-specific non-immune 
serum (1:5000, 1:10000) diluted in 5% or 10% normal goat serum in PBS instead of primary 
antibody or primary antibody was omitted completely. For pre-adsorption control, diluted 
primary antibody was incubated with a 20-fold excess concentration of complementary 
blocking peptide for 2-4 h in a shaker (300 rpm, 20°C). The mixture was centrifuged for 
10 min at 13,000 rpm and the supernatant was used instead of primary antibody. 
 
1.13.3 Peritubular cell culture 
HTPCs were obtained by explant culture of human testicular tissue samples as described 
previously67,96. Briefly, testicular tissue samples stemming from patients (28-56 years old) 
undergoing reconstructive surgery of the vas deferens were dissected and placed under 
plasma drops in culture until outgrowth of HTPCs occurred. Patients granted written 
informed consent and the ethical committee (Ethikkommission, Technische Universität 
München, Fakultät für Medizin, München, project number 5158/11) approved the scientific 
use of the cells. HTPCs were screened for presence of smooth muscle-cell specific markers 
and absence of markers from possibly contaminating cells as well as mycoplasma before use 
or cryopreservation. In this thesis only cryopreserved cells in passages 5-16 were used. 
 
1.13.3.1 Cell cultivation 
Cells were cultivated at 37°C, 5% (v/v) CO2 and 95% humidity. The culture medium 
(DMEM, high glucose including 10% FBS and 1% penicillin/streptomycin) was replaced 
every other day. If confluent, HTPCs were subcultivated. For this purpose, cells were 
washed with PBS and incubated with 1 mL Trypsin-EDTA for 4 min at 37°C. The reaction 
was stopped by applying at least an equal amount of culture medium and HTPCs were 
pelleted at 700 rpm for 3 min. The pellet was divided onto culture dishes in a 1:3 ratio for 
mere expansion purposes or used for cell count determination and defined cell seeding for 
experiments. 
 
1.13.3.2 Thawing and freezing of cells 
Cryopreserved HTPCs were thawed in a water bath (37°C) and immediately resuspended in 
pre-warmed culture medium. Cells were centrifuged at 700 rpm for 3 min. The cell pellet 
was resuspended in culture medium and transferred to a P60 cell culture dish. 
For cryopreservation HTPCs were trypsinized as described. The pellet was resuspended in 
1 mL culture medium containing 10% DMSO and transferred to a cryo vial. The vial was 
cooled down slowly to -80°C over night in a cell freezing container and subsequently 
transferred to liquid nitrogen for long-term storage. 
 
1.13.3.3 Cell count determination and seeding 
If confluent, the cell count was determined by using an automated cell counting and 
analyzing device, CASY. A trypsinized HTPC pellet was resuspended in 1 mL PBS, diluted 
1:500 in 10 mL CASYton and measured by CASY in three cycles of 400 µL sample volume 
each. The diameter range for viable cells was set from 14 µm to 50 µm. The determined 
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concentration of viable cells was used to seed equal cell numbers into the appropriate culture 
vessels for experiments. Approximate cell numbers are depicted in Table 0.1. 
Table 0.1 Approximate total cell numbers seeded per culture vessels depending on the method 
Culture vessel Method Number of cells seeded 
35 mm Æ µ-dish Ca2+ imaging 50000 
35 mm Æ µ-dish  Live cell imaging 40000 
60 mm Æ culture dish RNA/protein isolation 200000 
96 well plate LDH assay 5000 
 
1.13.3.4 Treatment of HTPCs 
For experiments in general, HTPCs were seeded in defined numbers and grown to 
approximately 90% confluence. 24 h prior treatment, cells were washed with PBS and 
deprived of FBS supplementation in the culture medium. Stimulation was performed in 
serum-free culture medium missing phenol red (DMEM, high glucose, no glutamine, no 
phenol red supplemented with 4 mM L-glutamine and 1% penicillin/streptomycin). As 
untreated controls, HTPCs were incubated in serum-free culture media only. If an agent for 
treatment was not soluble in culture medium, the solvent was added to the control experiment 
in equal concentration. Pilot studies for RNA and protein isolation were performed to 
determine optimal time periods for treatment depending on stimulating agent and type of 
experiment. For RNA isolation, 6 h and 24 h were chosen, respectively. 48 h were used for 
protein analyses and collection of supernatants. Agents and corresponding solvents used for 
experiments are shown in Table 0.2. 
Table 0.2 Stimulating and blocking agents with corresponding solvents used in experiments 
Agent Solvent Final concentration Experiment 
ATP Serum-free culture medium 1 mM RNA/protein isolation 
AZ11645373 DMSO 0.5 µM Ca2+ imaging 
BzATP PBS 100 µM Ca2+ imaging 
 
1.13.4 Functional assessment of peritubular cells 
1.13.4.1 Live cell imaging 
To monitor HTPC response to treating agents treated versus untreated cells were imaged in 
a heating and gas incubation system (37°C, 5% (v/v) CO2, 95% relative humidity), which 
was set up on a transmitted light microscope. Cells were observed for up to 72 h, thereby 
taking a picture every 20 min to generate time-lapse series. Cell count and confluence were 
determined at 6 h, 24 h, 48 h and 72 h, respectively. Cells were counted manually using the 
Fiji cell counter plug-in579. Confluence was calculated using the Fiji plug-in PHANTAST580. 
Differences in cell numbers or confluence between treated and untreated HTPCs were 
examined by paired t-tests (two-tailed; statistical significance p < 0.05). 
 
4 Material and Methods 70 
1.13.4.2 Cytotoxicity Assay 
Chemical compound-mediated cytotoxicity was determined via lactate dehydrogenase 
(LDH) release from cells as sign of membrane disruption and therefore viability loss. The 
LDH Cytotoxicity Assay Kit was used according to the manufacturer’s instructions. The 
colorimetric assay was performed in quadruplicates for each treatment and absorbance was 
measured at 492 nm and 690 nm, respectively. LDH activity was calculated by subtracting 
absorbance at 690 nm from absorbance at 492 nm. Cytotoxicity was determined via 
following formula (1). 
 Cytotoxicity = Compound	treated	LDH	activity − Basal	LDH	activityMaximum	LDH	activity − Basal	LDH	activity 					(1) 
 
Statistical analysis of cytotoxicity extent was determined using a one-sample t-test 
(statistical significance p < 0.05). 
 
1.13.4.3 Imaging of intracellular calcium transients 
Alterations of intracellular Ca2+ levels in response to extracellular stimuli were recorded in 
order to assess receptor presence and functionality. Therefore, HTPCs were loaded with a 
calcium-sensitive fluorescent dye, Fluo4 or Fluoforte, (5 µM) for 30 min under standard 
conditions (37°C, 5% (v/v) CO2, 95% relative humidity). After dye removal, cells were 
transferred to the stage of on an inverted confocal microscope using a peristaltic pump with 
flexible tubes and needles to generate a set-up for applying and removing substances for a 
specified course of time. Typically, once a steady baseline was obtained, stimulating agent 
(100 µM BzATP) was applied for 30-60 s, then washed out over a period of several minutes, 
then applied again. In case, receptor activities were attempted to be blocked, the inhibitor 
(0.5 µM AZ11645373, Ca2+-free culture medium) was already administered while dye 
loading and remained present until washout. As positive control 0.005% trypsin was used at 
the end of each experiment64,67,68. Fluorescent intensity (excitation wavelength 488 nm) was 
monitored with a long-pass filter (505 nm) at a cycle time of 1.97 s. Ca2+-dependent 
fluorescent levels in each cell were evaluated individually by defining regions of interest. 
Baseline-corrected fluorescent intensities for regions of interest were displayed as a function 
of time. 
 
1.13.5 Molecular biology methods 
1.13.5.1 RNA isolation 
Total RNA from HTPCs was isolated using the RNeasy Plus Micro Kit. Cells were harvested 
by removing the culture media and washing the culture dishes with PBS once. Then, cells 
were gently scraped from the surface in 350 µL RLT buffer supplemented with 1% β-
Mercaptoethanol. At this point samples were either stored at -80°C or directly processed. 
RNA was extracted following the manufacturer’s instructions and eluted in 20 µL nuclease-
free H2O. 
Total RNA from mouse testes was isolated using TRIsure. A piece of frozen testicular tissue 
was homogenized with one stainless steel bead in 1 mL TRIsure for 1 min at 50 Hz. RNA 
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extraction was performed according to the manufacturer’s protocol with the additional use 
of Glycoblue (1.5 µL per 500 µL aqueous phase) for better visualization of the RNA pellet. 
RNA concentration and quality were determined using a NanoDrop device. If necessary, 
RNA was purified by sodium acetate precipitation before cDNA synthesis. RNA was stored 
at -80°C. 
 
1.13.5.2 RNA purification by precipitation 
To remove contaminants from RNA with low quality, sodium acetate precipitation was 
performed. To this, RNA was precipitated by adding 10% (v/v) 3 M sodium acetate, 400% 
(v/v) EtOH (100%) and 1 µL of Glycoblue dye. The solution was mixed thoroughly, then 
frozen at -80°C o/n. Precipitate was pelleted by centrifugation (16000 rpm, 30 min, 4°C) and 
washed twice with ice-cold EtOH (80%) by removing the supernatant, adding 500 µL EtOH 
and centrifugation (16000 rpm, 10 min, 4°C). After discarding the supernatant and removing 
all residual fluid, the pellet was air-dried for approximately 10 min, then dissolved in 40 µL 
nuclease free H2O. 
 
1.13.5.3 cDNA synthesis 
RNA isolated from HTPCs was transcribed using the SuperScript II Reverse Transcriptase 
Kit. 200 ng of RNA were pre-mixed with 0.8 µL random 15mer primers (100 µM) and filled 
up to 11.5 µL with nuclease free H2O. In case qRT-PCR of low abundant mRNAs was the 
ultimate goal, 1 µg instead of 200 ng RNA was transcribed. The mix was incubated for 
10 min at 70°C and for 5 min at 25°C. Then 7.5 µL nucleotide master mix consisting of 4 µL 
5x First Strand Buffer, 2 µL 0.1 M DTT, 1 µL 10 mM dNTPs and 0.5 µL 40 U/µL RNasin 
were added. RNA and nucleotide mix were incubated for 10 min at 25°C and 2 min at 42°C. 
1 µL SuperScript II Reverse Transcriptase (200 U/µL) was added and incubation was carried 
out for 50 min at 42°C, 15 min at 70°C and 10 min at 4°C. To exclude genomic DNA 
contamination, -RT control samples were generated by omitting the SuperScript II Reverse 
Transcriptase. Either, a corresponding control sample was generated for each individual 
sample or RNAs from samples with similar treatment were pooled and non-reverse 
transcribed together as one control sample. 
RNA from mouse testes was treated with DNaseI to eliminate genomic DNA prior to cDNA 
synthesis. Therefore, the DNaseI, Amplification Grade Kit was used according to the 
manufacturer’s instructions, albeit nuclease free H2O was used instead of DEPC-H2O. 
cDNA synthesis of 1 µg DNaseI-treated RNA was performed with the SensiFAST cDNA 
Synthesis Kit following the manufacturer’s instructions, but with an extended transcription 
of 30 min instead of 15 min at 42°C. One -RT control sample was generated per genotype 
and age group. 
cDNA was stored at -20°C. 
 
1.13.5.4 Quantitative real-time PCR 
Amplification of cDNA for quantification purposes was performed using the QuantiFast 
SYBR Green PCR Kit in a LightCycler 96 System. Primers (see section 1.12.5) were 
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designed using the Primer3 web-tool. Wherever possible, primer pairs were designed to span 
an exon-exon junction to exclude genomic DNA contamination. Initially, a temperature 
gradient qRT-PCR was performed to determine the optimal annealing temperature (Ta, see 
section 1.12.5) for each set of primers. Samples were analyzed in duplicates or triplicates 
with following reaction mix (Table 0.3) and cycler program (Table 0.4). Non-reverse 
transcribed RNA as template (-RT) and nuclease free H2O as non-template (–) were included 
as control reactions in each experiment to exclude sample contamination. 
Table 0.3 Reaction mix composition for qRT-PCR 
Reagent Volume [µL] 
2x QuantiFast SYBR Green PCR Master Mix 6.25 
Forward primer (3.33/5/10 µM) 1.125 
Reverse primer (3.33/5/10 µM) 1.125 
cDNA template (1-20 ng) 4 
 
Table 0.4 Cycler program for qRT-PCR reaction 
Step Temperature [°C] Time [s] 
Initiation 95 300 
Amplification (35-43x)   
     Denaturation 95 10 
     Annealing/Extension Ta 30 
Melting curve (0.2°C/s) 65-97 160 
Cool-down 37 30 
 
Obtained Cq values were analyzed according to the 2-ΔΔCq method581 using endogenous 
reference genes. For HPTCs, pair-wise analysis of treated versus untreated sample Cq values 
was performed with normalization to HPRT and RPL19 as reference genes. One-sample t-
tests of -ΔΔCq values revealed statistical significance (p < 0.05). Results of mouse testes 
lysates were normalized to the mean of the WT population using Hprt, Ppia and Rpl19 as 
endogenous reference. Statistical analyses were obtained by unpaired t-tests (two-tailed) or 
one-way ANOVA with Tukey’s post-test to correct for multiple comparisons of -ΔΔCq 
values (statistical significance p < 0.05). 
 
1.13.5.5 Agarose gel electrophoresis and DNA sequencing 
qRT-PCR products were analyzed on a 2% agarose gel. Therefore, agarose was dissolved 
and boiled in 1x TBE buffer. The gel was cooled down and MidoriGreen Advance DNA 
Stain (final concentration 0.005%) was added before casting. After complete 
polymerization, the gel was run in 1x TBE buffer at 80 V for 30-45 min. DNA fragments 
were visualized using blue LED light and compared to the DNA ladder for correct amplicon 
length. For each set of primers used in amplification, a DNA fragment was isolated from the 
gel and purified using the Wizard SV Gel and PCR Clean-Up System according to the 
manufacturer’s instructions. Purified amplicons were pre-mixed with forward primer (final 
concentration 2.5 µM) and sent for sequence analysis (GATC, Konstanz, Germany). 
Sequencing results were compared and verified using BLAST and SerialCloner.  
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1.13.6 Proteinbiochemical methods 
1.13.6.1 Protein isolation 
For protein isolation, cultured HTPCs (after stimulation) were harvested by washing them 
with PBS once and freezing them at -80°C until isolation. Isolation was performed on ice. 
Cells were scraped off the culture dish using 1.5 mL NPE buffer and transferred to a 2 mL-
tube. Cells were pelleted by centrifugation (10000 rpm, 3 min, 4°C) and resuspended in 
1.5 mL PBS. Centrifugation was repeated and the remaining pellet was dissolved in 100 µL 
protease and phosphatase inhibitor cocktail. Samples were cooled on ice for 30 min before 
cell lysis via ultrasound (10 times at cycle 0.5 and amplitude 40 in an ultra turrax).  
Protein concentration was assessed via the DC Protein Assay Kit based on an improved 
Lowry assay582,583 according to the Microplate Assay Protocol of the manufacturer. 
Absorption of samples at 690 nm was determined in duplicates after 30 min incubation using 
a dilution series of albumin (0.0-2.0 µg/µL) as calibrator.  
 
1.13.6.2 SDS-Polyacrylamide gel electrophoresis 
Protein samples were analyzed according to their molecular weight on a denaturing SDS-
PAGE. First, proteins were concentrated in a 4.5% stacking gel at the dye front, then 
separated by a 12% separating gel. Gels were cast in reverse order using following protocol 
(Table 0.5). 
Table 0.5 Reaction mix composition for separating and stacking gel 
Reagent Separating gel Stacking gel 
Acrylamide (30%) 5.2 mL 0.9 mL 
4x Separating gel buffer  3.25 mL – 
4x Stacking gel buffer – 1.5 mL 
dH2O 4.55 mL 3.55 mL 
TEMED 26 µL 15 µL 
APS (10%) 52 µL 30 µL 
 
5-7 µg of protein were denatured by adding 10% (v/v) bromophenol blue and 10% (v/v) b-
mercaptoethanol and incubating the mix at 95°C for 5 min. The gel was loaded with the 
samples and run in 1x Laemmli buffer at 90 V for 15 min followed by 120 V for 90 min. 
 
1.13.6.3 Western Blot 
To specifically detect the presence of individual proteins, Western blotting of proteins 
already separated by SDS-PAGE was performed. Proteins were transferred from acrylamide 
gel to a nitrocellulose membrane in a wet blotting system at 100 V for 75 min using 
1x Transfer buffer. The membrane was stained with 1x Ponceau S to validate the protein 
transfer, then destained using 0.1% acetic acid. To reduce unspecific primary antibody 
binding, the membrane was incubated in 5% milk powder in 1x TBST for 60 min before 
applying the primary antibody in 1% milk powder in 1x TBST over night at 4°C. For pre-
adsorption control, primary antibody in 1x TBST (2:1 of final concentration) was incubated 
with a 20-fold excess concentration of complementary blocking peptide for 2-3 h in a shaker 
(300 rpm, 20°C). The mixture was centrifuged for 10 min at 13,000 rpm. The supernatant 
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was diluted 1:2 with 2% milk powder in 1x TBST (final concentration 1% milk powder) and 
used instead of primary antibody. The membrane was washed 15 min with 1x TBST four 
times, then incubated with the corresponding peroxidase-conjugated secondary antibody in 
1% milk powder in 1x TBST for 60 min. Again, the membrane was washed with 1x TBST 
for 15 min four times. Chemiluminescence was detected using the SuperSignal West Femto 
Maximum Sensitivity Substrate. 
 
1.13.6.4 Supernatant profiling assay 
To analyze regulation of 102 cytokines in whole HTPC supernatant simultaneously, the 
membrane-based sandwich immunoassay Proteome Profiler Human XL Cytokine Array Kit 
was used. Supernatants were harvested by centrifugation (8000 rpm, 3 min) and transferred 
to a new tube to remove any cell debris. 500 µL supernatant were either directly used in the 
assay or stored at -20°C. Total cell protein was isolated using RIPA buffer. Cells were 
washed with PBS once, then gently scratched off the surface using 1 mL PBS. Cells were 
pelleted by centrifuging (2000 rpm, 5 min, 4°C), then washed in 300 µL ice-cold PBS and 
pelleted again. Cells were lysed by resuspending thoroughly in 150 µL RIPA buffer. 
Samples were kept on ice for 30 min before sonication. Then, cell debris was removed by 
centrifugation (13000 rpm, 10 min, 4°C) and transferring the supernatant containing the 
proteins into a new tube. Protein concentration was determined with the DC Protein Assay 
Kit as described. The Proteome Profiler Human XL Cytokine Array Kit was used according 
to the manufacturer’s instructions. Chemiluminescent signal intensity was detected and used 
for relative quantification of cytokines. Individual spot intensity on the membrane was 
analyzed using a Fiji Macro developed by Dr. Anna Klemm (Core Facility Bioimaging, 
Biomedical Center Munich, LMU). Means and of duplicate spots were determined, the mean 
density of the negative control spots was subtracted as blank. Values were corrected for 
whole lysate protein content and values from treated samples were normalized to the 
corresponding untreated sample to obtain relative cytokine levels. Relative cytokine levels 
in the supernatant of four patients were analysed for statistical significance (p < 0.05) via a 
one-sample t-tests of logarithmized values. 
 
1.13.6.5 Mass spectrometry 
ATP-treated and untreated HTPCs from six patients were harvested for mass spectrometric 
analysis. Therefore, the cells were trypsinized as described. After pelleting the cells once, 
the pellet was resuspended and centrifuged down (700 rpm, 3 min) again five times, three 
times in 1 mL serum-free culture medium and two times in 1 mL PBS, to remove all serum 
contaminants from the cells. Before the last centrifugation step a 20 µL sample was taken to 
ensure viability and approximately equal cell count and of paired samples by CASY 
measurement. After complete removal of any remaining supernatant, the obtained cell pellet 
was frozen at -80°C. Processing of ATP-treated versus control HTPC samples and mass 
spectrometric analyses (MS/MS) were performed by the Laboratory for Functional Genome 
Analysis (LAFUGA) at the LMU Gene Center. A candidate list of proteins affected in 
abundance by ATP was generated. Enrichment analysis of protein subsets with elevated or 
decreased abundance was performed with the STRING analysis tool using default options469. 
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Supporting results 
 
Supplementary Figure 1 Pre-adsorption control for P2RX4 expression in HTPCs. 
Identity of the P2RX4 band in Western blotting (upper panel) was confirmed via pre-adsorption of the 
anti-P2RX4 antibody (a) versus antibody only (b). No signal was detected in the pre-adsorbed control. 
Detection of b-Actin (lower panel) on the same membrane served as protein loading control. Labels 
indicate corresponding protein weight in [kDa].   
70
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Additional projects during the thesis 
a1-adrenergic signaling in HTPCs 
Stress-induced catecholamines may foster an inflammatory environment in the testis, 
thereby contributing to testicular changes that eventually cause infertility. The 
catecholamine epinephrine is released during stress response of the sympathetic nervous 
system and non-selectively activates a and b adrenergic receptors (ADRs). Various 
testicular cell types express ADRs and could thus be targets of catecholamine actions. 
HTPCs were found to possess ADR isoforms a1(B,D), b1 and b2. Selective agonist 
treatment of HTPCs revealed that phenylephrine (a1-ADR agonist) mimicked epinephrine 
responses in HTPCs. Both molecules induced COX2 expression and elevated IL6 as well as 
CCL2 production and secretion in HTPCs. These effects were obliterated in the presence of 
the inverse a1-ADR prazosin. Hence, a1-ADR-mediated signaling in HTPCs participates 
in testicular inflammation584. 
My contribution to this project was the functional assessment of a1-ADR signaling. Since 
a1-ADR is a GPCR that activates PLC eventually leading to intracellular Ca2+ 
mobilization585, Ca2+ imaging of HTPCs was employed. Exposure of HTPCs to the selective 
a1-ADR agonist phenylephrine uncovered robust and transient elevations of intracellular 
[Ca2+] in two independent experiments (Supplementary Figure 2). 
 
 
Supplementary Figure 2 Functional a1-ADR assessment in HTPCs via calcium imaging. 
Top: Graphic representation of representative Ca2+-dependent fluorescent signals in individual HTPCs 
loaded with Fluo4 or Fluoforte (5 µM) over time when exposed to different conditions. Stimulation 
time periods are indicated by horizontal bars. 0.005% trypsin was used as a positive control (+) in all 
experiments. y axis bar represents 20 a.u. fluorescent intensity. Bottom: Pseudocolor single frame 
images of fluorescent intensity at the beginning of the experiment (0 s) and at peak elevations during 
agent and positive control exposure depict the response of the measured HTPCs (arrowhead). 
Bars = 50 µm. A/B. Response to agonist exposure (a, 10 µM phenylephrine) revealed robust Ca2+ 
transients in HTPCs in two independent experiments. 
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